{"text": "Consult drug interactions database for more detailed information .Special populations : .Elderly patients exhibit higher rivaroxaban concentrations compared to younger patients due primarily to reduced clearance .", "label": "", "metadata": {}, "score": "24.061003"}
{"text": "Therefore , the current analysis focused on these groups of patients and , in addition , analyzed the performance of rivaroxaban in patients with previous VTE and in those presenting with a large clot burden .", "label": "", "metadata": {}, "score": "24.233353"}
{"text": "Therefore , the current analysis focused on these groups of patients and , in addition , analyzed the performance of rivaroxaban in patients with previous VTE and in those presenting with a large clot burden .", "label": "", "metadata": {}, "score": "24.233353"}
{"text": "Patients with concurrent renal or hepatic dysfunction are likely to be particularly sensitive to drug interaction - induced changes in rivaroxaban elimination .PT .References .", "label": "", "metadata": {}, "score": "24.261051"}
{"text": "Subgroup analyses from the EINSTEIN - DVT trial suggest that rivaroxaban may be associated with a slightly lower risk of bleeding than LMWH / VKA in cancer patients , but this needs to be further prospectively investigated in a larger population .", "label": "", "metadata": {}, "score": "26.631466"}
{"text": "Clinical experience is limited , but some of the potential drug interactions are likely to alter patient response to rivaroxaban .The anticoagulant response to rivaroxaban is related to its plasma concentration .", "label": "", "metadata": {}, "score": "27.23117"}
{"text": "Particularly in those patients in whom VKA therapy is associated with an increase in complications , use of rivaroxaban resulted in an important safety advantage .", "label": "", "metadata": {}, "score": "28.155657"}
{"text": "Particularly in these patients , rivaroxaban yielded favorable clinical results .In fragile patients , the incidence of major bleeding was reduced from 4.5 % with standard - therapy to 1.3 % with rivaroxaban .", "label": "", "metadata": {}, "score": "28.524813"}
{"text": "Particularly in these patients , rivaroxaban yielded favorable clinical results .In fragile patients , the incidence of major bleeding was reduced from 4.5 % with standard - therapy to 1.3 % with rivaroxaban .", "label": "", "metadata": {}, "score": "28.524813"}
{"text": "Despite this , rivaroxaban still demonstrated superior efficacy compared to enoxaparin for the primary outcome ( RR 0.5 , 95%CI 0.34 - 0.73 , .However , in each of the RECORD trials , the rate of bleeding complications was higher in the rivaroxaban group , although not statistically significant .", "label": "", "metadata": {}, "score": "28.656414"}
{"text": "Based on the observed results in patients with cancer , a head - to - head comparison of rivaroxaban with long - term low - molecular - weight heparin seems warranted .", "label": "", "metadata": {}, "score": "28.809376"}
{"text": "Based on the observed results in patients with cancer , a head - to- head comparison of rivaroxaban with long - term low- molecular - weight heparin seems warranted .", "label": "", "metadata": {}, "score": "28.809376"}
{"text": "Consider these risks when scheduling patients for spinal procedures .The optimal timing between the administration of rivaroxaban and neuraxial procedures is not known .Monitor patients frequently for signs and symptoms of neurological impairment .", "label": "", "metadata": {}, "score": "28.931124"}
{"text": "Special Populations : Renal Function Impairment .Rivaroxaban exposure is increased by 44 % in patients with mild impairment ( CrCl 50 to 79 mL / minute ) and by 52 % in patients with moderate impairment ( CrCl 30 to 49 mL / minute ) .", "label": "", "metadata": {}, "score": "29.445263"}
{"text": "In addition to bleeding , rivaroxaban was also associated with increased risk for other adverse events .Pooled data demonstrated that patients on rivaroxaban had a higher rate of serious on - treatment adverse events ( OR 1.27 , 95%CI 1.09 - 1.48 , .", "label": "", "metadata": {}, "score": "29.515211"}
{"text": "The lower dose of rivaroxaban in patients with moderate renal impairment showed noninferiority to warfarin therapy in a subgroup analysis [ 45 ] .A subgroup analysis of ARISTOTLE showed a consistent effect for both efficacy and safety across the spectrum of renal function .", "label": "", "metadata": {}, "score": "29.53778"}
{"text": "The prespecified , individual , patient data meta - analysis presented here included more than 8000 patients and shows that rivaroxaban can be used as a single - drug approach for the treatment of acute symptomatic DVT and/or PE .", "label": "", "metadata": {}, "score": "29.61596"}
{"text": "In most patients , routine laboratory monitoring of the anticoagulant effect is not required but the assessment of the estimated renal clearance is necessary [ 9 ] .", "label": "", "metadata": {}, "score": "29.728518"}
{"text": "In case of heparin bridging therapy , the rate of cardiovascular events is not reduced .There is a significantly higher rate of bleeding complications due to heparin bridging or major procedures .", "label": "", "metadata": {}, "score": "29.81039"}
{"text": "Conclusion : The single - drug approach with rivaroxaban resulted in similar efficacy to standard - therapy and was associated with a significantly lower rate of major bleeding .", "label": "", "metadata": {}, "score": "29.848671"}
{"text": "However , unless rivaroxaban or standard - therapy could have differential effects on a new diagnosis of cancer during the trial , the principle of randomization was maintained using an intention - to - treat approach to the analysis .", "label": "", "metadata": {}, "score": "31.041374"}
{"text": "However , unless rivaroxaban or standard - therapy could have differential effects on a new diagnosis of cancer during the trial , the principle of randomization was maintained using an intention - to - treat approach to the analysis .", "label": "", "metadata": {}, "score": "31.041374"}
{"text": "This prespecified pooled analysis of two large , randomized studies evaluated the efficacy and safety of a single - drug approach with oral , fixed - dose rivaroxaban versus the combination of subcutaneous enoxaparin and INR - titrated VKA therapy in patients with acute symptomatic VTE .", "label": "", "metadata": {}, "score": "31.725925"}
{"text": "Except for the rifampin study , all reported drug interaction studies used a single 10-mg dose of rivaroxaban .Approximately 50 % of rivaroxaban is metabolized ( CYP3A4 [ major pathway ] and CYP2J2 , based on in vitro studies ) , and approximately 40 % of a dose is eliminated unchanged by the kidneys .", "label": "", "metadata": {}, "score": "31.963459"}
{"text": "[ 71 ] as well as Feng et al .[72 ] showed an increased risk of bleeding with similar thrombotic risk among patients who underwent periprocedural bridging therapy with heparin bridging .", "label": "", "metadata": {}, "score": "32.08144"}
{"text": "J. L\u00fctzner , L. Donath , L. Tittl et al . , \" Efficacy and safety of thromboprophylaxis with low - molecular - weight heparin or rivaroxaban in hip and knee replacement surgery : findings from the ORTHO - TEP registry , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "32.332966"}
{"text": "This hypothesis is a plausible mechanism for the association between rising levels of NT - proBNP and increased risk of thromboembolic events and cardiovascular mortality in the RE - LY biomarker study [ 17 ] .", "label": "", "metadata": {}, "score": "32.578053"}
{"text": "View at Google Scholar . A. G. Turpie , M. R. Lassen , B. I. Eriksson et al . , \" Rivaroxaban for the prevention of venous thromboembolism after hip or knee arthroplasty : pooled analysis of four studies , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "32.58717"}
{"text": "The primary efficacy outcome occurred in 6.9 % of patients in the rivaroxaban group and in 10.1 % of patients in the enoxaparin group ( . )", "label": "", "metadata": {}, "score": "33.026596"}
{"text": "Drs .Horn and Hansten are both professors of pharmacy at the University of Washington School of Pharmacy .The Efficacy and Safety of Rivaroxaban for Venous Thromboembolism Prophylaxis after Total Hip and Total Knee Arthroplasty .", "label": "", "metadata": {}, "score": "33.061497"}
{"text": "Other observational studies with a more interrupted approach showed equivalent bleeding and embolic events compared to therapeutic warfarin [ 84 - 87 ] .For rivaroxaban , uninterrupted rivaroxaban appears to be a feasible and safe alternative to uninterrupted warfarin therapy in patients undergoing AF ablation .", "label": "", "metadata": {}, "score": "33.11095"}
{"text": "Mueck W , Borris LC , Dahl OE , et al .Population pharmacokinetics and pharmacodynamics of once- and twice - daily rivaroxaban for the prevention of venous thromboembolism in patients undergoing total hip replacement .", "label": "", "metadata": {}, "score": "33.137405"}
{"text": "6 , pp .1466 - 1474 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Helld\u00e9n , I. Odar - Cederl\u00f6f , G. Nilsson et al . , \" Renal function estimations and dose recommendations for dabigatran , gabapentin and valaciclovir : a data simulation study focused on the elderly , \" BMJ Open , vol .", "label": "", "metadata": {}, "score": "33.173515"}
{"text": "The primary efficacy outcome occurred in 9.6 % of patients in the rivaroxaban group and in 18.9 % of patients in the enoxaparin group ( . )", "label": "", "metadata": {}, "score": "33.258846"}
{"text": "The characteristics of the patients in the treatment groups were similar at baseline in both studies ( Table 1 ) [ 8,9].The mean duration of study treatment was similar in both treatment arms overall ( 207.6 \u00b1 95.9 days in the rivaroxaban group and 204.0 \u00b1 97.2 days in the standard - therapy group in the intention - to - treat population ) and in prespecified patient subgroups ( Table 2 ) .", "label": "", "metadata": {}, "score": "33.96335"}
{"text": "However , major bleeding , the most worrying complication , was statistically significantly less frequent in patients treated with rivaroxaban .This reduction was seen mainly in fatal and nonfatal critical - site bleeding , such as intracranial and retroperitoneal bleeding .", "label": "", "metadata": {}, "score": "34.186882"}
{"text": "Patients with hepatocellular carcinoma commonly have underlying cirrhosis and the use of rivaroxaban would also be limited in these patients , as it is contraindicated in Child 's class B and C cirrhosis .", "label": "", "metadata": {}, "score": "34.28521"}
{"text": "Avoid combination .Erythromycin ( Systemic ) : May increase the serum concentration of Rivaroxaban .Management : In patients with impaired renal function , erythromycin should not be used unless the potential benefits outweigh the potential risks .", "label": "", "metadata": {}, "score": "34.48034"}
{"text": "Prompt clinical evaluation is warranted with any unexplained decrease in hemoglobin or blood pressure .Note : No specific antidote exists for rivaroxaban reversal ; not dialyzable due to high plasma protein binding .", "label": "", "metadata": {}, "score": "34.49816"}
{"text": "Another large retrospective cohort study comparing rivaroxaban to LMWH after THA and TKA found that patients taking rivaroxaban were less likely to experience bleeding , return to the operating room for wound complications , and had a shorter hospital stay [ 33 ] .", "label": "", "metadata": {}, "score": "34.513367"}
{"text": "Management : A comprehensive risk to benefit assessment should be done for all patients before any concurrent use of rivaroxaban and nonsteroidal anti - inflammatory drugs ( NSAIDs ) .", "label": "", "metadata": {}, "score": "34.75869"}
{"text": "This implies that efflux of rivaroxaban from the brain to the blood may be modulated by p - gp action and inhibition .Postmarketing Surveillance of NOACs .", "label": "", "metadata": {}, "score": "34.95842"}
{"text": "Dosage form specific issues : .Other warnings / precautions : .Consider the addition of alternative anticoagulant therapy when discontinuing rivaroxaban for reasons other than pathological bleeding or completion of a course of therapy .", "label": "", "metadata": {}, "score": "35.0644"}
{"text": "Similarly , with the RECORD 2 trial excluded , pooled analysis demonstrated higher rates of major plus clinically relevant non - major bleeding in patients taking rivaroxaban ( RR 1.29 , 95%CI 1.03 - 1.63 ) [ 31 ] .", "label": "", "metadata": {}, "score": "35.10422"}
{"text": "The use of activated prothrombin complex concentrate ( aPCC ) or recombinant factor VIIa has not been evaluated .The use of a four - factor PCC ( Cofact , not available in the US ) in healthy subjects has been shown to reverse the anticoagulant effect ( ie , normalize the prothrombin time ) of rivaroxaban ( Eerenberg 2011 ) .", "label": "", "metadata": {}, "score": "35.179"}
{"text": "However , there is a lack of efficacy or safety data for the combined impact of antithrombotic drugs in patients requiring arterial and venous thromboembolic prophylaxis due to their underlying co - morbidities .", "label": "", "metadata": {}, "score": "35.27842"}
{"text": "Thrombin clotting time tests calibrated to dabigatran , and factor Xa assays calibrated to rivaroxaban have been developed .However , outside of the specific circumstances alluded to above , the use of these tests for dose adjustment of NOACs remains untested and contentious .", "label": "", "metadata": {}, "score": "35.308586"}
{"text": "However , there is also evidence suggesting that rivaroxaban has an increased risk of bleeding complications compared to enoxaparin [ 22 , 23 ] .While rivaroxaban appears to be a promising alternative to LMWH or warfarin for VTE prophylaxis after THA and TKA , the long - term safety of rivaroxaban remains to be determined .", "label": "", "metadata": {}, "score": "35.370556"}
{"text": "Likewise , the efficacy of rivaroxaban was simi- lar both in patients presenting with a first episode of VTE and in those with a history of one or more epi- sodes of VTE .", "label": "", "metadata": {}, "score": "35.58782"}
{"text": "Thus , the novel oral anticoagulants appear to be a good choice in patients older than 75 years .Elevated Liver Enzymes .Patients with abnormal liver enzymes at baseline were excluded from the novel oral anticoagulant trials as there was concern given that the first oral direct thrombin inhibitor , ximelagatran , caused liver function abnormalities .", "label": "", "metadata": {}, "score": "35.601986"}
{"text": "Conclusion .The single - drug approach with rivaroxaban resulted in similar efficacy to standard - therapy and was associated with a significantly lower rate of major bleeding .", "label": "", "metadata": {}, "score": "35.629143"}
{"text": "In patients with previous VTE , the net clinical benefit ( hazard ratio , 0.52 ; 95 % CI , 0.31 to 0.90 ) was statistically significantly more favorable in patients treated with rivaroxaban ( Table 2 ) .", "label": "", "metadata": {}, "score": "35.70594"}
{"text": "Several studies showed that the dTT or the ecarin chromogenic assay ( ECA ) highly correlates with dabigatran plasma concentrations measured by LC - MS / MS in patient 's plasma [ 102 - 104 ] .", "label": "", "metadata": {}, "score": "35.70647"}
{"text": "Rivaroxaban possesses good bioavailability and requires concomitant strong inhibition of intestinal wall p - gp and liver CYP3A4 by drugs like ketoconazole or ritonavir for a clinically significant increase in blood concentrations [ 19 ] .", "label": "", "metadata": {}, "score": "35.724144"}
{"text": "Special Populations : Hepatic Function Impairment .Significant increases in rivaroxaban exposure were observed in subjects with moderate hepatic impairment ( Child - Pugh class B ) .", "label": "", "metadata": {}, "score": "35.889877"}
{"text": "Likewise , the efficacy of rivaroxaban was similar both in patients presenting with a first episode of VTE and in those with a history of one or more episodes of VTE .", "label": "", "metadata": {}, "score": "36.316475"}
{"text": "Clinical outcomes in postoperative thromboprophylaxis trials were also not affected by weight ( up to 190 kg ) ( Turpie 2011 ) .Therefore , dosage adjustment is not required .", "label": "", "metadata": {}, "score": "36.322083"}
{"text": "Patients .Patients were potentially eligible if they had symptomatic DVT and/or PE .Treatment regimens .Identical rivaroxaban and standard - therapy regimens were evaluated in both trials .", "label": "", "metadata": {}, "score": "36.938316"}
{"text": "Pooled Data from Clinical Trials .Pooled analyses of the data from the RECORD trials have demonstrated similar findings of increased efficacy of rivaroxaban at all time intervals [ 29 , 30 ] .", "label": "", "metadata": {}, "score": "36.940468"}
{"text": "Trial registration .Keywords .Rivaroxaban Standard therapy Venous thromboembolism Randomized controlled trials .Electronic supplementary material .The online version of this article ( doi : 10 .", "label": "", "metadata": {}, "score": "36.950714"}
{"text": "Most recently , Steinberg et al .looked into the effect of aspirin therapy with concurrent anticoagulation .They found that major bleeding and bleeding hospitalizations were significantly higher in patients on both oral anticoagulation and aspirin than those patients on oral anticoagulation alone [ 68 ] .", "label": "", "metadata": {}, "score": "36.998566"}
{"text": "The effects on coagulation activation will also be studied after a single dose of dabigatran , rivaroxaban or ticagrelor and at a therapeutic INR of phenprocoumon .", "label": "", "metadata": {}, "score": "37.101265"}
{"text": "The mean time during which the INR was in the therapeutic range was calculated after the discontinuation of enoxaparin , with correction for interruptions in the administration of VKAs or the use of concomitant heparins .", "label": "", "metadata": {}, "score": "37.232544"}
{"text": "The mean time during which the INR was in the therapeutic range was calculated after the discontinuation of enoxaparin , with correction for interruptions in the administration of VKAs or the use of concomitant heparins .", "label": "", "metadata": {}, "score": "37.232544"}
{"text": "There were no differences in adverse events between the two arms .In subgroup analyses , the net clinical benefit ( composite of the primary outcome and major bleeding ) in patients with active cancer was 3.4 % with rivaroxaban and 5.4 % with LMWH / VKA , with a hazard ratio favoring rivaroxaban .", "label": "", "metadata": {}, "score": "37.506577"}
{"text": "The safety and efficacy of rivaroxaban has been assessed in two phase III trials each for patients undergoing THA and TKA [ 18 - 21 ] ( Table 1 ) .", "label": "", "metadata": {}, "score": "37.519577"}
{"text": "Monitor therapy .Anticoagulants : May enhance the anticoagulant effect of Rivaroxaban .Avoid combination .Antiplatelet Agents ( P2Y12Inhibitors ) : May enhance the adverse / toxic effect of Rivaroxaban .", "label": "", "metadata": {}, "score": "37.58664"}
{"text": "The use of antiplatelet drugs ( eg , nonsteroidal anti - inflammatory drugs , clopidogrel , prasugrel , ticagrelor ) with rivaroxaban should be carefully monitored for excess anticoagulation .", "label": "", "metadata": {}, "score": "37.593334"}
{"text": "Rivaroxaban is currently FDA approved for VTE prophylaxis with hip and knee arthroplasty .Phase III Clinical Trials .The phase III EINSTEIN - DVT trial [ 39 ] randomized patients with acute symptomatic proximal DVT to receive either rivaroxaban 15 mg daily for 3 weeks followed by 20 mg daily for 3 , 6 , or 12 months ( . , or LMWH followed by dose - adjusted VKA ( .", "label": "", "metadata": {}, "score": "37.618546"}
{"text": "Once - a - day dosing differentiates rivaroxaban from dabigatran and apixaban and may enhance patient acceptance and compliance with treatment .Not only are NOACs alternatives to VKAs for stroke prevention in patients with AF , but also they appear to hit the sweet spot of both improved efficacy and safety .", "label": "", "metadata": {}, "score": "37.626785"}
{"text": "In addition , chemotherapeutics , targeted agents , and medications used in supportive management all have the potential to interact with anticoagulants .The randomized CLOT trial [ 28 ] established the superiority of LMWH over vitamin K antagonists ( VKAs ) for reduction in the risk of recurrent cancer - associated VTE .", "label": "", "metadata": {}, "score": "37.634686"}
{"text": "In the dabigatran 110 mg group , .With rivaroxaban , .Table 4 : Relative risk reductions ( RRRs ) of efficacy outcome event rates versus VKA control groups .", "label": "", "metadata": {}, "score": "37.861755"}
{"text": "Although rivaroxaban is a substrate for both CYP3A4 and P - gp , the only reported drug interactions have been with drugs that affect both of these elimination pathways .", "label": "", "metadata": {}, "score": "37.888065"}
{"text": "According to the AHA / ACC / HRS , may consider dose reduction in patients with moderate - to - severe chronic kidney disease ( CKD ) , although safety and efficacy of this approach has not been established ( AHA / ACC / HRS [ January 2014 ] ) .", "label": "", "metadata": {}, "score": "38.02848"}
{"text": "Prins et al .patients and in 2.0 % ( 26 of 1327 ) of standard - therapy patients ( Table 2 ) .In patients with previous VTE , the net clinical benefit ( hazard ratio , 0.52 ; 95 % CI , 0.31 to 0.90 ) was statistically significantly more favorable in patients treated with rivaroxaban ( Table 2 ) .", "label": "", "metadata": {}, "score": "38.097755"}
{"text": "Nine percent of the 1196 patients treated had malignancy - associated VTE .Rivaroxaban was superior to placebo for prevention of recurrent VTE ( 1.3 % versus 7.1 % , HR 0.18 , .", "label": "", "metadata": {}, "score": "38.169804"}
{"text": "4 , pp .315 - 322 , 2012 .View at Google Scholar .K. A. Fox , J. P. Piccini , D. Wojdyla , et al . , \" Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non - valvular atrial fibrillation and moderate renal impairment , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "38.202805"}
{"text": "A further 43 and 40 patients in the rivaroxaban and enoxaparin / VKA groups , respectively , did not have confirmed DVT and PE .CI Confidence interval , DVT Deep vein thrombosis , HR Hazard ratio , PE Pulmonary embolism , VKA Vitamin K antagonist .", "label": "", "metadata": {}, "score": "38.336304"}
{"text": "A further 43 and 40 patients in the rivaroxaban and enoxaparin / VKA groups , respectively , did not have confirmed DVT and PE .CI Confidence interval , DVT Deep vein thrombosis , HR Hazard ratio , PE Pulmonary embolism , VKA Vitamin K antagonist .", "label": "", "metadata": {}, "score": "38.336304"}
{"text": "This study can provide information on haemostatic system activation in vivo during triple treatment with antithrombotic drugs , which is indicated for patients with AF and ACS .", "label": "", "metadata": {}, "score": "38.341232"}
{"text": "In fragile and nonfragile patients , the difference in recurrence rates be- tween the rivaroxaban and standard - therapy groups was not statistically significant ( Table 2 ) .", "label": "", "metadata": {}, "score": "38.609936"}
{"text": "In patients with cancer , the net clinical benefit ( hazard ratio , 0.60 ; 95 % CI , 0.36 to 0.99 ) was statistically significantly more favorable in rivaroxaban patients ( Table 2 ) .", "label": "", "metadata": {}, "score": "38.614456"}
{"text": "In animal models , rivaroxaban and apixaban are found in much lower concentrations in the brain compared to plasma [ 61 - 63 ] .P - gp , and possibly other yet to be identified cotransporters , may play a role in this ( rivaroxaban and apixaban , but not active dabigatran , are p - gp substrates )", "label": "", "metadata": {}, "score": "38.623512"}
{"text": "Prins et al .Rivaroxaban Enoxaparin / VKA No . at risk Rivaroxaban Enoxaparin / VKA No .a. Primary efficacy outcome , b. Principal safety outcome and c. Major bleeding .", "label": "", "metadata": {}, "score": "38.829994"}
{"text": "However , a distinction should be drawn between reversal of coagulation parameters and actual reduction of bleeding [ 41 ] .In another study of mice given supratherapeutic doses of dabigatran , PCC reduced both bleeding time and size of intracerebral haematoma [ 42 ] .", "label": "", "metadata": {}, "score": "38.877583"}
{"text": "In the same population , rising cystatin C levels were independently associated with increased rates of stroke or systemic embolism , mortality , and major bleeding .", "label": "", "metadata": {}, "score": "38.918316"}
{"text": "The EINSTEIN - DVT and EINSTEIN - PE studies were each designed to test the hypothesis that rivaroxaban would be noninferior to standard - therapy .", "label": "", "metadata": {}, "score": "38.940094"}
{"text": "A second similar study , EINSTEIN - PE ( NCT00439777 ) , is ongoing to evaluate the efficacy of rivaroxaban in patients with PE with or without DVT .", "label": "", "metadata": {}, "score": "39.30348"}
{"text": "Commonly available coagulation assays such as PT and aPTT time are not suitable for routine coagulation monitoring of the NOACs , but may provide qualitative information concerning the presence or absence of the drug , especially in the surgical setting .", "label": "", "metadata": {}, "score": "39.306225"}
{"text": "As in the RE - COVER study , the median age was around 55 years and most patients had normal renal function .The primary endpoint of noninferiority for recurrent VTE was reached with 2.1 % of patients in the experimental arm and 3 % of patients in the control arm experiencing recurrent VTE ( HR 0.68 , 95 % CI 0.44 - 1.04 , .", "label": "", "metadata": {}, "score": "39.489017"}
{"text": "Clinicians should note that the anticoagulant effect can not be easily monitored or readily reversed .Prompt clinical evaluation is warranted with any unexplained decrease in hemoglobin , hematocrit or blood pressure , or fetal distress .", "label": "", "metadata": {}, "score": "39.563007"}
{"text": "Rivaroxaban has superior efficacy compared to enoxaparin for the prevention of symptomatic VTE for patients undergoing THA and TKA .Although the patient compliance rate while taking rivaroxaban remains unknown , rivaroxaban is administered orally with fixed dosing and does not require monitoring which makes it attractive .", "label": "", "metadata": {}, "score": "39.633286"}
{"text": "1,4 These changes are similar in magnitude to those observed with drugs that inhibit rivaroxaban elimination .Patients stabilized on rivaroxaban should be monitored for altered response ( bleeding or loss of anticoagulant effect ) if CYP3A4 or P - gp inhibitors or inducers are added to or removed from their drug regimen .", "label": "", "metadata": {}, "score": "39.704178"}
{"text": "Methods : A prespecified pooled analysis of the EINSTEIN - DVT and EINSTEIN - PE studies compared the efficacy and safety of rivaroxaban ( 15 mg twice - daily for 21 days , followed by 20 mg once - daily ) with standard - therapy ( enoxaparin 1.0 mg / kg twice - daily and warfarin or acenocoumarol ) .", "label": "", "metadata": {}, "score": "39.75287"}
{"text": "This article is published under license to BioMed Central Ltd.Rivaroxaban : A New Oral Anticoagulant .Rivaroxaban ( Xarelto ) was recently approved as an oral anticoagulant ( direct inhibitor of factor Xa ) for prophylaxis of deep vein thrombosis and to reduce the risk of embolism in patients with atrial fibrillation .", "label": "", "metadata": {}, "score": "39.83953"}
{"text": "Drugs Aging 1999 , 14 : 303 - 312 .10.2165/00002512 - 199914040 - 00005 View Article PubMed .Bauersachs R , Lensing AWA , Pap A , Decousus H : No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism [ abstract].", "label": "", "metadata": {}, "score": "39.845833"}
{"text": "View at Publisher \u00b7 View at Google Scholar .B. I. Eriksson , L. C. Borris , R. J. Friedman et al . , \" Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "39.85369"}
{"text": "The 110 mg twice - daily dose was found to be noninferior to warfarin for stroke or systemic embolism but had lower rates of major bleeding .", "label": "", "metadata": {}, "score": "39.8574"}
{"text": "The bleeding events , including fatal ones , occurred up to several months after initiation of treatment .Some have been linked to use of dabigatran in elderly patients with severe renal impairment , a group that is known to have increased bleeding risk [ 59 ] .", "label": "", "metadata": {}, "score": "39.863255"}
{"text": "Methods .A prespecified pooled analysis of the EINSTEIN - DVT and EINSTEIN - PE studies compared the efficacy and safety of rivaroxaban ( 15 mg twice - daily for 21 days , followed by 20 mg once - daily ) with standard - therapy ( enoxaparin 1.0 mg / kg twice - daily and warfarin or acenocoumarol ) .", "label": "", "metadata": {}, "score": "40.005947"}
{"text": "Routine monitoring of coagulation tests not required ; in major clinical trials , monitoring of coagulation tests ( eg , aPTT , PT / INR , or antifactor Xa activity ) did not occur .", "label": "", "metadata": {}, "score": "40.121284"}
{"text": "The risk of bleeding should be weighed against the urgency of the procedure ; reinitiate rivaroxaban when adequate hemostasis has been achieved unless oral therapy can not be administered , then consider administration of a parenteral anticoagulant .", "label": "", "metadata": {}, "score": "40.146355"}
{"text": "J. Graff and S. Harder , \" Anticoagulant therapy with the oral direct factor Xa inhibitors rivaroxaban , apixaban and edoxaban and the thrombin inhibitor dabigatran etexilate in patients with hepatic impairment , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "40.185314"}
{"text": "9S-16S , 2009 .View at Google Scholar .J. Stangier , K. Rathgen , H. Sthle , and D. Mazur , \" Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate : an open - label , parallel - group , single - centre study , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "40.2041"}
{"text": "Management : Carefully weigh the prospective benefits of progestins against the potential increased risk of procoagulant effects and thromboembolism .Use is considered contraindicated under some circumstances .", "label": "", "metadata": {}, "score": "40.20503"}
{"text": "With data pooled from all 4 RECORD trials , rivaroxaban significantly reduced the rate of symptomatic VTE and death over the total study duration ( 0.81 % versus 1.63 % , . ; HR 0.42 , 95%CI 0.29 - 0.63 ) [ 29 , 30 ] .", "label": "", "metadata": {}, "score": "40.220078"}
{"text": "Bauersachs R , Lensing AWA , Pap A , Decousus H : No need for a rivaroxaban dose reduction in renally impaired patients with symptomatic venous thromboembolism [ abstract].", "label": "", "metadata": {}, "score": "40.2584"}
{"text": "12 , pp .1139 - 1151 , 2009 .View at Google Scholar .M. R. Patel , K. W. Mahaffey , J. Garg , et al . , \" Rivaroxaban versus warfarin in nonvalvular atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "40.520115"}
{"text": "14 , 2011 .View at Google Scholar .G. Lu , F. R. Deguzman , M. J. Karbarz , et al . , \" Reversal of rivaroxaban mediated anticoagulation in animal models by a recombinant antidote protein ( r - Antidote , PRT064445 ) , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "40.53979"}
{"text": "Two studies , EINSTEIN - DVT and EINSTEIN - PE , compared a single - drug approach using the oral , direct factor Xa inhibitor rivaroxaban with standard - therapy consisting of enoxaparin overlapping with and followed by a VKA for the treatment of DVT and/or PE [ 8 , 9 ] .", "label": "", "metadata": {}, "score": "40.544502"}
{"text": "240 - 248 , 2014 .View at Google Scholar .S. J. Francart , E. M. Hawes , A. M. Deal et al . , \" Performance of coagulation tests in patients on therapeutic doses of rivaroxaban .", "label": "", "metadata": {}, "score": "40.5472"}
{"text": "The combined incidence of major and clinically relevant non - major bleeding was 3.3 % in the rivaroxaban group and 2.7 % in the enoxaparin group , which was not statistically significant [ 20 ] .", "label": "", "metadata": {}, "score": "40.622276"}
{"text": "74 - 81 , 2009 .View at Google Scholar .R. Kreutz , \" Pharmacodynamic and pharmacokinetic basics of rivaroxaban , \" Fundamental & Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "40.635056"}
{"text": "Fusidic Acid ( Systemic ) : May increase the serum concentration of Rivaroxaban .Management : Consider alternatives to this combination when possible .Rivaroxaban dose adjustments may be required when used with systemic fusidic acid .", "label": "", "metadata": {}, "score": "40.65309"}
{"text": "B. A. Steinberg , S. Kim , J. P. Piccini , et al . , \" Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation : insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "40.672775"}
{"text": "Kubitza D , Becka M , Mueck W , et al .Effects of renal impairment on the pharmacokinetics , pharmacodynamics , and safety of rivaroxaban , an oral , direct Factor Xa inhibitor .", "label": "", "metadata": {}, "score": "40.768288"}
{"text": "Rivaroxaban is one of the new oral anticoagulants and is a direct factor Xa inhibitor that has demonstrated superior efficacy to that of enoxaparin .However , the data also suggest that rivaroxaban has an increased risk of bleeding compared to enoxaparin .", "label": "", "metadata": {}, "score": "40.79474"}
{"text": "View at Google Scholar .M. J. Gnoth , U. Buetehorn , U. Muenster , T. Schwarz , and S. Sandmann , \" In vitro and in vivo P - glycoprotein transport characteristics of rivaroxaban , \" Journal of Pharmacology and Experimental Therapeutics , vol .", "label": "", "metadata": {}, "score": "40.897305"}
{"text": "Recent trials of new oral anticoagulants ( NOACs ) have demonstrated efficacy for stroke prevention in AF and good safety profiles , without detectable hepatotoxicity signals [ 13 - 16 ] .", "label": "", "metadata": {}, "score": "41.05891"}
{"text": "The European Society of Anaesthesiology ( ESA ) [ 80 ] recommends extreme caution when using neuraxial blockade in the presence of rivaroxaban / apixaban .", "label": "", "metadata": {}, "score": "41.069683"}
{"text": "Two studies , EINSTEIN - DVT and EINSTEIN - PE , com- pared a single - drug approach using the oral , direct factor Xa inhibitor rivaroxaban with standard - therapy consisting of enoxaparin overlapping with and followed by a VKA for the treatment of DVT and/or PE [ 8,9].", "label": "", "metadata": {}, "score": "41.09597"}
{"text": "The effects on recurrent VTE and bleeding were consistent across the individual components that defined the fragile population ( Figure 3 ) .In fragile patients , the net clinical benefit ( hazard ratio , 0.51 ; 95 % CI , 0.34 to 0.77 ) was statistically significantly more favorable in rivaroxaban patients ( Table 2 ) .", "label": "", "metadata": {}, "score": "41.102203"}
{"text": "The RECORD 2 trial included 2,509 patients undergoing THA that were assigned to receive either rivaroxaban 10 mg daily for 31 - 39 days or enoxaparin 40 mg daily for 10 - 14 days .", "label": "", "metadata": {}, "score": "41.194553"}
{"text": "The New Oral Anticoagulants .Dabigatran , an oral direct thrombin inhibitor , and rivaroxaban and apixaban , both oral direct activated factor X inhibitors , exhibited favourable pharmacodynamics and predictable pharmacokinetic profiles in early phase trials , making them candidate alternatives to VKAs [ 22 - 25 ] .", "label": "", "metadata": {}, "score": "41.39302"}
{"text": "An analysis of major bleeding patients in the RE - LY study concludes that the overall resources required to manage bleeding were not greater than those after warfarin - related bleeding .", "label": "", "metadata": {}, "score": "41.46991"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Kubitza , M. Becka , W. Mueck et al . , \" Effects of renal impairment on the pharmacokinetics , pharmacodynamics and safety of rivaroxaban , an oral , direct Factor Xa inhibitor , \" British Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "41.49846"}
{"text": "CYP3A4 Inducers ( Moderate ) : May decrease the serum concentration of CYP3A4 Substrates .Monitor therapy .CYP3A4 Inducers ( Strong ) : May decrease the serum concentration of Rivaroxaban .", "label": "", "metadata": {}, "score": "41.503708"}
{"text": "Table 3 : Hazard ratios with 95 % CI for subgroup analyses for novel agents versus warfarin .Trial Summaries and Drug Descriptions .The RE - LY trial was an open label randomized trial , which studied dabigatran , a direct thrombin inhibitor .", "label": "", "metadata": {}, "score": "41.56015"}
{"text": "Although it is estimated that dabigatran concentration would increase about threefold in patients with moderate renal impairment compared to those with normal kidney function [ 46 ] , dabigatran dose was not stratified by CrCl in RE - LY .", "label": "", "metadata": {}, "score": "41.56468"}
{"text": "Bioavailability is between 80 and 100 % for 10 mg and around 66 % for 15 or 20 mg under fasting conditions .Rivaroxaban is bound to plasma proteins in more than 90 % , making hemodialysis ineffective to eliminate this drug .", "label": "", "metadata": {}, "score": "41.59113"}
{"text": "11 , pp .2168 - 2175 , 2011 .View at Google Scholar .B. I. Eriksson , L. C. Borris , O. E. Dahl et al . , \" A once - daily , oral , direct Factor Xa inhibitor , rivaroxaban ( BAY 59 - 7939 ) , for thromboprophylaxis after total hip replacement , \" Circulation , vol .", "label": "", "metadata": {}, "score": "41.63612"}
{"text": "Each of the novel agents was found to decrease hemorrhagic stroke in patients with a history of previous stroke or TIA .The novel agents should be considered in patients with previous stroke or TIA .", "label": "", "metadata": {}, "score": "41.65689"}
{"text": "To view content sources and attributions , please refer to our editorial policy .Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism - a pooled analysis of the EINSTEIN - DVT and PE randomized studies - Thrombosis Journal 2013 .", "label": "", "metadata": {}, "score": "41.70842"}
{"text": "Other drugs known to inhibit CYP3A4 and P - gp ( eg , itraconazole , amiodarone , conivaptan , cyclosporine , posaconazole , telaprevir , and verapamil ) would also be expected to interact with rivaroxaban and produce elevated rivaroxaban plasma concentrations and anticoagulant response .", "label": "", "metadata": {}, "score": "41.73395"}
{"text": "Hepatic impairment or liver disease with expected impact on survival is also a contraindication [ 33 , 34 ] .Rivaroxaban .Rivaroxaban is a selective and reversible oral direct FXa inhibitor .", "label": "", "metadata": {}, "score": "41.7508"}
{"text": "444 - 453 , 2011 .View at Publisher \u00b7 View at Google Scholar .N. G. Espada , R. G. Merino , and T. C. Gonz\u00e1lez , \" Dabigatran , Rivaroxaban and Apixaban versus Enoxaparin for thomboprophylaxis after total knee or hip arthroplasty : pool - analysis of phase III randomized clinical trials , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "41.755066"}
{"text": "All of these groups should probably require a longer interval of NOACs ' arrest , and a measurement of the anticoagulant residual activity should be considered before an invasive procedure .", "label": "", "metadata": {}, "score": "41.8258"}
{"text": "Their cessation is indisputable in most elective procedure , but the risk between thrombosis and bleeding should be balanced [ 12 ] .In some settings , the therapeutic window is bridged by low molecular weight heparin ( LMWH ) or unfractionated heparin ( UFH ) to prevent thromboembolic risk [ 13 , 14 ] .", "label": "", "metadata": {}, "score": "41.828487"}
{"text": "View at Publisher \u00b7 View at Google Scholar .R. Bauersachs , S. D. Berkowitz , B. Brenner , et al . , \" Oral rivaroxaban for symptomatic venous thromboembolism , \" New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "41.857304"}
{"text": "Thromb Haemost 2000 , 83 : 657 - 660 .PubMed .Prandoni P , Lensing AW , Buller HR , Carta M , Cogo A , Vigo M , Casara D , Ruol A , ten Cate JW : Comparison of subcutaneous low - molecular - weight heparin with intravenous standard heparin in proximal deep - vein thrombosis .", "label": "", "metadata": {}, "score": "41.86384"}
{"text": "2342 - 2352 , 2009 .View at Publisher \u00b7 View at Google Scholar .S. Schulman , D. Baanstra , H. Eriksson , et al . , \" Dabigatran versus placebo for extended maintenance therapy of venous thromboembolism , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "41.908047"}
{"text": "Moderate risk of falling in the elderly population should not be an absolute contraindication to anticoagulation [ 27 , 36 ] .Warfarin continues to be underused , particularly in the high - risk populations , despite the evidence that the benefit from reduction of thromboembolic events outweighs bleeding risk .", "label": "", "metadata": {}, "score": "41.948227"}
{"text": "An increasing number of patients on long - term treatment with NOACs are encountered in the perioperative setting and it is essential for physicians to be aware of the pharmacological properties of these drugs .", "label": "", "metadata": {}, "score": "41.98178"}
{"text": "In patients with extensive clots , recurrent VTE was found in 2.6 % ( 35 of 1364 ) of rivaroxaban patients and in 2.0 % ( 26 of 1327 ) of standard - therapy patients ( Table 2 ) .", "label": "", "metadata": {}, "score": "42.00419"}
{"text": "This resulted in nearly 120 days ' difference between median durations of study drug exposure and study followup .Consequently , ITT analysis that does not take into consideration protocol compliance may not be ideal for demonstration of noninferiority compared to VKAs .", "label": "", "metadata": {}, "score": "42.11128"}
{"text": "Among the 167 patients diagnosed with cancer during the study , recurrent VTE was diagnosed in 10 ( 11.9 % ) of 84 rivaroxaban patients and in 12 ( 14.5 % ) of 83 standard- therapy patients .", "label": "", "metadata": {}, "score": "42.224716"}
{"text": "The duration of treatment was 33 days on average in both groups .The primary efficacy outcome occurred in 1.1 % of patients in the rivaroxaban group and in 3.7 % of patients in the enoxaparin group ( . )", "label": "", "metadata": {}, "score": "42.456974"}
{"text": "Pharmacodynamics and Pharmacokinetics .Dabigatran inhibits thrombin directly , and potentially the various downstream actions of thrombin [ 26 ] .The highly selective direct inhibitors of factor Xa , rivaroxaban and apixaban , inhibit factor Xa activation of prothrombin to thrombin with limited effects outside the coagulation cascade [ 27 ] .", "label": "", "metadata": {}, "score": "42.560436"}
{"text": "It is important to note that the current guidelines on anticoagulation in the setting of stent placement were not available at the time these patients were followed .", "label": "", "metadata": {}, "score": "42.57586"}
{"text": "Gastrointestinal bleeds were increased with dabigatran 150 mg and rivaroxaban , but these did not translate into potentially lethal bleeds for both doses of dabigatran or fatal bleeding with rivaroxaban , the event rates of which were significantly reduced [ 14 , 21 ] .", "label": "", "metadata": {}, "score": "42.615105"}
{"text": "This review focuses on NOAs currently in development and their potential role in the management of malignancy - associated VTE in gastrointestinal cancer patients .The oral anticoagulants dabigatran etexilate , rivaroxaban , and apixaban will be discussed in this section .", "label": "", "metadata": {}, "score": "42.61884"}
{"text": "However , INR monitoring was intensive and required assessment at least once a month .The time patients spent in the target therapeutic range ( INR , 2.0 - 3.0 ) was in line with that achieved in contemporary studies [ 18 ] .", "label": "", "metadata": {}, "score": "42.72629"}
{"text": "Table 1 : Description of RECORD trials comparing rivaroxaban to enoxaparin for VTE prophylaxis in patients undergoing THA and TKA .The RECORD 1 trial included 4,541 patients undergoing THA that were assigned to received either rivaroxaban 10 mg daily or enoxaparin 40 mg daily , plus either a placebo tablet or injection .", "label": "", "metadata": {}, "score": "42.84085"}
{"text": "Therefore , strong inhibitors or inducers of P - gp may alter the absorption of DE [ 39 ] .Rivaroxaban and apixaban are metabolized by CYP3A4/5 and are both substrates for P - gp .", "label": "", "metadata": {}, "score": "42.85618"}
{"text": "But , for NOACs , the residual drug level that can be considered as safe is not known , except for dabigatran .A French group of experts called GIHP proposed the threshold of 30 ng / mL ( for dabigatran and rivaroxaban ) [ 88 ] .", "label": "", "metadata": {}, "score": "42.88764"}
{"text": "Reported subanalyses of ROCKET AF confirm the same for rivaroxaban with regard to INR control [ 14 ] , prior stroke status [ 56 ] , prior MI status [ 57 ] , and renal insufficiency [ 58 ] .", "label": "", "metadata": {}, "score": "42.907055"}
{"text": "The treatment of malignancy - associated VTE is associated with both benefits and complications .The inconvenience of daily injections and platelet monitoring required with LMWH , or frequent INR monitoring and dose adjustments that accompany VKA therapy , can adversely impact patient quality of life .", "label": "", "metadata": {}, "score": "43.060997"}
{"text": "Finally , gastrointestinal cancers tend to have a median age of onset between 65 - 75 years of age .Pharmacokinetic studies suggest 40 - 60 % increased exposure of dabigatran in older versus younger patients [ 33 ] , likely relating to age - related decline in renal function .", "label": "", "metadata": {}, "score": "43.19344"}
{"text": "52 - 61 , 2014 .View at Publisher \u00b7 View at Google Scholar .S. H. Hohnloser , Z. Hijazi , L. Thomas et al . , \" Efficacy of apixaban when compared with warfarin in relation to renal function in patients with atrial fibrillation : insights from the ARISTOTLE trial , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "43.199863"}
{"text": "The field of oral anticoagulation has evolved with the arrival of non - vitamin K antagonist oral anticoagulants ( NOACs ) including an anti - IIa agent ( dabigatran etexilate ) and anti - Xa agents ( rivaroxaban and apixaban ) .", "label": "", "metadata": {}, "score": "43.215134"}
{"text": "Agents with Antiplatelet Properties ( e.g. , P2Y12 inhibitors , NSAIDs , SSRIs , etc . ) : May enhance the anticoagulant effect of Rivaroxaban .", "label": "", "metadata": {}, "score": "43.264267"}
{"text": "Choosing the most appropriate antithrombotic regimen in this group is challenging , given the increased risk for bleeding related to both age and concomitant antiplatelet therapy .", "label": "", "metadata": {}, "score": "43.293106"}
{"text": "Thus , while patients on well - controlled warfarin are a lower priority regarding treatment with the new agents , they nevertheless would be expected to benefit .", "label": "", "metadata": {}, "score": "43.53873"}
{"text": "Given their shorter half - life , no heparin bridging during the interruption interval seems necessary , except for patients at high cardiovascular risk undergoing major surgery .", "label": "", "metadata": {}, "score": "43.578735"}
{"text": "Rivaroxaban Pharmacology .The bioavailability of rivaroxaban is dose dependent .2,3 It is reported to be about 80 % to 100 % for a 10-mg dose and about 66 % for a 20-mg dose .", "label": "", "metadata": {}, "score": "43.60138"}
{"text": "There is increasing evidence to support risk stratification with the use of biomarkers for myocardial injury , cardiovascular hemodynamic stress , renal dysfunction , coagulation , and inflammation .", "label": "", "metadata": {}, "score": "43.658295"}
{"text": "Consider therapy modification .Prostacyclin Analogues : May enhance the adverse / toxic effect of Anticoagulants .Specifically , the antiplatelet effects of these agents may lead to an increased risk of bleeding with the combination .", "label": "", "metadata": {}, "score": "43.701775"}
{"text": "This paper reviews the existing efficacy and safety data for the use of NOAs dabigatran etexilate , rivaroxaban , and apixaban and discusses the potential role of these agents in the management of gastrointestinal cancer - related VTE .", "label": "", "metadata": {}, "score": "43.859825"}
{"text": "Patients receiving rivaroxaban had a lower risk of hemorrhagic stroke and intracranial bleeding compared with warfarin .At baseline , ROCKET - AF had three times as many patients with CHADS2 scores 3 - 6 as RE - LY and ARISTOTLE , resulting in a higher overall risk for thromboembolic events .", "label": "", "metadata": {}, "score": "43.866505"}
{"text": "An important set of analyses addresses the question of whether the direct oral anticoagulants perform well against warfarin when there is good INR control .This is relevant since a substantial portion of patients currently on warfarin , particularly in anticoagulation clinics or in countries with systems in place to optimize warfarin use , have a \" time in therapeutic range \" of INR 2 - 3 over 65 to 70 % of the time .", "label": "", "metadata": {}, "score": "43.874836"}
{"text": "Baseline characteristics of the study populations in the trials are summarised in Table 3 .All three trials recruited sizable numbers of female , VKA na\u00efve , elderly , and renal - impaired patients .", "label": "", "metadata": {}, "score": "43.94908"}
{"text": "For the pooled analysis , the prespecified noninferiority margin was 1.75 [ 14 ] .The primary efficacy analysis was performed on an intention - to - treat basis with the use of a Cox proportional hazards model stratified according to the qualifying DVT or PE and the intended duration of treatment , with adjustment for the presence or absence of active cancer at baseline .", "label": "", "metadata": {}, "score": "43.97213"}
{"text": "Consider the benefits and risks before neuraxial intervention in patients who are anticoagulated or are to be anticoagulated for thromboprophylaxis .Warnings / Precautions .Concerns related to adverse effects : .", "label": "", "metadata": {}, "score": "43.994404"}
{"text": "As with LMWH , careful monitoring of renal function as well as assessment for bleeding would be necessary during the use of NOAs in these patients .", "label": "", "metadata": {}, "score": "44.05638"}
{"text": "b. Major bleeding .CI , Confidence interval ; HR , Hazard ratio ; VKA , Vitamin K antagonist .Prins et al .Discussion This prespecified pooled analysis of two large , random- ized studies evaluated the efficacy and safety of a single- drug approach with oral , fixed - dose rivaroxaban versus the combination of subcutaneous enoxaparin and INR- titrated VKA therapy in patients with acute symptomatic VTE .", "label": "", "metadata": {}, "score": "44.1246"}
{"text": "Prandoni P , Lensing AW , Buller HR , Carta M , Cogo A , Vigo M , Casara D , Ruol A , ten Cate JW : Comparison of subcutaneous low - molecular - weight heparin with intravenous standard heparin in proximal deep - vein thrombosis .", "label": "", "metadata": {}, "score": "44.234116"}
{"text": "4 , pp .412 - 421 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Kubitz , M. Becka , A. Roth , and W. Mueck , \" Dose - escalation study of the pharmacokinetics and pharmacodynamics of rivaroxaban in healthy elderly subjects , \" Current Medical Research and Opinion , vol .", "label": "", "metadata": {}, "score": "44.34809"}
{"text": "Inhibitors of CYP3A4 ( Strong ) and P - glycoprotein : May increase the serum concentration of Rivaroxaban .Exceptions : Clarithromycin .Avoid combination .", "label": "", "metadata": {}, "score": "44.390663"}
{"text": "5 , pp .703 - 712 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Kubitza , M. Becka , M. Zuehlsdorf , and W. Mueck , \" Body weight has limited influence on the safety , tolerability , pharmacokinetics , or pharmacodynamics of rivaroxaban ( BAY 59 - 7939 ) in healthy subjects , \" Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "44.431946"}
{"text": "6 , pp .1116 - 1127 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. M. Samama , J. L. Martinoli , L. LeFlem et al . , \" Assessment of laboratory assays to measure rivaroxaban - an oral , direct factor Xa inhibitor , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "44.43855"}
{"text": "Nonspecific pro - coagulants , such as nonactivated and activated prothrombin complex concentrate ( PCC ) and recombinant factor VIIa have been advocated for management of major bleeding or rapid reversal for emergency - invasive procedures [ 39 ] .", "label": "", "metadata": {}, "score": "44.456665"}
{"text": "Uninterrupted warfarin therapy with therapeutic anticoagulation has been shown to be associated with lower risk of periprocedural thromboembolic events after AF ablation and is increasingly being accepted as the preferred anticoagulation strategy [ 82 ] .", "label": "", "metadata": {}, "score": "44.461426"}
{"text": "9745 , pp .975 - 983 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. J. Hankey , M. R. Patel , S. R. Stevens , et al . , \" Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack : a subgroup analysis of ROCKET AF , \" The Lancet Neurology , vol .", "label": "", "metadata": {}, "score": "44.485226"}
{"text": "4 , pp .721 - 729 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. I. Eriksson , A. K. Kakkar , A. G. Turpie , et al . , \" Oral rivaroxaban for the prevention of symptomatic venous thromboembolism after elective hip and knee replacement , \" The Journal of Bone and Joint Surgery , vol .", "label": "", "metadata": {}, "score": "44.61834"}
{"text": "Major bleeding occurred in only 1 patient in each group .However , the rate of clinically relevant non - major bleeding occurred in 6.5 % of patients in the rivaroxaban group compared to 5.5 % of patients in the enoxaparin group [ 19 ] .", "label": "", "metadata": {}, "score": "44.62913"}
{"text": "N Engl J Med 2009 , 361:2342 - 2352 .Schulman S , Kearon C , Kakkar AK , Schellong S , Eriksson H , Baanstra D , Kvamme AM , Friedman J , Mismetti P , Goldhaber SZ : Extended use of dabigatran , warfarin , or placebo in venous thromboembolism .", "label": "", "metadata": {}, "score": "44.723736"}
{"text": "These analyses show that whether or not a patient is or has been on warfarin , one can expect the same advantages of the novel agents versus warfarin .", "label": "", "metadata": {}, "score": "44.72915"}
{"text": "Agnelli G , Buller HR , Cohen A , Curto M , Gallus AS , Johnson M , Porcari A , Raskob GE , Weitz JI , AMPLIFY - EXT Investigators : Apixaban for extended treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "44.736244"}
{"text": "This implies the necessity of an accurate anamnesis of the drugs taken by the patient to avoid overestimation of drug concentrations in plasma .In addition , for the accurate determination of dabigatran plasma concentrations below 50 ng / mL , the more sensitive liquid chromatography - mass spectrometry / mass spectrometry ( LC - MS / MS ) method is still required [ 102 , 104 ] .", "label": "", "metadata": {}, "score": "44.750298"}
{"text": "J Thromb Haemost 2011 , 9:1500 - 1507 .Erkens PM , Ten Cate H , Buller HR , Prins MH : Benchmark for time in therapeutic range in venous thromboembolism : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "44.768612"}
{"text": "884 - 890 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. G. Turpie , R. Kreutz , J. Llau , B. Norrving , and S. Haas , \" Management consensus guidance for the use of rivaroxaban - an oral , direct factor Xa inhibitor , \" Thrombosis & Haemostasis , vol .", "label": "", "metadata": {}, "score": "44.90976"}
{"text": "981 - 992 , 2011 .View at Google Scholar .M. R. Lassen , A. Gallus , G. E. Raskob , G. Pineo , D. Chen , and L. M. Ramirez , \" Apixaban versus enoxaparin for thromboprophylaxis after hip replacement , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "44.915836"}
{"text": "5 , pp .669 - 676 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. A. A. Fox , J. P. Piccini , D. Wojdyla et al . , \" Prevention of stroke and systemic embolism with rivaroxaban compared with warfarin in patients with non - valvular atrial fibrillation and moderate renal impairment , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "44.995865"}
{"text": "Awaiting future clinical trial data , it seems to be important to establish a hospital - wide policy for bleeding management in patients taking NOACs , in accordance to the available blood products and laboratory assays of each institution .", "label": "", "metadata": {}, "score": "44.9988"}
{"text": "For this high - risk patient population and particularly in those patients with upper gastrointestinal primary tumors , identification of novel , more effective treatment methods that minimize bleeding risk while preventing VTE recurrence are highly important .", "label": "", "metadata": {}, "score": "45.130177"}
{"text": "4 , pp .446 - 451 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .O. Grottke , J. van Ryn , H. M. Spronk , and R. Rossaint , \" Prothrombin complex concentrates and a specific antidote to dabigatran are effective ex - vivo in reversing the effects of dabigatran in an anticoagulation / liver trauma experimental model , \" Critical Care , vol .", "label": "", "metadata": {}, "score": "45.135185"}
{"text": "10.1056/NEJMoa0906598 View Article PubMed .Schulman S , Kearon C , Kakkar AK , Schellong S , Eriksson H , Baanstra D , Kvamme AM , Friedman J , Mismetti P , Goldhaber SZ : Extended use of dabigatran , warfarin , or placebo in venous thromboembolism .", "label": "", "metadata": {}, "score": "45.17797"}
{"text": "The study group responsible for these trials is the Regulation of Coagulation in Orthopedic Surgery to Prevent Deep Venous Thrombosis and Pulmonary Embolism ( RECORD ) .", "label": "", "metadata": {}, "score": "45.227306"}
{"text": "Treatment regimens Identical rivaroxaban and standard - therapy regimens were evaluated in both trials .Patients assigned to rivaroxaban were given 15 mg orally twice - daily for 21 days , followed by 20 mg once - daily .", "label": "", "metadata": {}, "score": "45.24359"}
{"text": "All other results for thrombosis and PE were classified as intermediate .Statistical analysis The EINSTEIN - DVT and EINSTEIN - PE studies were each designed to test the hypothesis that rivaroxaban Prins et al .", "label": "", "metadata": {}, "score": "45.335556"}
{"text": "However , major bleeding , the most worrying complication , was statistically significantly less frequent in patients treated with rivaroxaban .This re- duction was seen mainly in fatal and nonfatal critical- site bleeding , such as intracranial and retroperitoneal bleeding .", "label": "", "metadata": {}, "score": "45.344154"}
{"text": "9632 , pp .31 - 39 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Lassen , W. Ageno , L. C. Borris et al . , \" Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "45.345444"}
{"text": "Three new oral anticoagulants have been developed .Dabigatran is a direct factor IIa ( thrombin ) inhibitor .Rivaroxaban and apixaban both are direct factor Xa inhibitors .", "label": "", "metadata": {}, "score": "45.37854"}
{"text": "In addition to increased incidence of VTE seen in gastrointestinal cancers , therapies for these cancers may exacerbate bleeding risk and promote recurrent VTE .Gastrointestinal cancers are frequently treated with targeted / antiangiogenic therapy ( such as bevacizumab , sunitinib , or sorafenib ) and chemotherapeutics that commonly induce thrombocytopenia ( such as gemcitabine and carboplatin ) , all of which may increase bleeding risk with anticoagulation .", "label": "", "metadata": {}, "score": "45.391724"}
{"text": "143 - 149 , 2012 .View at Google Scholar . E. S. Eerenberg , P. W. Kamphuisen , M. K. Sijpkens , et al . , \" Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate : a randomized , placebo - controlled , crossover study in healthy subjects , \" Circulation , vol .", "label": "", "metadata": {}, "score": "45.42163"}
{"text": "10 , pp .1152 - 1160 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier , K. Rathgen , H. Sthle , and D. Mazur , \" Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate : an open - label , parallel - group , single - centre study , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "45.495117"}
{"text": "Acknowledgment .This paper was supported by Bayer HealthCare .References .R. G. Hart , L. A. Pearce , and M. I. Aguilar , \" Meta - analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "45.524025"}
{"text": "It may be appropriate to distinguish between dabigatran , which is predominantly renally cleared , and the factor Xa inhibitors which are one - quarter to one - third renally cleared .", "label": "", "metadata": {}, "score": "45.629333"}
{"text": "Loss of circulating proteins and albumins is frequently seen in the later stages of this syndrome , and , it could potentially affect the binding and levels of NOAs , which are variably protein bound ( rivaroxaban 95 % , dabigatran 35 % ) .", "label": "", "metadata": {}, "score": "45.758465"}
{"text": "Major and nonmajor clinically relevant bleeding rates with NOACs are acceptable compared to VKAs .There were significant reductions in intracranial bleeds observed for all the new drugs , the mechanism of which , including the role of membrane transport molecules such as p - gp at the blood - brain barrier , remains to be fully elucidated .", "label": "", "metadata": {}, "score": "45.87604"}
{"text": "14 , pp . 1573- 1579 , 2011 .View at Google Scholar . A. Godier , A. Miclot , B. Le Bonniec , et al . , \" Evaluation of prothrombin complex concentrate and recombinant activated factor VII to reverse rivaroxaban in a rabbit model , \" Anesthesiology , vol .", "label": "", "metadata": {}, "score": "45.889122"}
{"text": "26 , pp .2765 - 2775 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. K. Kakkar , B. Brenner , O. E. Dahl et al . , \" Extended duration rivaroxaban versus short - term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty : a double - blind , randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "45.899853"}
{"text": "6 , pp .652 - 660 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .V. Trkulja and R. Kolund\u017eic , \" Rivaroxaban vs dabigatran for thromboprophylaxis after joint - replacement surgery : exploratory indirect comparison based on metaanalysis of pivotal clinical trials , \" Croatian Medical Journal , vol .", "label": "", "metadata": {}, "score": "45.969154"}
{"text": "Pharmacokinetics of Rivaroxaban .The recommended dose of rivaroxaban is 10 mg daily for 10 to 35 days for VTE prophylaxis starting 6 - 10 hours after THA or TKA [ 24 ] .", "label": "", "metadata": {}, "score": "45.98905"}
{"text": "22 , pp .2374 - 2381 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Graff , N. Von Hentig , F. Misselwitz et al . , \" Effects of the oral , direct factor Xa inhibitor rivaroxaban on platelet - induced thrombin generation and prothrombinase activity , \" Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "46.003967"}
{"text": "22 , pp .2246 - 2253 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. C. Diener , S. J. Connolly , M. D. Ezekowitz et al . , \" Dabigatran compared with warfarin in patients with atrial fibrillation and previous transient ischaemic attack or stroke : a subgroup analysis of the RE - LY trial , \" The Lancet Neurology , vol .", "label": "", "metadata": {}, "score": "46.03778"}
{"text": "Agnelli G , Buller HR , Cohen A , Curto M , Gallus AS , Johnson M , Masiukiewicz U , Pak R , Thompson J , Raskob GE , Weitz JI , AMPLIFY Investigators : Oral apixaban for the treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "46.13751"}
{"text": "Agnelli G , Buller HR , Cohen A , Curto M , Gallus AS , Johnson M , Masiukiewicz U , Pak R , Thompson J , Raskob GE , Weitz JI , AMPLIFY Investigators : Oral apixaban for the treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "46.13751"}
{"text": "26 , pp .2776 - 2786 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. G. Turpie , M. R. Lassen , B. L. Davidson et al . , \" Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty ( RECORD4 ) : a randomised trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "46.19751"}
{"text": "Elderly patients with AF have very high risk of thromboembolic events and , given a consistent relative risk reduction with anticoagulation , are a population that has some of the largest benefits from anticoagulation .", "label": "", "metadata": {}, "score": "46.19912"}
{"text": "It is also eliminated by the kidneys , and reduced renal function will result in drug accumulation ; dose reductions are suggested in patients with renal dysfunction .", "label": "", "metadata": {}, "score": "46.201042"}
{"text": "The reports of increased bleeding in the postmarketing surveillance phase should be interpreted in context .While several hundred fatal events have occurred , it is impossible to interpret these data without information concerning the total number of patients treated with dabigatran as well as information concerning the expected event rates if these same patients had been treated with warfarin .", "label": "", "metadata": {}, "score": "46.218548"}
{"text": "Beyer - Westendorf et al .[14 ] had recently presented the first prospective data from a national registry that supported the concept of short - term interruption without heparin bridging .", "label": "", "metadata": {}, "score": "46.384285"}
{"text": "Rivaroxaban .Background .Rivaroxaban ( Xarelto , Janssen Pharmaceuticals , Titusville , NJ ) is an oral direct inhibitor of factor Xa with excellent bioavailability ( 80 - 100 % ) , rapid onset of action ( maximum inhibitory activity is reached within 1 - 4 hours ) , no significant dietary interactions [ 37 ] .", "label": "", "metadata": {}, "score": "46.407074"}
{"text": "569 - 574 , 2001 .View at Google Scholar \u00b7 View at Scopus .J. L. Mega , E. Braunwald , S. D. Wiviott , et al . , \" Rivaroxaban in patients with a recent acute coronary syndrome , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "46.476315"}
{"text": "10 , pp .795 - 804 , 2011 .View at Publisher \u00b7 View at Google Scholar . A. G. Turpie , M. R. Lassen , A. K. Kakkar et al . , \" Pooled analysis of four studies of rivaroxaban : effect on symptomatic events and bleeding and the influence of clinically relevant patient subgroups , \" Chest , vol .", "label": "", "metadata": {}, "score": "46.497604"}
{"text": "9676 , pp .1673 - 1680 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. V. Huisman , D. J. Quinlan , O. E. Dahl , and S. Schulman , \" Enoxaparin versus Dabigatran or rivaroxaban for thromboprophylaxis after hip or knee arthroplasty : results of separate pooled analyses of phase III multicenter randomized trials , \" Circulation , vol .", "label": "", "metadata": {}, "score": "46.53324"}
{"text": "10 , pp .2757 - 2765 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Bauersachs , S. D. Berkowitz , B. Brenner et al . , \" Oral rivaroxaban for symptomatic venous thromboembolism , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "46.556915"}
{"text": "1206 - 1214 , 2013 .View at Google Scholar . A. Avezum , R. D. Lopes , P. J. Schulte et al . , \" Apixaban versus warfarin in patients with atrial fibrillation and valvular heart disease : findings from the ARISTOTLE study , \" European Heart Journal , vol .", "label": "", "metadata": {}, "score": "46.565178"}
{"text": "The results of the RE - LY study were confirmed in the ARISTOTLE biomarker study , showing improvement in risk stratification for overall stroke , as well as for ischemic and for hemorrhagic subtypes , with the addition of NT - proBNP to clinical risk assessment tools [ 18 ] .", "label": "", "metadata": {}, "score": "46.571526"}
{"text": "A significant association between baseline D - dimer levels and risk of stroke , cardiovascular death , and major bleeding was seen in the RE - LY biomarker study and confirmed in the larger ARISTOTLE data set [ 17 , 18 ] .", "label": "", "metadata": {}, "score": "46.60152"}
{"text": "9 - 19 , 2012 .View at Google Scholar .K. Uchino and A. V. Hernandez , \" Dabigatran association with higher risk of acute coronary events : meta - analysis of noninferiority randomized controlled trials , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "46.642868"}
{"text": "There was a linear relation between anticoagulant activity of dabigatran and its plasma levels .These results support hemodialysis as a suitable approach to eliminate dabigatran in emergency situations [ 92 ] .", "label": "", "metadata": {}, "score": "46.646263"}
{"text": "For nonvalvular atrial fibrillation , administer with the evening meal .Missed doses : Patients receiving 15 mg twice daily dosing who miss a dose should take a dose immediately to ensure 30 mg of rivaroxaban is administered per day ( two 15 mg tablets may be taken together ) ; resume therapy the following day as previously taken .", "label": "", "metadata": {}, "score": "46.64823"}
{"text": "Consider therapy modification .Dasatinib : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Deferasirox : May decrease the serum concentration of CYP3A4 Substrates .", "label": "", "metadata": {}, "score": "46.672134"}
{"text": "71 - 74 , 2012 .View at Google Scholar .R. A. Moore , N. Adel , E. Riedel et al . , \" High incidence of thromboembolic events in patients treated with cisplatin - based chemotherapy : a large retrospective analysis , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "46.737698"}
{"text": "Once again , in the postoperative period , the bleeding risk must be weighted with the thromboembolic risk ; however the risk for major bleeding exceeds the risk for thromboembolic complications after surgery [ 118 ] .", "label": "", "metadata": {}, "score": "46.784534"}
{"text": "However , a different type of bias is introduced because on - treatment analysis may not preserve the integrity of the randomised comparison .Thus , the validity of the on - treatment analysis shall require that subjects excluded from the analysis in both arms of the trial be , at the minimum , balanced in terms of their withdrawal rates , reasons for withdrawal , and baseline characteristics .", "label": "", "metadata": {}, "score": "46.850563"}
{"text": "In this group , major bleeding occurred in three ( 3.6 % ) and six ( 7.3 % ) patients , respectively .Of the 16 events in the rivaroxaban group , 13 occurred while patients were still on assigned treatment ; the corresponding numbers in the standard - therapy group were 20 and 16 events .", "label": "", "metadata": {}, "score": "46.866222"}
{"text": "764 - 772 , 2014 .View at Publisher \u00b7 View at Google Scholar .C. B. Granger , J. H. Alexander , J. J. McMurray , et al . , \" Apixaban versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "46.885845"}
{"text": "( Table 4 ) improves the predictive value for thromboembolism .Only a small proportion of patients belong to the low risk and intermediate risk categories [ 46 , 48 ] .", "label": "", "metadata": {}, "score": "46.89691"}
{"text": "This guarded against drug overexposure in subjects with advanced age and low body weight , as age , body weight , gender , and serum creatinine value were incorporated into the equation [ 45 ] .", "label": "", "metadata": {}, "score": "46.92417"}
{"text": "However , the bleeding risk with rivaroxaban after THA and TKA is not fully understood .Pooled data from the phase III clinical trials indicate that patients taking rivaroxaban experience more bleeding complications than those patients taking Lovenox .", "label": "", "metadata": {}, "score": "46.930008"}
{"text": "Finally , the RE - LY biomarker study showed an independent association between IL-6 and stroke or systemic embolism , while CRP levels were associated with cardiovascular mortality after multivariate adjustments [ 17 ] .", "label": "", "metadata": {}, "score": "46.935402"}
{"text": "During the first 2 days of concomitant therapy , usual doses of warfarin may be given without INR testing .Thereafter , while on concomitant therapy , measure INR daily just prior to the next scheduled rivaroxaban dose , as appropriate .", "label": "", "metadata": {}, "score": "46.96974"}
{"text": "It is validated for predicting AF - related thromboembolic risk events and helps for the optimal selection of VKAs and NOACs therapies [ 46 , 47 ] .", "label": "", "metadata": {}, "score": "47.010967"}
{"text": "Data are insufficient to evaluate the safety of oral factor Xa inhibitors during pregnancy ; use during pregnancy should be avoided ( Guyatt 2012 ) .", "label": "", "metadata": {}, "score": "47.061054"}
{"text": "These patients have frequently undergone prior surgeries which may alter the anatomy of the gastrointestinal tract or may have chemotherapy - related gastrointestinal toxicity , both of which can potentially affect the absorption of medications .", "label": "", "metadata": {}, "score": "47.07774"}
{"text": "Laboratory Testing for NOACs in a Perioperative Setting .NOACs do not require routine coagulation monitoring .This point is considered as an advantage for the physicians and an improvement of quality of life for their patients .", "label": "", "metadata": {}, "score": "47.10443"}
{"text": "Similar findings with cystatin C were identified in the RE - LY biomarker study [ 20 ] .While cystatin C had improved risk stratification for stroke , GFR was a better predictor of bleeding , so both markers have the potential to improve risk prediction in patients with AF .", "label": "", "metadata": {}, "score": "47.126556"}
{"text": "RE - MOBILIZE Writing Committee , J. S. Ginsberg , B. L. Davidson et al . , \" Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery , \" Journal of Arthroplasty , vol .", "label": "", "metadata": {}, "score": "47.184635"}
{"text": "Follow - up and outcome assessment .Both studies used the same protocol to ascertain outcomes .Patients were followed for the intended treatment period and assessed at fixed intervals that were identical in the two treatment groups [ 8 , 9 ] .", "label": "", "metadata": {}, "score": "47.261948"}
{"text": "11 , pp .2178 - 2185 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. I. Eriksson , O. E. Dahl , M. H. Huo et al . , \" Oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty ( RE - NOVATE II ) : a randomised , double - blind , non - inferiority trial , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "47.266037"}
{"text": "As the risk of stroke increases , the rate of anticoagulation use is not different or decreases .This may be due to concerns of providers , regarding the risk of bleeding and the risk - benefit tradeoff of treatment for higher - risk populations .", "label": "", "metadata": {}, "score": "47.35116"}
{"text": "Avoid combination .Aspirin : May enhance the adverse / toxic effect of Rivaroxaban .Specifically , the risk of bleeding may be increased .Management : Carefully consider risks and benefits of this combination and monitor closely .", "label": "", "metadata": {}, "score": "47.37195"}
{"text": "The aim of the study is to document and increase the rates of appropriate use of oral anticoagulation and patient adherence to and persistence with the treatment plans .", "label": "", "metadata": {}, "score": "47.398613"}
{"text": "For the Venous Side .The RIETE score ( Registro Informatizado de Enfermedad Tromboemb\u00f3lica ) assesses the risk of fatal bleeding in VTE patients and seems better in predicting gastrointestinal than intracranial fatal bleeding [ 59 ] .", "label": "", "metadata": {}, "score": "47.401104"}
{"text": "6 , pp .1263 - 1271 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .K. H. Liesenfeld , T. Lehr , C. Dansirikul , et al . , \" Population pharmacokinetic analysis of the oral thrombin inhibitor dabigatran etexilate in patients with non - valvular atrial fibrillation from the RE - LY trial , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "47.40138"}
{"text": "View Article .Schulman S , Kearon C , Kakkar AK , Mismetti P , Schellong S , Eriksson H , Baanstra D , Schnee J , Goldhaber SZ , for the RE - COVER Study Group : Dabigatran versus warfarin in the treatment of acute venous thromboembolism .", "label": "", "metadata": {}, "score": "47.40681"}
{"text": "The most robust result in a noninferiority trial would be to demonstrate consistency of the on - treatment and intention - to - treat analyses , but this is not always achievable in practice [ 7 - 9 , 13 ] .", "label": "", "metadata": {}, "score": "47.41552"}
{"text": "Ibrutinib : May enhance the adverse / toxic effect of Anticoagulants .Monitor therapy .Inhibitors of CYP3A4 ( Moderate ) and P - glycoprotein : May increase the serum concentration of Rivaroxaban .", "label": "", "metadata": {}, "score": "47.436256"}
{"text": "Guidelines recommend VKAs for higher risk AF patients on the basis of estimated efficacy benefits versus the bleeding risk with treatment [ 71 , 72 ] .", "label": "", "metadata": {}, "score": "47.575737"}
{"text": "15 , pp .1729 - 1735 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Van Ryn , J. Stangier , S. Haertter et al . , \" Dabigatran etexilate - a novel , reversible , oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "47.600365"}
{"text": "15 , pp .625 - 651 , 2013 .View at Publisher \u00b7 View at Google Scholar .J. D. Douketis , \" Perioperative anticoagulation management in patients who are receiving oral anticoagulant therapy : a practical guide for clinicians , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "47.63332"}
{"text": "Of note , the NOACs caused significantly less intracranial haemorrhagic events compared to VKAs , the mechanisms of which are not completely clear .With convenient fixed - dose administration , the NOACs facilitate anticoagulant management in AF in the community , which has hitherto been grossly underutilised .", "label": "", "metadata": {}, "score": "47.642292"}
{"text": "Patients assigned to standard - therapy received enoxaparin subcutaneously at a dose of 1.0 mg / kg body weight twice - daily and either oral warfarin or acenocoumarol ( international normalized ratio ( INR ) , 2.0 - 3.0 ) , started within 48 hours after randomization .", "label": "", "metadata": {}, "score": "47.67002"}
{"text": "NOACs indications vary among countries .Rivaroxaban is also approved in Europe for secondary prevention of atherothrombotic events after acute coronary syndrome ( ACS ) with elevated cardiac biomarkers [ 2 - 7 ] .", "label": "", "metadata": {}, "score": "47.68026"}
{"text": "Some workgroups propose algorithms based on NOAC 's plasma concentration , but their quantitative measurements are not currently routinely performed [ 88 ] .In case of bleeding that does not respond to supportive measures ( surgical hemostasis , embolization , fluid replacement , etc . ) in patients taking DE , ensure adequate diuresis and suggest hemodialysis .", "label": "", "metadata": {}, "score": "47.681366"}
{"text": "10.1056/NEJMoa1302507 View Article PubMed .Hutten BA , Lensing AW , Kraaijenhagen RA , Prins MH : Safety of treatment with oral anticoagulants in the elderly .", "label": "", "metadata": {}, "score": "47.74952"}
{"text": "Drug Interactions : Pharmacodynamic .As with any anticoagulant , the combination of 2 or more anticoagulants is likely to produce an increase in response .", "label": "", "metadata": {}, "score": "47.759407"}
{"text": "Despite their efficacy for preventing stroke in patients with AF , VKAs are grossly underused , especially in the elderly : a population with rapidly increasing AF prevalence [ 70 ] that actually stands to benefit the most from VKA treatment .", "label": "", "metadata": {}, "score": "47.791725"}
{"text": "Bosentan : May decrease the serum concentration of CYP3A4 Substrates .Monitor therapy .Clarithromycin : May increase the serum concentration of Rivaroxaban .Management : In patients with impaired renal function , clarithromycin should not be used unless the potential benefits outweigh the potential risks .", "label": "", "metadata": {}, "score": "47.795036"}
{"text": "9717 , pp .807 - 815 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Lassen , A. Gallus , G. E. Raskob , G. Pineo , D. Chen , and L. M. Ramirez , \" Apixaban versus enoxaparin for thromboprophylaxis after hip replacement , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "47.82612"}
{"text": "Due to these observations , the RE - LY trial design required that 50 % of the patients were VKA - na\u00efve .However , the treatment effect of dabigatran did not differ according to prior VKA use .", "label": "", "metadata": {}, "score": "47.906345"}
{"text": "In these patients ( provided life expectancy is reasonable ) , extended anticoagulation is generally recommended over short - course ( i.e. , 3 months ) therapy for VTE due to the high risk of recurrent VTE when anticoagulation is discontinued .", "label": "", "metadata": {}, "score": "47.916927"}
{"text": "Rifampin , a CYP3A4 and P - gp inducer , decreases the AUC of rivaroxaban by about 50 % .Doses of rivaroxaban will likely require an increase during concurrent rifampin administration .", "label": "", "metadata": {}, "score": "47.91986"}
{"text": "2499 - 2510 , 2010 .View at Google Scholar .S. Schulman , A. K. Kakkar , S. Z. Goldhaber , et al . , \" Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis , \" Circulation , vol .", "label": "", "metadata": {}, "score": "48.060123"}
{"text": "26 , pp .2487 - 2498 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. I. Eriksson , O. E. Dahl , N. Rosencher et al . , \" Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement : the RE - MODEL randomized trial , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "48.08236"}
{"text": "Patients with Prior Coronary Disease .Patients with prior coronary disease appear to have consistent treatment effects with the new drugs versus warfarin for both efficacy and safety .", "label": "", "metadata": {}, "score": "48.089283"}
{"text": "10.1056/NEJMoa1113697 View Article PubMed .Agnelli G , Buller HR , Cohen A , Curto M , Gallus AS , Johnson M , Porcari A , Raskob GE , Weitz JI , AMPLIFY - EXT Investigators : Apixaban for extended treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "48.110573"}
{"text": "94 - 102 , 2012 .View at Google Scholar .W. Zhou , S. Schwarting , S. Illanes , et al . , \" Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran , \" Stroke , vol .", "label": "", "metadata": {}, "score": "48.14633"}
{"text": "In addition , their perioperative management is challenging , especially with the absence of specific antidotes .Effectively , periods of interruption before surgery or invasive procedures depend on half - life and keeping a permanent balance between bleeding and thromboembolic risks .", "label": "", "metadata": {}, "score": "48.20188"}
{"text": "Extent of deep - vein thrombosis and pulmonary embolism at study entry .Among patients with limited thrombosis , recurrent VTE occurred in 10 ( 1.3 % ) of 799 rivaroxaban patients compared with 19 ( 2.3 % ) of 815 standard - therapy patients .", "label": "", "metadata": {}, "score": "48.247574"}
{"text": "There was no difference in major bleeding ( 1.6 % versus 1.9 % for experimental and control arms ) or treatment - related death .More patients treated with dabigatran experienced adverse events leading to drug discontinuation ( 9 % versus 6.8 % ) , but dyspepsia was the only adverse event observed more frequently with dabigatran ( 2.9 % versus 0.6 % ) .", "label": "", "metadata": {}, "score": "48.26108"}
{"text": "4 , pp .815 - 825 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. C. Barrett , Z. Wang , C. Frost , and A. Shenker , \" Clinical laboratory measurement of direct factor Xa inhibitors : anti - Xa assay is preferable to prothrombin time assay , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "48.31996"}
{"text": "The best method is to compare drugs in large - scale head - to - head randomised trials , but this is unlikely to happen soon .", "label": "", "metadata": {}, "score": "48.322655"}
{"text": "9717 , pp .807 - 815 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. I. Eriksson , O. E. Dahl , N. Rosencher et al . , \" Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement : the RE - MODEL randomized trial , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "48.32953"}
{"text": "However , this combination failed to prevent vascular events compared to standard VKA treatment [ 7 ] .The stroke prevention using oral thrombin inhibitor in atrial fibrillation ( SPORTIF AF ) trials , which compared fixed - dose direct thrombin inhibitor ximelagatran with an optimally dose adjusted VKA , provided the first clinical support for the feasibility of chronic anticoagulation without INR monitoring [ 8 - 10 ] .", "label": "", "metadata": {}, "score": "48.36873"}
{"text": "Unlike vitamin K antagonists ( VKAs ) , the new oral anticoagulants ( NOACs)-direct thrombin inhibitor , dabigatran , and direct activated factor X inhibitors , rivaroxaban , and apixaban - do not require routine INR monitoring .", "label": "", "metadata": {}, "score": "48.372597"}
{"text": "10 , supplement 1 , abstract A1.E2 , 2010 .View at Google Scholar .M. D. Ezekowitz , L. Wallentin , S. J. Connolly et al . , \" Dabigatran and warfarin in vitamin K antagonist - naive and -experienced cohorts with atrial fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "48.4335"}
{"text": "NOACs are at least equal to VKAs for stroke prevention in AF .Dabigatran 150 mg twice daily and apixaban showed superiority on ITT analyses , the acknowledged gold standard for assessing superiority , while rivaroxaban has superior efficacy based on on - treatment analysis .", "label": "", "metadata": {}, "score": "48.43862"}
{"text": "146 - 153 , 2003 .View at Google Scholar .G. Meyer , Z. Marjanovic , J. Valcke et al . , \" Comparison of low - molecular - weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer : a randomized controlled study , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "48.46138"}
{"text": "Given the increase in comorbidities , this population had a higher stroke risk based on CHADS2 and CHA2DS2-VASc scores , as well as increased bleeding risk based on the ATRIA bleeding score .", "label": "", "metadata": {}, "score": "48.464943"}
{"text": "Patients taking medications affecting the CYP3A4 pathway ( ketoconazole , clarithromycin , erythromycin , rifampin , and protease inhibitors ) were excluded from the ROCKET - AF trial due to potential drug - drug interactions [ 37 ] .", "label": "", "metadata": {}, "score": "48.494335"}
{"text": "a .Primary efficacy .b .Major bleeding .CI , Confidence interval ; HR , Hazard ratio ; VKA , Vitamin K antagonist .", "label": "", "metadata": {}, "score": "48.510307"}
{"text": "Further , the endogenous thrombin potential ( ETP ) , inhibition of factor Xa activity , activated partial thromboplastin time ( aPTT ) , prothrombin time ( PT ) , Biophen \u00ae and Hemoclot \u00ae will be assessed in venous blood .", "label": "", "metadata": {}, "score": "48.546173"}
{"text": "Based on these results , they concluded on a safety profile of DE [ 94 ] .There is currently no specific hemostatic agent for the reversal of NOACs in case of bleeding or in emergency situations but different antidotes are under development .", "label": "", "metadata": {}, "score": "48.579983"}
{"text": "The interpretation of the results requires education of the front staff in many specialties [ 98 ] .Finally , it has been clearly shown that NOACs influence the results of different coagulation assays used in the perioperative setting leading to misinterpretations [ 41 ] ( Table 11 ) .", "label": "", "metadata": {}, "score": "48.60314"}
{"text": "Patients undergoing TKA are at higher risk for developing DVT ; however , the rate of symptomatic DVT is higher after THA [ 1 , 3 , 4 ] .", "label": "", "metadata": {}, "score": "48.703506"}
{"text": "The last group proposes to stop NOACs 5 days before a surgery with medium or high risk of bleeding , to ensure a complete elimination of the drug in all patients .", "label": "", "metadata": {}, "score": "48.71499"}
{"text": "The prespecified noninferiority margin was 1.75 .Results .A total of 8282 patients were enrolled ; 4151 received rivaroxaban and 4131 received standard - therapy .", "label": "", "metadata": {}, "score": "48.71557"}
{"text": "Conversion to other anticoagulants ( other than warfarin ) : Discontinue rivaroxaban and initiate the anticoagulant at the time the next dose of rivaroxaban would have been taken .", "label": "", "metadata": {}, "score": "48.727444"}
{"text": "27 - 32 , 2012 .View at Google Scholar Abstract .Background .Standard treatment for venous thromboembolism ( VTE ) consists of a heparin combined with vitamin K antagonists .", "label": "", "metadata": {}, "score": "48.75631"}
{"text": "When higher doses are used ( eg , 20 mg once daily ) , some suggest avoidance of neuraxial procedures for at least 48 hours ( Rosencher 2013 ) .", "label": "", "metadata": {}, "score": "48.791763"}
{"text": "Patients are less compliant with administration of these drugs due to these barriers .One study reported only 75 % continued the medication after discharge [ 9 ] .", "label": "", "metadata": {}, "score": "48.81503"}
{"text": "21 , 2011 .View at Google Scholar .J. van Ryn , T. Litzenburger , A. Waterman , et al . , \" Dabigatran anticoagulant activity is neutralized by an antibody selective to dabigatran in in vitro and in vivo models , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "48.88822"}
{"text": "Pooling the results of EINSTEIN - DVT and EINSTEIN - PE enabled us to derive clinically relevant results for important subgroups of patients .Large clots and a history of ( multiple episodes of ) VTE are conditions that are of special concern to clinicians .", "label": "", "metadata": {}, "score": "48.928375"}
{"text": "543 - 549 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Douxfils , A. Tamigniau , B. Chatelain , et al . , \" Comparison of calibrated chromogenic anti - Xa assay and PT tests with LC - MS / MS for the therapeutic monitoring of patients treated with rivaroxaban , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "48.933125"}
{"text": "These oral anticoagulants have been approved by the Federal Drug Administration for stroke prevention in patients with AF .In this review , we will focus on a summary of trial results , drug pharmacokinetics and pharmacodynamics , and considerations in high - risk patient populations ( Tables 1 , 2 , and 3 ) [ 37 ] .", "label": "", "metadata": {}, "score": "48.934032"}
{"text": "For patients at low risk for thromboembolism , they suggest no bridging in case of stopping [ 60 , 71 ] .Patients classified as being at high risk have more than 10 % annual risk for thromboembolism while this risk is reduced to less than 5 % for those classified as being at low risk [ 60 ] .", "label": "", "metadata": {}, "score": "48.95034"}
{"text": "2325- 2332 , 2013 .View at Google Scholar .G. Lu , F. R. Deguzman , S. J. Hollenbach et al . , \" A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa , \" Nature Medicine , vol .", "label": "", "metadata": {}, "score": "48.963783"}
{"text": "Fragile patients .Rates of recurrent VTE were higher in fragile patients than in nonfragile patients ( rivaroxaban 2.7 % vs. 1.9 % ; standard - therapy 3.8 % vs. 1.9 % , respectively ) .", "label": "", "metadata": {}, "score": "49.01095"}
{"text": "SD Standard deviation , VKA Vitamin K antagonist , VTE Venous thromboembolism .Treatment and follow - up .The mean duration of study treatment was similar in both treatment arms overall ( 207.6 \u00b1 95.9 days in the rivaroxaban group and 204.0 \u00b1 97.2 days in the standard - therapy group in the intention - to - treat population ) and in prespecified patient subgroups ( Table 2 ) .", "label": "", "metadata": {}, "score": "49.024223"}
{"text": "The usefulness of dialysis in the setting of overdose or bleeding has been reported in anecdotal cases but has yet to be systematically and rigorously studied .", "label": "", "metadata": {}, "score": "49.049408"}
{"text": "5 , pp .634 - 640 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. Bahit , R. D. Lopes , D. M. Wojdyla et al . , \" Apixaban in patients with atrial fibrillation and prior coronary disease : insights from the ARISTOTLE trial , \" International Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "49.064144"}
{"text": "Additionally , a substantial portion of the aspirin - treated population had no clear reason ( such as vascular disease ) to be on the aspirin .", "label": "", "metadata": {}, "score": "49.12911"}
{"text": "163 - 174 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier , K. Rathgen , H. St\u00e4hle , D. Gansser , and W. Roth , \" The pharmacokinetics , pharmacodynamics and tolerability of dabigatran etexilate , a new oral direct thrombin inhibitor , in healthy male subjects , \" British Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "49.219368"}
{"text": "Both trials are ongoing .Discussion .The ease of administration , lack of required monitoring or dose - adjustments , and minimal food interactions make NOAs attractive agents for the treatment of VTE in the gastrointestinal cancer patient .", "label": "", "metadata": {}, "score": "49.29052"}
{"text": "R. J. Friedman , \" Novel oral anticoagulants for VTE prevention in orthopedic surgery : overview of phase 3 trials , \" Orthopedics , vol .", "label": "", "metadata": {}, "score": "49.322838"}
{"text": "22 , pp .2821 - 2830 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Hijazi , J. Oldgren , U. Andersson et al . , \" Cystatin C is prognostic for stroke , death and bleeding during anticoagulation of atrial fibrillation - a RELY substudy , \" Circulation , vol .", "label": "", "metadata": {}, "score": "49.32654"}
{"text": "Hutten BA , Lensing AW , Kraaijenhagen RA , Prins MH : Safety of treatment with oral anticoagulants in the elderly .A systematic review .", "label": "", "metadata": {}, "score": "49.328186"}
{"text": "The primary outcome of recurrent VTE and related deaths was observed in 1.8 % of patients receiving dabigatran and 1.3 % of patients receiving warfarin .", "label": "", "metadata": {}, "score": "49.349792"}
{"text": "Firstly , we used an open - label design that could have biased assessment of outcomes .Nevertheless , efforts were made to limit investigator bias , including the requirement to use objective and validated tests to confirm suspected recurrent VTE and the use of an independent committee , whose members were blinded to treatment assignment , to adjudicate outcome events .", "label": "", "metadata": {}, "score": "49.419018"}
{"text": "S. Husted , R. de Caterina , F. Andreotti , et al . , \" Non - vitamin K antagonist oral anticoagulants ( NOACs ) : no longer new or novel , \" Thrombosis and Haemostasis , vol . 111 , no .", "label": "", "metadata": {}, "score": "49.42522"}
{"text": "723 - 731 , 2013 .View at Google Scholar .J. Douxfils , C. Chatelain , B. Chatelain , J. Dogn\u00e9 , and F. Mullier , \" Impact of apixaban on routine and specific coagulation assays : a practical laboratory guide , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "49.43631"}
{"text": "1211 - 1220 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. B. Saad , I. P. Costa , R. E. da Costa et al . , \" Safety of ablation for atrial fibrillation with therapeutic INR : comparison with transition to low - molecular - weight heparin , \" Arquivos Brasileiros de Cardiologia , vol .", "label": "", "metadata": {}, "score": "49.441322"}
{"text": "Bayer HealthCare and Janssen Pharmaceuticals supported this study , were involved in the design of the trial , and collected and analyzed the data .MHP has received research support and honoraria , and participated in advisory boards for Bayer HealthCare , Sanofi - aventis , Boehringer Ingelheim , GlaxoSmithKline , Daiichi Sankyo , LeoPharma , ThromboGenics , and Pfizer .", "label": "", "metadata": {}, "score": "49.47106"}
{"text": "Recent completed phase III trials comparing NOACs with VKAs for stroke prevention in atrial fibrillation ( AF)-the RE - LY , ROCKET AF , and ARISTOTLE trials - demonstrated at least noninferior efficacy , largely driven by significant reductions in haemorrhagic stroke .", "label": "", "metadata": {}, "score": "49.48242"}
{"text": "Pooling the results of EINSTEIN - DVT and EINSTEIN- PE enabled us to derive clinically relevant results for im- portant subgroups of patients .Large clots and a history of ( multiple episodes of ) VTE are conditions that are of spe- cial concern to clinicians .", "label": "", "metadata": {}, "score": "49.544716"}
{"text": "4 , pp .243 - 254 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Siegal , J. Yudin , S. Kaatz , J. D. Douketis , W. Lim , and A. C. Spyropoulos , \" Periprocedural heparin bridging in patients receiving vitamin K antagonists : systematic review and meta - analysis of bleeding and thromboembolic rates , \" Circulation , vol .", "label": "", "metadata": {}, "score": "49.596947"}
{"text": "Consider therapy modification .Collagenase ( Systemic ) : Anticoagulants may enhance the adverse / toxic effect of Collagenase ( Systemic ) .Specifically , the risk of injection site bruising and/or bleeding may be increased .", "label": "", "metadata": {}, "score": "49.59893"}
{"text": "The RE - LY trial demonstrated that dabigatran 150 mg twice daily was superior to warfarin for the prevention of stroke ( ischemic and hemorrhagic ) and systemic embolism [ 39 ] .", "label": "", "metadata": {}, "score": "49.691967"}
{"text": "Efficacy and safety results were consistent among key patient subgroups .Overall , the rates of recurrent VTE and major bleeding were low in the standard - therapy group and were similar to those in contemporary clinical studies [ 5 , 10 , 16 , 17 ] .", "label": "", "metadata": {}, "score": "49.745544"}
{"text": "Efficacy and safety results were consistent among key patient subgroups .Overall , the rates of recurrent VTE and major bleeding were low in the standard - therapy group and were similar to those in contemporary clinical studies [ 5,10,16,17].", "label": "", "metadata": {}, "score": "49.745544"}
{"text": "Venous thromboembolism ( VTE ) is a frequent complication of gastrointestinal cancers that increases morbidity and may impact mortality .Low - molecular - weight heparins ( LMWHs ) and vitamin K antagonists ( VKAs ) are standard anticoagulation options for the ambulatory gastrointestinal cancer patient with VTE , but both of these agents are challenging to use for various reasons .", "label": "", "metadata": {}, "score": "49.798294"}
{"text": "The low risk of intracranial hemorrhage with novel agents may make these medications attractive options for this population .Patients who were older than 75 years were well represented in the oral anticoagulant trials .", "label": "", "metadata": {}, "score": "49.82566"}
{"text": "Omega-3 Fatty Acids : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Osimertinib : May increase the serum concentration of CYP3A4 Substrates .", "label": "", "metadata": {}, "score": "49.827698"}
{"text": "Although not statistically significant , there were numerically fewer incidents of MI with the factor Xa inhibitors and more with dabigatran , when compared with the VKA arms .", "label": "", "metadata": {}, "score": "49.84251"}
{"text": "Those data do not support a systematic bridging therapy but highlight its probable benefit in patients at cardiovascular risk undergoing high risk surgery .Table 7 shows categories of procedures defined by the severity of tissue trauma and the risk for periprocedural bleeding [ 14 ] .", "label": "", "metadata": {}, "score": "49.873352"}
{"text": "Hence , there is a need for regular monitoring of INR .Aspirin has limited efficacy for stroke prevention in AF .Furthermore the risk of bleeding on aspirin therapy is not inconsiderable [ 4 , 5 ] .", "label": "", "metadata": {}, "score": "49.905697"}
{"text": "In states of cardiovascular hemodynamic stress , the neurohormone B - type natriuretic peptide ( BNP ) is secreted from myocytes and BNP or its inactive N - terminal fragment ( NT - proBNP ) can be detected in the serum .", "label": "", "metadata": {}, "score": "49.92045"}
{"text": "9526 , pp .1903 - 1912 , 2006 .View at Publisher \u00b7 View at Google Scholar .M. Man - Son - Hing , G. Nichol , A. Lau , and A. Laupacis , \" Choosing antithrombotic therapy for elderly patients with atrial fibrillation who are at risk for falls , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "50.086384"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . D. Khadzhynov , F. Wagner , S. Formella et al . , \" Effective elimination of dabigatran by haemodialysis : a phase I single - centre study in patients with end - stage renal disease , \" Thrombosis & Haemostasis , vol .", "label": "", "metadata": {}, "score": "50.135845"}
{"text": "Subjects will receive ticagrelor + ASA in combination with dabigatran ( treatment A ) , rivaroxaban ( treatment B ) or phenprocoumon ( treatment C ) .", "label": "", "metadata": {}, "score": "50.19285"}
{"text": "5 , pp .669 - 676 , 2012 .View at Google Scholar .J. Oldgren , M. Alings , H. Darius , et al . , \" Dabigatran versus warfarin in atrial fibrillation patients with low , moderate and high CHADS2 score : a RE - LY subgroup analysis , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "50.214443"}
{"text": "Prior Warfarin Use .Therapy with vitamin K antagonists ( VKA ) has a higher risk of intracranial hemorrhage in the first three months of treatment [ 57 ] .", "label": "", "metadata": {}, "score": "50.258297"}
{"text": "292 - 303 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. Mueck , J. Stampfuss , D. Kubitza , and M. Becka , \" Clinical pharmacokinetic and pharmacodynamic profile of rivaroxaban , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "50.279827"}
{"text": "1630 - 1639 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Feng , Y. Li , J. Li , and B. Yu , \" Oral anticoagulation continuation compared with heparin bridging therapy among high risk patients undergoing implantation of cardiac rhythm devices : a meta - analysis , \" Thrombosis & Haemostasis , vol .", "label": "", "metadata": {}, "score": "50.333454"}
{"text": "In patients with cancer , the incidence of both bleeding and recurrent VTE tended to be lower , resulting in a favorable benefit- risk profile .", "label": "", "metadata": {}, "score": "50.36683"}
{"text": "In patients with cancer , the incidence of both bleeding and recurrent VTE tended to be lower , resulting in a favorable benefit - risk profile .", "label": "", "metadata": {}, "score": "50.36683"}
{"text": "Even if these specific coagulation tests to assess NOACs are promising , they suffer from difficulties to be implemented easily in the clinical setting .Moreover , assessment of lower levels of NOACs encountered in the perioperative setting is challenging due to the limit of quantitation of these tests but improvements in the low range are under development by several companies .", "label": "", "metadata": {}, "score": "50.367973"}
{"text": "The AVERROES trial provided some insight into reasons for patients were deemed to be \" unsuitable for warfarin \" with 42 % unable to maintain therapeutic INR , 43 % unlikely to monitor INR , and 37 % refusing warfarin [ 34 ] .", "label": "", "metadata": {}, "score": "50.38423"}
{"text": "6 , pp .409 - 418 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Nin , A. Sairaku , Y. Yoshida et al . , \" A randomized controlled trial of dabigatran versus warfarin for periablation anticoagulation in patients undergoing ablation of atrial fibrillation , \" PACE - Pacing and Clinical Electrophysiology , vol .", "label": "", "metadata": {}, "score": "50.415817"}
{"text": "Additional Clinical Trials .A series of additional clinical trials have been planned or are underway to refine our understanding of use of the new oral anticoagulants for AF .", "label": "", "metadata": {}, "score": "50.432915"}
{"text": "Efficacy and safety outcomes and net clinical benefit in all patients and selected patient subgroups .\u00a7 For recurrent VTE , the p - value for the treatment group \u00d7 previous DVT / PE was 0.032 .", "label": "", "metadata": {}, "score": "50.44433"}
{"text": "4 , pp .458 - 464 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. A. Shah , M. Capanu , G. Soff , T. Asmis , and D. P. Kelsen , \" Risk factors for developing a new venous thromboembolism in ambulatory patients with non - hematologic malignancies and impact on survival for gastroesophageal malignancies , \" Journal of Thrombosis and Haemostasis , vol . 8 , no . 8 , pp .", "label": "", "metadata": {}, "score": "50.4489"}
{"text": "Heparin bridging can be useful if the patient can not tolerate oral medication ( e.g. , in ileus or postoperative nausea and vomiting ) [ 66 ] .", "label": "", "metadata": {}, "score": "50.451523"}
{"text": "The prespecified noninferiority margin was 1.75 .Results : A total of 8282 patients were enrolled ; 4151 received rivaroxaban and 4131 received standard - therapy .", "label": "", "metadata": {}, "score": "50.48313"}
{"text": "10 , pp . 883 - 891 , 2011 .View at Google Scholar .C. B. Granger , J. H. Alexander , J. J. McMurray , et al . , \" Apixaban versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "50.543015"}
{"text": "However , variability exists among PT assays and even more so when converted to INR .Therefore , antifactor Xa activity measurement is the preferred test ( Asmis 2012 ; Barrett 2010 ; Kubitza 2005 ) .", "label": "", "metadata": {}, "score": "50.54401"}
{"text": "Ischaemic stroke events were significantly reduced with dabigatran 150 mg but increased , albeit insignificantly , with dabigatran 110 mg [ 21 ] .Cardiovascular and all - cause mortality were numerically reduced with all three drugs [ 14 , 15 , 21 ] .", "label": "", "metadata": {}, "score": "50.611473"}
{"text": "For LMWH , doses must be adapted in case of extreme body weight ( body mass index above 30 kg / m \u00b2 ) and poor renal function .", "label": "", "metadata": {}, "score": "50.647003"}
{"text": "Spinal / Epidural hematomas : .Epidural or spinal hematomas have occurred in patients treated with rivaroxaban who are receiving neuraxial anesthesia or undergoing spinal puncture .", "label": "", "metadata": {}, "score": "50.674606"}
{"text": "In fragile pa- tients , the net clinical benefit ( hazard ratio , 0.51 ; 95 % CI , 0.34 to 0.77 ) was statistically significantly more favorable in rivaroxaban patients ( Table 2 ) .", "label": "", "metadata": {}, "score": "50.74732"}
{"text": "5 , pp .838 - 847 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. A. Nutescu , S. A. Spinler , A. Wittkowsky , and W. E. Dager , \" Low - molecular - weight heparins in renal impairment and obesity : available evidence and clinical practice recommendations across medical and surgical settings , \" Annals of Pharmacotherapy , vol .", "label": "", "metadata": {}, "score": "50.7695"}
{"text": "677 - 685 , 1999 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. B. Leon , D. S. Baim , J. J. Popma et al . , \" A clinical trial comparing three antithrombotic - drug regimens after coronary - artery stenting , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "50.78743"}
{"text": "Consider therapy modification .Estrogen Derivatives : May diminish the anticoagulant effect of Anticoagulants .More specifically , the potential prothrombotic effects of some estrogens and progestin - estrogen combinations may counteract anticoagulant effects .", "label": "", "metadata": {}, "score": "50.78836"}
{"text": "View Article PubMed .J Thromb Haemost 2011 , 9 : 1500 - 1507 .10.1111/j.1538 -7836.2011.04388.x View Article PubMed .Erkens PM , Ten Cate H , Buller HR , Prins MH : Benchmark for time in therapeutic range in venous thromboembolism : a systematic review and meta - analysis .", "label": "", "metadata": {}, "score": "50.81523"}
{"text": "Rivaroxaban has a half - life of approximately 5 to 12 hours .It has not been demonstrated to inhibit any CYP enzyme or active transporter .", "label": "", "metadata": {}, "score": "50.849346"}
{"text": "Monitor therapy .Nonsteroidal Anti - Inflammatory Agents : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .NSAID ( Nonselective ) : May enhance the adverse / toxic effect of Rivaroxaban .", "label": "", "metadata": {}, "score": "50.853775"}
{"text": "215 - 220 , 2013 .View at Google Scholar .J. W. Eikelboom , S. J. Connolly , M. Brueckmann et al . , \" Dabigatran versus warfarin in patients with mechanical heart valves , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "50.853794"}
{"text": "12 , pp .1157 - 1163 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wallentin , S. Yusuf , M. D. Ezekowitz et al . , \" Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE - LY trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "50.932278"}
{"text": "C. N. Hess , S. Broderick , J. P. Piccini et al . , \" Antithrombotic therapy for atrial fibrillation and coronary artery disease in older patients , \" American Heart Journal , vol .", "label": "", "metadata": {}, "score": "50.98652"}
{"text": "Current research has focused on the development of novel oral anticoagulants ( NOAs ) that are safer and easier to administer without compromising efficacy .Ideally , these drugs should be orally administered , have minimal food and drug - drug interactions , wide therapeutic window and predictable pharmacokinetics , no need for monitoring or dose adjustment , low bleeding risk , and rapid onset of action with short half - life .", "label": "", "metadata": {}, "score": "50.99027"}
{"text": "Careful analyses have defined the treatment effect of the new drugs versus warfarin according to time in therapeutic range for warfarin - treated patients at the site level .", "label": "", "metadata": {}, "score": "51.00294"}
{"text": "26 , pp .2487 - 2498 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Lassen , G. E. Raskob , A. Gallus , G. Pineo , D. Chen , and P. Hornick , \" Apixaban versus enoxaparin for thromboprophylaxis after knee replacement ( ADVANCE-2 ) : a randomised double - blind trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "51.006683"}
{"text": "465 - 468 , 1968 .View at Google Scholar \u00b7 View at Scopus .J. Van Ryn , J. Stangier , S. Haertter et al . , \" Dabigatran etexilate - a novel , reversible , oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "51.083447"}
{"text": "Use is considered contraindicated under some circumstances .Refer to related guidelines for specific recommendations .Exceptions : Tibolone .Consider therapy modification .Factor X ( Human ) : Anticoagulants ( Inhibitors of Factor Xa ) may diminish the therapeutic effect of Factor X ( Human ) .", "label": "", "metadata": {}, "score": "51.116844"}
{"text": "The education and system - based intervention will be executed over the course of the project .We will prospectively follow the impact of the intervention on clinical outcomes such as admission for stroke , bleeding , and death .", "label": "", "metadata": {}, "score": "51.13552"}
{"text": "69 , no .11 , pp .1875 - 1881 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. M. Hawes , A. M. Deal , D. Funk - Adcock et al . , \" Performance of coagulation tests in patients on therapeutic doses of dabigatran : a cross - sectional pharmacodynamic study based on peak and trough plasma levels , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "51.145493"}
{"text": "Some specific populations have an increased half - life of NOACs ' elimination and need therefore special attention .This concerns patients with renal or hepatic impairment , particularly the elderly with fluctuating renal function , diuretic use , hypovolemia , liver chronic infections , liver cirrhosis , alcohol abuse , obstructed bile flow , hepatorenal syndrome , and associated coagulopathy .", "label": "", "metadata": {}, "score": "51.195927"}
{"text": "Continuous monitoring of safety parameters ( haemoglobin , haematocrit , platelet count , coagulation ) and surveillance of the overall status will be performed during study participation .", "label": "", "metadata": {}, "score": "51.286366"}
{"text": "Furthermore , the striking reductions in ICH with these NOACs compared to VKAs make these drugs eminently suitable for use in patients at high risk of ICH , a fact best exemplified by ROCKET AF , which recruited patients at high risk of stroke and bleeding .", "label": "", "metadata": {}, "score": "51.346214"}
{"text": "Two recently presented trials evaluated long - term VTE treatment with dabigatran etexilate .The RE - SONATE study [ 36 ] compared 6 months of dabigatran etexilate versus placebo following a 6 - 18 month course of anticoagulant therapy for long - term treatment of VTE .", "label": "", "metadata": {}, "score": "51.376175"}
{"text": "5 , pp .820 - 829 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .W. Wienen , J. M. Stassen , H. Priepke , U. J. Ries , and N. Hauel , \" In - vitro profile and ex - vivo anticoagulant activity of the direct thrombin inhibitor dabigatran and its orally active prodrug , dabigatran etexilate , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "51.390053"}
{"text": "The most commonly used VTE chemoprophylaxes after THA and TKA are low - molecular - weight heparin ( LMWH ) , adjusted - dose warfarin with a targeted INR of 2 - 3 , fondaparinux , or aspirin [ 2 ] .", "label": "", "metadata": {}, "score": "51.390434"}
{"text": "On - treatment analysis avoids biases resulting from differential adherence to study drug in a noninferiority trial .This is especially pertinent where treatment is continuous and demanding , and withdrawal rates expected to be high .", "label": "", "metadata": {}, "score": "51.444324"}
{"text": "1493 - 1502 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Douxfils , J. M. Dogn\u00e9 , F. Mullier et al . , \" Comparison of calibrated dilute thrombin time and aPTT tests with LC - MS / MS for the therapeutic monitoring of patients treated with dabigatran etexilate , \" Thrombosis & Haemostasis , vol .", "label": "", "metadata": {}, "score": "51.46324"}
{"text": "LMWH has become the standard first - line agents for malignancy - associated VTE , however , by warfarin or further enoxaparin [ 29 ] .", "label": "", "metadata": {}, "score": "51.46437"}
{"text": "Actual data are based mainly on expert 's opinions , except one national registry study .In some situation , interruption periods of NOACs are necessary and should be based on their respective half - life , on the bleeding risk of procedures , and on the thromboembolic risk of patients .", "label": "", "metadata": {}, "score": "51.464497"}
{"text": "The Phase III Clinical Trials : Trial Design .These three studies constitute the largest prospective VKA - controlled trials of anticoagulation for stroke prevention in patients with AF with median followup of about 2 years each ( Table 2 ) .", "label": "", "metadata": {}, "score": "51.55213"}
{"text": "9S-16S , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. K. Maccallum , R. Mathur , S. A. Hull , et al . , \" Patient safety and estimation of renal function in patients prescribed new oral anticoagulants for stroke prevention in atrial fibrillation : a cross - sectional study , \" BMJ Open , vol .", "label": "", "metadata": {}, "score": "51.561897"}
{"text": "For dabigatran , a humanized selective and specific monoclonal antibody fragment ( idarucizumab ) is under development [ 96 ] .Aripazine ( PER977 ) , another small synthetic molecule , reverses anticoagulant activity of all clinically used NOACs in rat bleeding models [ 97 ] .", "label": "", "metadata": {}, "score": "51.583412"}
{"text": "Llau and Ferrandis [ 79 ] provided recommendations based on NOAC 's pharmacokinetics in the setting of thromboprophylaxis .For spinal anesthesia , if the puncture is atraumatic , the first dose of DE can be administrated 1 - 4 hours after the end of surgery and after 6 - 8 hours for rivaroxaban .", "label": "", "metadata": {}, "score": "51.597496"}
{"text": "721 - 728 , 2013 .View at Publisher \u00b7 View at Google Scholar . K. He , J. M. Luettgen , D. Zhang et al . , \" Preclinical pharmacokinetics and pharmacodynamics of apixaban , a potent and selective factor Xa inhibitor , \" European Journal of Drug Metabolism and Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "51.60417"}
{"text": "Standard therapy for these patients consists of low - molecular - weight heparin combined with a vitamin K antagonist ( VKA ) [ 3,4].", "label": "", "metadata": {}, "score": "51.66365"}
{"text": "Standard therapy for these patients consists of low - molecular - weight heparin combined with a vitamin K antagonist ( VKA ) [ 3 , 4 ] .", "label": "", "metadata": {}, "score": "51.66365"}
{"text": "11 , pp .1398 - 1407 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. Wagner , H. Peters , S. Formella , et al . , \" Effective elimination of dabigatran with haemodialysis : a phase I single centre study in patients with end - stage renal disease , \" Circulation , vol .", "label": "", "metadata": {}, "score": "51.664383"}
{"text": "We also prespecified to analyze net clinical benefit , which was defined as the composite of the primary efficacy outcome and major bleeding .Key clinical subgroups .", "label": "", "metadata": {}, "score": "51.66651"}
{"text": "Creatinine clearance ( CrCl ) must be assessed by the Cockroft and Gault method .Estimation of renal function by Modification of Diet in Renal Disease Equation 4 ( MDRD 4 ) leads to an overestimation of the renal function at lower levels .", "label": "", "metadata": {}, "score": "51.76112"}
{"text": "Severe hypersensitivity to rivaroxaban or any component of the formulation ; active pathological bleeding .Dosage .Deep vein thrombosis ( DVT ) , pulmonary embolism ( PE ) treatment : Adults : Oral : Initial : 15 mg twice daily with food for 21 days followed by 20 mg once daily with food .", "label": "", "metadata": {}, "score": "51.76232"}
{"text": "The primary endpoint of the study was to demonstrate noninferiority in 6-month incidence of recurrent VTE and VTE - related deaths .1274 patients were treated and only 10 % of the total study population had malignancy - associated DVT .", "label": "", "metadata": {}, "score": "51.779034"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Lassen , G. E. Raskob , A. Gallus , G. Pineo , D. Chen , and R. J. Portman , \" Apixaban or enoxaparin for thromboprophylaxis after knee replacement , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "51.783936"}
{"text": "MHP has received research support and honoraria , and participated in advisory boards for Bayer HealthCare , Sanofi - aventis , Boehringer Ingelheim , Prins et al .", "label": "", "metadata": {}, "score": "51.860962"}
{"text": "View at Publisher \u00b7 View at Google Scholar .R. Ferrandis , J. Castillo , J. de Andr\u00e9s et al . , \" The perioperative management of new direct oral anticoagulants : a question without answers , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "51.941895"}
{"text": "231 - 236 , 2014 .View at Google Scholar . H. T. Benzon , M. J. Avram , D. Green , and R. O. Bonow , \" New oral anticoagulants and regional anaesthesia , \" British Journal of Anaesthesia , vol . 111 , supplement 1 , pp .", "label": "", "metadata": {}, "score": "51.95669"}
{"text": "Impaired Renal Function .Patients with AF and renal impairment are at high risk for thromboembolism and also for bleeding .Given the higher drug concentrations of the novel anticoagulants with decreased renal excretion , it is important to consider the risk of bleeding in this high - risk population .", "label": "", "metadata": {}, "score": "51.99169"}
{"text": "No clinical data are available for patients with severe hepatic impairment .Special Populations : Elderly .The terminal elimination half - life is 11 to 13 hours in elderly patients .", "label": "", "metadata": {}, "score": "51.99777"}
{"text": "Consider therapy modification .Obinutuzumab : Anticoagulants may enhance the adverse / toxic effect of Obinutuzumab .Specifically , the risk of serious bleeding - related events may be increased .", "label": "", "metadata": {}, "score": "52.005043"}
{"text": "Monitor therapy .Urokinase : May enhance the anticoagulant effect of Anticoagulants .Avoid combination .Vitamin E : May enhance the anticoagulant effect of Anticoagulants .", "label": "", "metadata": {}, "score": "52.059853"}
{"text": "Chest 2012 , 141:e419S - e494S. doi:10.1186/1477 - 9560 - 11 - 21 Cite this article as : Prins et al .: Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism : a pooled analysis of the EINSTEIN - DVT and PE randomized studies .", "label": "", "metadata": {}, "score": "52.066208"}
{"text": "Both studies used an identical design , treatment regi- mens , outcome definitions , and adjudication processes to allow for an a priori pooled analysis based on individ- ual patient data .", "label": "", "metadata": {}, "score": "52.097496"}
{"text": "Vitamin K antagonists ( e.g. , warfarin ) , direct thrombin inhibitors ( dabigatran ) , and factor Xa inhibitors ( rivaroxaban and apixaban ) are all oral anticoagulants that have been FDA approved for the prevention of stroke in atrial fibrillation .", "label": "", "metadata": {}, "score": "52.103035"}
{"text": "Patients who are at high risk of stroke are identified using the CHADS2 and CHA2DS2-VASc risk classification tools [ 47 , 48 ] .", "label": "", "metadata": {}, "score": "52.126427"}
{"text": "11 , pp .2178 - 2185 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. I. Eriksson , O. E. Dahl , N. Rosencher et al . , \" Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement : a randomised , double - blind , non - inferiority trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "52.166786"}
{"text": "5 , pp .1093 - 1100 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. D. Lopes , S. M. Al - Khatib , L. Wallentin et al . , \" Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation : a secondary analysis of a randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "52.18023"}
{"text": "6 , pp .997 - 1011 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. G. E. Zarraga and J. Kron , \" Oral anticoagulation in elderly adults with atrial fibrillation : integrating new options with old concepts , \" Journal of the American Geriatrics Society , vol .", "label": "", "metadata": {}, "score": "52.31185"}
{"text": "However , hemodialysis might be more effective than unspecific reversal treatment with factor concentrates .A single - center study including patients with end - stage renal disease measured DE elimination with hemodialysis .", "label": "", "metadata": {}, "score": "52.358555"}
{"text": "Emergency surgeries , invasive procedures , or bleeding patients remain a real challenge given the absence of antidote .Possibilities of reversal are poor and based on few experimental data and case reports .", "label": "", "metadata": {}, "score": "52.359924"}
{"text": "Which Laboratory Tests Should We Use in the Perioperative Setting and How to Interpret Them ?Activated partial thromboplastin time ( aPTT ) and prothrombin time ( PT ) are global assays not reflecting plasma NOACs concentrations .", "label": "", "metadata": {}, "score": "52.364292"}
{"text": "Multiple studies have suggested an association between VTE and mortality for patients with pancreas cancer [ 10 , 15 - 22 ] .A retrospective analysis of the effect of VTE on survival suggested shortened survival from the time of VTE , which varied according to disease site .", "label": "", "metadata": {}, "score": "52.392784"}
{"text": "Homogeneity of the DVT and PE evaluations was tested with the Gail - Simon test of qualitative interaction [ 15].Weighted absolute risk differences and their CIs were cal- culated using the Mantel - Haenszel asymptotic method with the weights based upon sample sizes per stratum .", "label": "", "metadata": {}, "score": "52.446503"}
{"text": "292 - 303 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Weinz , T. Schwarz , D. Kubitza , W. Mueck , and D. Lang , \" Metabolism and excretion of rivaroxaban , an oral , direct factor Xa inhibitor , in rats , dogs , and humans , \" Drug Metabolism and Disposition , vol .", "label": "", "metadata": {}, "score": "52.464954"}
{"text": "Hess et al .analyzed the use of evidence based therapies for treating other cardiovascular existing risk factors .More than 93 % of patients in the registry were eligible for at least one guideline - based therapy for a coexisting cardiovascular disease , but only 46 % of patients received all recommended treatments , highlighting an opportunity to improve care [ 66 ] .", "label": "", "metadata": {}, "score": "52.484524"}
{"text": "View at Publisher \u00b7 View at Google Scholar .J. D. Douketis , \" Pharmacologic properties of the new oral anticoagulants : a clinician - oriented review with a focus on perioperative management , \" Current Pharmaceutical Design , vol .", "label": "", "metadata": {}, "score": "52.576942"}
{"text": "Patients with mechanical bileaflet aortic or mitral valves were studied in an open label randomized , blinded endpoint phase II trial that evaluated the safety of dabigatran compared with warfarin , called RE - ALIGN [ 54 ] .", "label": "", "metadata": {}, "score": "52.62039"}
{"text": "During the ROCKET - AF trial , patients who required temporary interruption of anticoagulant therapy for surgery and invasive procedure were bridged only in 6 % of the cases , predominantly by LMWH .", "label": "", "metadata": {}, "score": "52.703285"}
{"text": "Monitor therapy .Pentosan Polysulfate Sodium : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Progestins : May diminish the therapeutic effect of Anticoagulants .", "label": "", "metadata": {}, "score": "52.763527"}
{"text": "4 , pp .412 - 421 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. C. Wong , E. J. Crain , B. Xin et al . , \" Apixaban , an oral , direct and highly selective factor Xa inhibitor : in vitro , antithrombotic and antihemostatic studies , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "52.777332"}
{"text": "Abstract AS 20.2 .Prandoni P , Lensing AWA , Piccioli A , Bernardi E , Simioni P , Girolami B , Marchiori A , Sabbion P , Prins MH , Noventa F , Girolami A : Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis .", "label": "", "metadata": {}, "score": "52.78794"}
{"text": "Abstract AS 20.2 .Prandoni P , Lensing AWA , Piccioli A , Bernardi E , Simioni P , Girolami B , Marchiori A , Sabbion P , Prins MH , Noventa F , Girolami A : Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis .", "label": "", "metadata": {}, "score": "52.78794"}
{"text": "4 , pp .259 - 268 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. Schulman , C. Kearon , A. K. Kakkar , et al . , \" Dabigatran versus warfarin in the treatment of acute venous thromboembolism , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "52.83419"}
{"text": "515 - 519 , 2001 .View at Google Scholar \u00b7 View at Scopus . A. Y. Lee , M. N. Levine , R. I. Baker et al . , \" Low - molecular - weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "52.853096"}
{"text": "515 - 522 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier , K. Rathgen , H. St\u00e4hle , D. Gansser , and W. Roth , \" The pharmacokinetics , pharmacodynamics and tolerability of dabigatran etexilate , a new oral direct thrombin inhibitor , in healthy male subjects , \" British Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "52.91555"}
{"text": "Risk Stratification Using Biomarkers .The CHADS2 and CHA2DS2-VASc scores are the primary tools currently used to calculate risk of stroke in patients with AF for the purpose of deciding who has sufficient risk to warrant oral anticoagulation .", "label": "", "metadata": {}, "score": "52.933186"}
{"text": "It is important to understand if underuse of warfarin therapy in the elderly is due to appropriate reasons that may include the risk of bleeding and falls .", "label": "", "metadata": {}, "score": "52.993538"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Van Ryn , J. Stangier , S. Haertter et al . , \" Dabigatran etexilate - a novel , reversible , oral direct thrombin inhibitor : interpretation of coagulation assays and reversal of anticoagulant activity , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "53.020065"}
{"text": "372 - 380 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. N. Beasley , E. F. Unger , and R. Temple , \" Anticoagulant options - why the FDA approved a higher but not a lower dose of dabigatran , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "53.070076"}
{"text": "The prespecified efficacy outcome was symptomatic recurrent VTE , i.e. the com- posite of fatal or nonfatal PE or DVT [ 8,9].The pre- specified principal safety outcome was clinically relevant bleeding , defined as the composite of major and nonmajor clinically relevant bleeding , as described previously [ 8,9].", "label": "", "metadata": {}, "score": "53.09092"}
{"text": "Much of this work has been led by investigators at Uppsala Clinical Research Institute and some of it in collaboration with investigators at Duke .While the mechanism of cardiac troponin elevation in patients with AF is not entirely understood , detecting an elevated level of cardiac troponin has been associated with an increased risk of stroke or systemic embolism and of cardiovascular death .", "label": "", "metadata": {}, "score": "53.11401"}
{"text": "Conclusions .LMWH should remain standard first - line therapy for cancer - related DVT .Prospective investigations of NOAs specific to the cancer population are necessary .", "label": "", "metadata": {}, "score": "53.1307"}
{"text": "5 , pp .397 - 402 , 2012 .View at Google Scholar .S. H. Hohnloser , J. Oldgren , S. Yang , et al . , \" Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE - LY trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "53.20035"}
{"text": "While the more reliable pharmacokinetics of NOAs may partially mitigate this risk , bleeding complications of NOAs are not well defined in this patient population who at baseline may be predisposed to hemorrhage for multiple other reasons including chemotherapy - induced thrombocytopenia or receipt of antiangiogenic therapy .", "label": "", "metadata": {}, "score": "53.26466"}
{"text": "Phase III Clinical Trials .Currently there are 2 phase III trials underway to evaluate apixaban in the treatment of VTE .In the noninferiority AMPLIFY - VTE trial ( NCT00643201 ) , patients are randomized to receive either apixaban 10 mg twice daily for 7 days followed by 5 mg twice daily for 6 months or LMWH followed by VKA .", "label": "", "metadata": {}, "score": "53.3579"}
{"text": "Dalteparin significantly reduced the risk of recurrent VTE with no significant differences in bleeding ( major or any ) or 6-month overall mortality .", "label": "", "metadata": {}, "score": "53.381012"}
{"text": "2172 - 2174 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Wanek , E. T. Horn , S. Elapavaluru , S. C. Baroody , and G. Sokos , \" Safe use of hemodialysis for dabigatran removal before cardiac surgery , \" Annals of Pharmacotherapy , vol .", "label": "", "metadata": {}, "score": "53.455738"}
{"text": "For the Venous Side .Patients with venous thromboembolism are at high risks of recurrent thrombosis , thrombus propagation , and embolization until 3 months after diagnosis and initiation of anticoagulation therapy [ 51 ] .", "label": "", "metadata": {}, "score": "53.4935"}
{"text": "26 , pp .2499 - 510 , 2010 .View at Google Scholar .N. Raghavan , C. E. Frost , Z. Yu et al . , \" Apixaban metabolism and pharmacokinetics after oral administration to humans , \" Drug Metabolism and Disposition , vol .", "label": "", "metadata": {}, "score": "53.527794"}
{"text": "Additional outcome variables : .D - Dimer , TxB2 , CD40L and p - Selectin in shed blood .\u03b2 - TG , F1 + 2 , TAT , D - Dimer , TxB2 , CD40L , p - Selectin , ETP , aPTT , PT , inhibition of factor Xa , Biophen \u00ae and Hemoclot \u00ae in venous blood .", "label": "", "metadata": {}, "score": "53.54908"}
{"text": "We also prespecified to analyze net clinical benefit , which was defined as the composite of the primary effi- cacy outcome and major bleeding .Key clinical subgroups Efficacy and safety outcomes were separately analyzed in key prespecified subgroups of patients , i.e. fragile pa- tients , those with cancer , patients with a previous VTE , and patients presenting with a large clot burden .", "label": "", "metadata": {}, "score": "53.605247"}
{"text": "The results for apixaban and dabigatran have demonstrated similar efficacy and safety profiles when compared to enoxaparin , and these drugs have been approved in Canada and countries in Europe [ 12 - 17 ] .", "label": "", "metadata": {}, "score": "53.683495"}
{"text": "87 , no .6 , pp .1076 - 1077 , 2002 .View at Google Scholar \u00b7 View at Scopus .M. J. Moore , D. Goldstein , J. Hamm et al . , \" Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer : a phase III trial of the National Cancer Institute of Canada Clinical Trials Group , \" Journal of Clinical Oncology , vol .", "label": "", "metadata": {}, "score": "53.6969"}
{"text": "636 - 644 , 2009 .View at Google Scholar .B. I. Eriksson , D. J. Quinlan , and J. I. Weitz , \" Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "53.714775"}
{"text": "129 - 139 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. P. Giugliano , C. T. Cuff , E. Braunwald , et al . , \" Edoxaban versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "53.715797"}
{"text": "Ticagrelor is a reversible P2Y12 receptor antagonist with superior efficacy compared to clopidogrel in the prevention of cardiovascular death in these patients .Atrial fibrillation ( AF ) is also associated with thromboembolic events and substantial mortality .", "label": "", "metadata": {}, "score": "53.740623"}
{"text": "focused their analysis on oral anticoagulant use with increasing stroke and bleeding risk .They found that oral anticoagulant use increased with higher CHADS2 scores but fell slightly with increasing ATRIA bleeding risk .", "label": "", "metadata": {}, "score": "53.767063"}
{"text": "Mild hepatic impairment ( Child - Pugh class A ) : There are no dosage adjustments provided in the manufacturer 's labeling .Limited data indicate pharmacokinetics and pharmacodynamic response were similar to healthy subjects .", "label": "", "metadata": {}, "score": "53.769493"}
{"text": "22 , pp .2113- 2124 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Si\u00e9 , C. M. Samama , A. Godier et al . , \" Surgery and invasive procedures in patients on long - term treatment with direct oral anticoagulants : thrombin or factor - Xa inhibitors .", "label": "", "metadata": {}, "score": "53.780655"}
{"text": "172 - 179 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. A. Winkle , R. H. Mead , G. Engel , M. H. Kong , and R. A. Patrawala , \" The use of dabigatran immediately after atrial fibrillation ablation , \" Journal of Cardiovascular Electrophysiology , vol .", "label": "", "metadata": {}, "score": "53.78968"}
{"text": "25 , pp .3466 - 3473 , 2011 .View at Google Scholar .P. Prandoni , A. W. A. Lensing , A. Piccioli et al . , \" Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis , \" Blood , vol .", "label": "", "metadata": {}, "score": "53.80217"}
{"text": "View at Google Scholar . D. S. G. Conway , P. Buggins , E. Hughes , and G. Y. H. Lip , \" Prognostic significance of raised plasma levels of interleukin-6 and C - reactive protein in atrial fibrillation , \" American Heart Journal , vol .", "label": "", "metadata": {}, "score": "53.838585"}
{"text": "2370 - 2375 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. D. Furberg , B. M. Psaty , T. A. Manolio et al . , \" Prevalence of atrial fibrillation in elderly subjects ( the Cardiovascular Health Study ) , \" The American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "53.84281"}
{"text": "Concomitant Antiplatelet Therapy .Antiplatelet therapy was given to about 38 % of the population at baseline in the RE - LY trial and about 31 % of the trial population in the ARISTOTLE trial [ 51 , 52 ] .", "label": "", "metadata": {}, "score": "53.890884"}
{"text": "These agents are both contraindicated in patients with severely impaired renal function .Increased trough concentrations of dabigatran have been observed with even mild renal impairment , and dabigatran exposure ( AUC ) is 2.7-fold higher in moderate renal insufficiency [ 33 ] .", "label": "", "metadata": {}, "score": "53.917667"}
{"text": "355 - 363 , 2012 .View at Google Scholar .J.-M. Januel , G. Chen , C. Ruffieux et al . , \" Symptomatic in - hospital deep vein thrombosis and pulmonary embolism following hip and knee arthroplasty among patients receiving recommended prophylaxis : a systematic review , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "53.942886"}
{"text": "ASA , dabigatran and rivaroxaban can cause gastrointestinal discomfort .Other side effects are rare .The combination of these novel anticoagulants ( dabigatran , rivaroxaban , ticagrelor ) has not been investigated so far .", "label": "", "metadata": {}, "score": "54.114754"}
{"text": "The study included patients with AF , aging greater than 65 years , and angiographically confirmed coronary artery disease between 2000 and 2010 .Analysis of this group of patients showed that the use of warfarin was concordant with patient risk , such that there was increased use with higher stroke risk ( defined by CHADS2 and CHA2DS2-VASc scores ) and decreased use with higher bleeding risk ( using the ATRIA score ) .", "label": "", "metadata": {}, "score": "54.132885"}
{"text": "For stroke prevention in AF , dabigatran and apixaban are administered twice daily , and rivaroxaban once daily .Dabigatran is predominantly excreted by the renal route .", "label": "", "metadata": {}, "score": "54.18759"}
{"text": "4 , pp .259 - 268 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .F. J. A. Penning - Van Beest , E. Van Meegen , F. R. Rosendaal , and B. H. C. Stricker , \" Characteristics of anticoagulant therapy and comorbidity related to overanticoagulation , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "54.212994"}
{"text": "Rivaroxaban is metabolized in the liver and primarily excreted renally ( 66 % ) , with the remainder excreted through the gastrointestinal tract [ 25 ] .", "label": "", "metadata": {}, "score": "54.251297"}
{"text": "9397 , pp .1691 - 1698 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. W. Albers , H. C. Diener , L. Frison , et al . , \" Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation : a randomized trial , \" JAMA , vol .", "label": "", "metadata": {}, "score": "54.30263"}
{"text": "141 , supplement , no . 2 , pp .e278S - e325S , 2012 .View at Publisher \u00b7 View at Google Scholar .M. H. Huo , D. L. Spencer , B. J. Borah et al . , \" Post - discharge venous thromboembolism and bleeding in a large cohort of patients undergoing total hip or total knee arthroplasty , \" Journal of Clinical Outcomes Management , vol .", "label": "", "metadata": {}, "score": "54.311905"}
{"text": "781 - 782 , 2014 .View at Publisher \u00b7 View at Google Scholar .J. H. Levy , D. Faraoni , J. L. Spring , J. D. Douketis , and C. M. Samama , \" Managing new oral anticoagulants in the perioperative and intensive care unit setting , \" Anesthesiology , vol .", "label": "", "metadata": {}, "score": "54.32632"}
{"text": "12 , pp .999 - 1015 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. T. Horlocker , D. J. Wedel , H. Benzon et al . , \" Regional anesthesia in the anticoagulated patient : defining the risks ( the second ASRA Consensus Conference on Neuraxial Anesthesia and Anticoagulation ) , \" Regional Anesthesia and Pain Medicine , vol .", "label": "", "metadata": {}, "score": "54.346413"}
{"text": "Prins MH , Lensing AWA : Derivation of the non - inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "54.37958"}
{"text": "Prins MH , Lensing AWA : Derivation of the non - inferiority margin for the evaluation of direct oral anticoagulants in the treatment of venous thromboembolism .", "label": "", "metadata": {}, "score": "54.37958"}
{"text": "This amount of venous blood is considered to be acceptable in this healthy population .Blood sampling procedures may cause mild and transient pain .A minor haematoma may occur at the site of needle insertions .", "label": "", "metadata": {}, "score": "54.38582"}
{"text": "Dabigatran Etexilate : May enhance the anticoagulant effect of Anticoagulants .Avoid combination .Dabrafenib : May decrease the serum concentration of CYP3A4 Substrates .Management : Seek alternatives to the CYP3A4 substrate when possible .", "label": "", "metadata": {}, "score": "54.43065"}
{"text": "Moderate to severe hepatic impairment ( Child - Pugh class B or C ) and patients with any hepatic disease associated with coagulopathy : Avoid use .", "label": "", "metadata": {}, "score": "54.455177"}
{"text": "With the aging of the population , the number of patients with AF is expected to increase 150 % by 2050 , with more than 50 % of AF patients being over the age of 80 [ 3 - 8 ] .", "label": "", "metadata": {}, "score": "54.471226"}
{"text": "A Particular Case : Atrial Fibrillation Ablation .The ideal management of oral anticoagulation during catheter ablation for AF 112 - 114 is still controversial with a wide range of procedures available .", "label": "", "metadata": {}, "score": "54.625538"}
{"text": "C. Weinz , U. Buetehorn , H. Daehler , et al . , \" Pharmacokinetics of BAY 59 - 7939-an oral , direct Factor Xa inhibitor - in rats and dogs , \" Pathophysiology of Haemostasis and Thrombosis , vol .", "label": "", "metadata": {}, "score": "54.630917"}
{"text": "View at Publisher \u00b7 View at Google Scholar .B. T. Bj\u00f8rnar\u00e5 , T. E. Gudmundsen , and O. E. Dahl , \" Frequency and timing of clinical venous thromboembolism after major joint surgery , \" Journal of Bone and Joint Surgery , vol . 88 , no . 3 , pp .", "label": "", "metadata": {}, "score": "54.632202"}
{"text": "There has been an explosion of data emanating from these trial databases and from registries over the past 5 years which is redefining much of the knowledge around antithrombotic therapy for AF .", "label": "", "metadata": {}, "score": "54.646477"}
{"text": "6 , pp .1133 - 1140 , 2013 .View at Publisher \u00b7 View at Google Scholar . A. Tamigniau , J. Douxfils , and J. B. Nicolas , \" Why , when and how to monitor new oral anticoagulants , \" Revue M\u00e9dicale Suisse , vol .", "label": "", "metadata": {}, "score": "54.674007"}
{"text": "Dabigatran has been approved by the FDA for patients with a creatinine clearance of 15 - 30 mL / min , albeit with a lower dose that was not tested in the trials [ 69 ] .", "label": "", "metadata": {}, "score": "54.684814"}
{"text": "Administration of the study drugs , in particular as triple combination for 5 days , results in transient hypocoagulability and may cause overt or occult bleeding .", "label": "", "metadata": {}, "score": "54.71208"}
{"text": "4 , pp .279 - 293 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Brinker , R. He , M. Desai , K. Gelperin , K. Robie - Suh , and V. Gurewich , \" Safety of ximelagatran , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "54.721462"}
{"text": "As the burden of AF in the community greatly exceeds the capacity of specialist care , these NOACs open up opportunities for primary care physicians to initiate and maintain anticoagulation treatment in the wider , hitherto undertreated , group of eligible patients with AF .", "label": "", "metadata": {}, "score": "54.738617"}
{"text": "Both studies used an identical design , treatment regimens , outcome definitions , and adjudication processes to allow for an a priori pooled analysis based on individual patient data .", "label": "", "metadata": {}, "score": "54.74682"}
{"text": "Key pharmacokinetic characteristics of dabigatran , rivaroxaban and apixaban are summarised in Table 1 [ 18 - 20 ] .Dabigatran etexilate , a prodrug , is hydrolysed by plasma esterases into its active principle , dabigatran , after intestinal absorption ( Figure 1 ) .", "label": "", "metadata": {}, "score": "54.76851"}
{"text": "Further investigations are needed to demonstrate superior efficacy , particularly given the lack of significant safety benefit .There is insufficient data to clearly define the role of NOAs in the gastrointestinal cancer population and further investigation should be undertaken before guidelines can be developed for their use in these patients .", "label": "", "metadata": {}, "score": "54.83201"}
{"text": "Factor Xa is responsible for the conversion of prothrombin to thrombin in the coagulation cascade [ 25 ] .Rivaroxaban has a rapid onset of action , reaching maximum plasma concentrations after 2 - 3 hours and has a half - life of 8 - 10 hours [ 25 , 26 ] .", "label": "", "metadata": {}, "score": "54.83252"}
{"text": "Systemic anticoagulation therapy is central to the management of VTE .Goals of therapy include clot stabilization and prevention of clot extension / embolization , avoidance of VTE recurrence , and prevention of long - term complications .", "label": "", "metadata": {}, "score": "54.835785"}
{"text": "After including incident silent MI events , the significant increase in MI was no longer nominally significant .Importantly , the main finding of the RE - LY trial remained unaltered [ 21 ] .", "label": "", "metadata": {}, "score": "54.85565"}
{"text": "Implementation Research .Despite the effectiveness of anticoagulation , recent literature reviews and studies have documented that current practice does not follow published guidelines , with undertreatment resulting in substantial occurrence of preventable ischemic stroke [ 62 ] .", "label": "", "metadata": {}, "score": "54.96135"}
{"text": "6 , pp .299S-339S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. Fujita , A. Shiotani , T. Murao , et al . , \" Safety of gastrointestinal endoscopic biopsy in patients taking antithrombotics , \" Digestive Endoscopy , 2014 .", "label": "", "metadata": {}, "score": "54.962948"}
{"text": "Reduced renal function can be measured by calculations of glomerular filtration rates ( GFR ) , based on creatinine , or by cystatin C , which is a small protein that is freely filtered by the glomerulus .", "label": "", "metadata": {}, "score": "54.993805"}
{"text": "While pharmacokinetic studies of NOAs account for weight differences [ 33 , 41 ] , the effect of nutritional status on the pharmacokinetics and pharmacodynamics of these agents is less well studied .", "label": "", "metadata": {}, "score": "55.011898"}
{"text": "The free interval is increased to at least 4 days for patients on DE with CrCl between 30 and 50 mL / min or for patients on rivaroxaban / apixaban with a CrCl between 15 and 30 mL / min ( Table 6 ) .", "label": "", "metadata": {}, "score": "55.061993"}
{"text": "Edoxaban is another factor Xa inhibitor that is likely to be FDA approved in the coming months .In this paper , we will not cover the edoxaban experience in the Effective Anticoagulation with Factor Xa", "label": "", "metadata": {}, "score": "55.095085"}
{"text": "There is an association between lower stroke and lower bleeding risk with better INR control as reported from the Stroke Prevention Using ORal Thrombin Inhibitor in Atrial Fibrillation ( SPORTIF ) III and V studies [ 30 ] .", "label": "", "metadata": {}, "score": "55.09601"}
{"text": "The optimal time for NOAC 's resumption depends mainly on the postoperative risk of bleeding [ 16 ] .This paper aims at providing a review on the management of NOACs in the perioperative setting in accordance with the current literature .", "label": "", "metadata": {}, "score": "55.115166"}
{"text": "Dabigatran is 35 % bound to plasma proteins , allowing theoretically its elimination by hemodialysis .Eighty percent of the drug is directly eliminated in the urine , explaining that , in the setting of renal insufficiency , the anticoagulant effect accumulates .", "label": "", "metadata": {}, "score": "55.14489"}
{"text": "View at Google Scholar . D. Kubitza , M. Becka , B. Voith , M. Zuehlsdorf , and G. Wensing , \" Safety , pharmacodynamics , and pharmacokinetics of single doses of BAY 59 - 7939 , an oral , direct factor Xa inhibitor , \" Clinical Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "55.158215"}
{"text": "Prins et al .Stroke Prevention in Atrial Fibrillation : Understanding the New Oral Anticoagulants Dabigatran , Rivaroxaban , and Apixaban .Received 29 June 2012 ; Accepted 1 August 2012 .", "label": "", "metadata": {}, "score": "55.199665"}
{"text": "By day 21 , major bleeding had occurred in 16 ( 0.4 % ) rivaroxaban patients and in 33 ( 0.8 % ) standard - therapy patients .", "label": "", "metadata": {}, "score": "55.218826"}
{"text": "International normalized ratio .PE : .Pulmonary embolism .VKA : .Vitamin K antagonist .VTE : .Venous thromboembolism .Declarations .Acknowledgments .", "label": "", "metadata": {}, "score": "55.242336"}
{"text": "e419S - e494S , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. G. de Jong , M. Coppens , and S. Middeldorp , \" Duration of anticoagulant therapy for venous thromboembolism : balancing benefits and harms on the long term , \" British Journal of Haematology , vol .", "label": "", "metadata": {}, "score": "55.26818"}
{"text": "No subgroup analyses for safety were provided .While hepatotoxicity was rare ( . in the total study population ) with no differences observed between the groups , 5 of these patients had underlying malignancy ( pancreas cancer , . , and uterine cancer , .", "label": "", "metadata": {}, "score": "55.279625"}
{"text": "ESA does not routinely apply the same guidelines as for neuraxial blockades [ 81 ] , but the American Society of Regional Anesthesia ( ASRA ) does [ 78 ] .", "label": "", "metadata": {}, "score": "55.330734"}
{"text": "Perhaps , in the near future , except for male patients younger than 65 years without any other risk factors ( i.e. , CHA2DS2-VASc score 0 ) , all other patients with AF should be anticoagulated , preferably with a NOAC .", "label": "", "metadata": {}, "score": "55.33999"}
{"text": "23 , pp .1665 - 1671 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. D. Pokorney , M. W. Sherwood , and R. C. Becker , \" Clinical strategies for selecting oral anticoagulants in patients with atrial fibrillation , \" Journal of Thrombosis and Thrombolysis , vol .", "label": "", "metadata": {}, "score": "55.3845"}
{"text": "Understanding why patients are not being treated is necessary to develop targeted strategies to increase the proportion of patients who are treated worldwide .Few quality improvement interventions have been evaluated to determine impact on patient care and clinical outcomes for patients with AF with the goal of decreasing underuse of anticoagulation to reduce preventable stroke rates .", "label": "", "metadata": {}, "score": "55.404015"}
{"text": "Consider therapy modification .Ibritumomab : Anticoagulants may enhance the adverse / toxic effect of Ibritumomab .Both agents may contribute to an increased risk of bleeding .", "label": "", "metadata": {}, "score": "55.41815"}
{"text": "US labeling : Discontinue rivaroxaban and initiate both warfarin and a parenteral anticoagulant at the time the next dose of rivaroxaban would have been taken ( other approaches to this conversion may be acceptable ) .", "label": "", "metadata": {}, "score": "55.420975"}
{"text": "This may have been because warfarin is effective in preventing myocardial infarction rather than a hazard of dabigatran [ 39 ] .In contrast , when apixaban was used alone without aspirin , there were numerically fewer myocardial infarctions than warfarin [ 53 ] .", "label": "", "metadata": {}, "score": "55.454018"}
{"text": "6 , pp .924 - 930 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Heidbuchel , P. Verhamme , M. Alings , et al . , \" European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non - valvular atrial fibrillation .", "label": "", "metadata": {}, "score": "55.457424"}
{"text": "Important ongoing research is addressing how to safely and effectively use the new drugs in general practice and how to more effectively implement oral anticoagulation , including with warfarin , to better prevent AF - related stroke in the US and around the world .", "label": "", "metadata": {}, "score": "55.488358"}
{"text": "Because of a potential risk of retroperitoneal hematoma in lumbar plexus and paravertebral blocks , ESA recommends the same guidelines for these two peripheral nerve blocks as for neuraxial blockades [ 78 , 80 ] .", "label": "", "metadata": {}, "score": "55.508106"}
{"text": "NOACs fundamentally alter the above - treatment paradigm .With their efficacy for stroke prevention at least equal to VKAs and convenient fixed - dose administration , acceptability among physicians and patients should increase .", "label": "", "metadata": {}, "score": "55.606743"}
{"text": "476 - 487 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. Gouin - Thibault , C. Flaujac , X. Delavenne , et al . , \" Assessment of apixaban plasma levels by laboratory tests : suitability of three anti - Xa assays .", "label": "", "metadata": {}, "score": "55.65673"}
{"text": "9855 , pp .1749 - 1758 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. L. Dans , S. J. Connolly , L. Wallentin et al . , \" Concomitant use of antiplatelet therapy with dabigatran or warfarin in the randomized evaluation of long - term anticoagulation therapy ( RE - LY ) trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "55.657883"}
{"text": "[ 119 ] concluded that patients with chronic AF had twice as much risks of postoperative stroke , especially in neurosurgery and vascular surgery .But first of all surgical bleeding risk must be under control [ 121 ] .", "label": "", "metadata": {}, "score": "55.67135"}
{"text": "11 , pp .1245 - 1248 , 2002 .View at Google Scholar \u00b7 View at Scopus .I. A. Naess , S. C. Christiansen , P. Romundstad , S. C. Cannegieter , F. R. Rosendaal , and J. Hammerstr\u00f8m , \" Incidence and mortality of venous thrombosis : a population - based study , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "55.67393"}
{"text": "References .K. H. Xing , G. Morrison , W. Lim , J. Douketis , A. Odueyungbo , and M. Crowther , \" Has the incidence of deep vein thrombosis in patients undergoing total hip / knee arthroplasty changed over time ?", "label": "", "metadata": {}, "score": "55.696297"}
{"text": "23 , pp .2859 - 2860 , 2005 .View at Google Scholar \u00b7 View at Scopus .S. J. Connolly , M. D. Ezekowitz , S. Yusuf , et al . , \" Dabigatran versus warfarin in patients with atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "55.728897"}
{"text": "The presence of cancer was categorized as known active cancer at study entry or cancer diagnosed during treatment .All other results for thrombosis and PE were classified as intermediate .", "label": "", "metadata": {}, "score": "55.757927"}
{"text": "There is little data available to identify the risk of blood loss related to the invasive procedure or surgery [ 60 ] , except for cardiac surgery [ 61 ] .", "label": "", "metadata": {}, "score": "55.818974"}
{"text": "Should NOAs Be Used for the Management of VTE in Gastrointestinal Cancer Patients ?Existing data indicate noninferior therapeutic efficacy and acceptable safety of NOAs in comparison to VKAs and LMWH in the general population .", "label": "", "metadata": {}, "score": "55.83438"}
{"text": "11 , pp .981 - 992 , 2011 .View at Google Scholar . D. Kubitza , M. Becka , B. Voith , M. Zuehlsdorf , and G. Wensing , \" Safety , pharmacodynamics , and pharmacokinetics of single doses of BAY 59 - 7939 , an oral , direct factor Xa inhibitor , \" Clinical Pharmacology and Therapeutics , vol .", "label": "", "metadata": {}, "score": "55.895607"}
{"text": "4 , pp .575 - 579 , 2002 .View at Google Scholar \u00b7 View at Scopus .L. A. Menapace , D. R. Peterson , A. Berry , T. Sousou , and A. A. Khorana , \" Symptomatic and incidental thromboembolism are both associated with mortality in pancreatic cancer , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "55.898"}
{"text": "299 - 306 , 2008 .View at Publisher \u00b7 View at Google Scholar .S. Sallah , J. Y. Wan , and N. P. Nguyen , \" Venous thrombosis in patients with solid tumors : determination of frequency and characteristics , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "55.994473"}
{"text": "The two doses of dabigatran tested were double blinded .While both study designs have advantages and limitations , it is worth noting the impact of trial design on outcomes [ 43 ] .", "label": "", "metadata": {}, "score": "55.994522"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. R. Lassen , G. E. Raskob , A. Gallus , G. Pineo , D. Chen , and P. Hornick , \" Apixaban versus enoxaparin for thromboprophylaxis after knee replacement ( ADVANCE-2 ) : a randomised double - blind trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "56.007744"}
{"text": "The ORBIT - AF II registry has started to enroll .Similar to ORBIT - AF , ORBIT - AF II is a multicentered prospective outpatient registry ; however , this registry will focus on postapproval observational data to evaluate outcomes of novel oral anticoagulant therapies in a broader outpatient setting .", "label": "", "metadata": {}, "score": "56.007782"}
{"text": "9745 , pp .975 - 983 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wallentin , R. D. Lopes , M. Hanna et al . , \" Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for Stroke prevention in atrial fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "56.063446"}
{"text": "Avoid combination .Sugammadex : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Thrombolytic Agents : May enhance the anticoagulant effect of Anticoagulants .", "label": "", "metadata": {}, "score": "56.082233"}
{"text": "As such , they may not predict similar degrees of ICH risk , which are significantly attenuated with NOACs .While extracranial bleeds are still troubling , they do not appear to increase the rates of fatal or potentially fatal bleeds .", "label": "", "metadata": {}, "score": "56.084"}
{"text": "5 , pp .373 - 379 , 2005 .View at Google Scholar \u00b7 View at Scopus .S. Kaatz , J. D. Douketis , H. Zhou , B. F. Gage , and R. H. White , \" Risk of stroke after surgery in patients with and without chronic atrial fibrillation , \" Journal of Thrombosis and Haemostasis , vol . 8 , no .", "label": "", "metadata": {}, "score": "56.085052"}
{"text": "Conclusion .There has been an enormous amount of data generated and analyses performed , including those in collaboration with our research groups at the Duke Clinical Research Institute , regarding oral anticoagulation for preventing stroke in AF .", "label": "", "metadata": {}, "score": "56.086594"}
{"text": "HB has received research grant support from the Swiss National Foundation , Daiichi Sankyo , and Bayer Schering Pharma as well as honoraria for lectures or consultancy from Pfizer and Bayer Schering Pharma .", "label": "", "metadata": {}, "score": "56.091816"}
{"text": "HB has received research grant support from the Swiss National Foundation , Daiichi Sankyo , and Bayer Schering Pharma as well as honoraria for lectures or consultancy from Pfizer and Bayer Schering Pharma .", "label": "", "metadata": {}, "score": "56.091816"}
{"text": "M. C. Fang , A. S. Go , Y. Chang , L. Borowsky , N. K. Pomernacki , and D. E. Singer , \" Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "56.15113"}
{"text": "11 , pp .970 - 979 , 1996 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. D. White , M. Gruber , J. Feyzi et al . , \" Comparison of outcomes among patients randomized to warfarin therapy according to anticoagulant control results from SPORTIF III and V , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "56.20127"}
{"text": "Official Title ICMJE .A Prospective , Randomized , Controlled , Analyst - blinded , Parallel Group Study to Investigate the Effect of Antithrombotic Triple Therapy With Ticagrelor and Acetylsalicylic Acid in Combination With Dabigatran or Rivaroxaban or Phenprocoumon on Markers of Coagulation Activation in Venous and Shed Blood in Healthy Male Subjects .", "label": "", "metadata": {}, "score": "56.21068"}
{"text": "160S-198S , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Sato , K. Ishikawa , A. Kitabatake et al . , \" Low - dose aspirin for prevention of stroke in low - risk patients with atrial fibrillation : Japan atrial fibrillation stroke trial , \" Stroke , vol .", "label": "", "metadata": {}, "score": "56.266888"}
{"text": "10.2307/2530862 View Article PubMed .B\u00fcller HR , Cohen AT , Davidson B , Decousus H , Gallus AS , Gent M , Pillion G , Piovella F , Prins MH , Raskob GE , van Gogh Investigators : Idraparinux versus standard therapy for venous thromboembolic disease .", "label": "", "metadata": {}, "score": "56.320755"}
{"text": "5 , pp .876 - 886 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. V. Huisman , G. Y. H. Lip , H. Diener , M. Brueckmann , J. van Ryn , and A. Clemens , \" Dabigatran etexilate for stroke prevention in patients with atrial fibrillation : resolving uncertainties in routine practice , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "56.340645"}
{"text": "143 - 150 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. D. Lopes , J. H. Alexander , S. M. Al - Khatib et al . , \" Apixaban for reduction in stroke and other ThromboemboLic events in atrial fibrillation ( ARISTOTLE ) trial : design and rationale , \" The American Heart Journal , vol .", "label": "", "metadata": {}, "score": "56.384094"}
{"text": "Of the three NOACs , apixaban demonstrated reduced bleeding ( major and/or nonmajor clinically relevant bleeds ) compared to a VKA . ROCKET AF studied a significantly higher - risk group of AF patients compared to RE - LY and ARISTOTLE , representing the population most difficult to treat who are at increased risk of both thromboembolic events and bleeds .", "label": "", "metadata": {}, "score": "56.38829"}
{"text": "19 , pp .2387 - 2394 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. N. Hess , S. M. Al - Khatib , C. B. Granger , and R. Lopes , \" A review of apixban for stroke prevention in atrial fibrillation : insights from ARISTOTLE , \" Expert Review of Cardiovascular Therapy , vol .", "label": "", "metadata": {}, "score": "56.39173"}
{"text": "5 , pp .1056 - 1064 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. H. Hohnloser , J. Oldgren , S. Yang et al . , \" Myocardial ischemic events in patients with atrial fibrillation treated with dabigatran or warfarin in the RE - LY ( Randomized evaluation of long - term anticoagulation therapy ) trial , \" Circulation , vol .", "label": "", "metadata": {}, "score": "56.407383"}
{"text": "M. Cushman , A. W. Tsai , R. H. White et al . , \" Deep vein thrombosis and pulmonary embolism in two cohorts : the longitudinal investigation of thromboembolism etiology , \" American Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "56.417423"}
{"text": "Furthermore , there is a high intercenter variability in red cell blood loss for the main procedure , mainly reflecting differences in surgical techniques .Similarly , classifications into different surgery bleeding risks according to the severity of trauma and the risk of periprocedural bleeding [ 12 , 60 , 62 - 65 ] are not always easy to use in daily practice .", "label": "", "metadata": {}, "score": "56.46747"}
{"text": "107 , no .6 , pp .1053 - 1065 , 2012 .View at Publisher \u00b7 View at Google Scholar .P. L. Hess , S. Kim , J. P. Piccini et al . , \" Use of evidence - based cardiac prevention therapy among outpatients with atrial fibrillation , \" The American Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "56.473263"}
{"text": "4 , pp .692 - 694 , 2005 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Nascimento , D. H. Birnie , J. S. Healey , et al . , \" Managing novel oral anticoagulants in patients with atrial fibrillation undergoing device surgery : Canadian survey , \" Canadian Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "56.50473"}
{"text": "861 - 867 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Apostolakis , D. A. Lane , Y. Guo , H. Buller , and G. Y. H. Lip , \" Performance of the HEMORR2HAGES , ATRIA , and HAS - BLED bleeding risk - prediction scores in nonwarfarin anticoagulated atrial fibrillation patients , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "56.507328"}
{"text": "View at Google Scholar .W. Gogarten , E. Vandermeulen , H. van Aken , S. Kozek , J. V. Llau , and C. M. Samama , \" Regional anaesthesia and antithrombotic agents : recommendations of the European Society of Anaesthesiology , \" European Journal of Anaesthesiology , vol .", "label": "", "metadata": {}, "score": "56.511223"}
{"text": "294 - 303 , 2012 .View at Publisher \u00b7 View at Google Scholar .R. H. White , H. Zhou , and P. S. Romano , \" Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures , \" Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "56.552757"}
{"text": "31 , pp .3436 - 3441 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier and A. Clemens , \" Pharmacology , pharmacokinetics , and pharmacodynamics of dabigatran etexilate , an oral direct thrombin inhibitor , \" Clinical and Applied Thrombosis / Hemostasis , vol .", "label": "", "metadata": {}, "score": "56.59117"}
{"text": "The incidence of bleeding ( major and nonmajor clinically relevant bleeding according to International Society on Thrombosis and Hemostasis definitions [ 75 ] ) was higher in case of bridging therapy , while stroke and systemic embolism were similar in both groups [ 42 ] .", "label": "", "metadata": {}, "score": "56.615425"}
{"text": "The optimal timing between the administration of rivaroxaban and neuraxial procedures is not known .Placement or removal of an epidural catheter or lumbar puncture is best performed when the anticoagulant effect of rivaroxaban is low .", "label": "", "metadata": {}, "score": "56.626396"}
{"text": "Tocilizumab : May decrease the serum concentration of CYP3A4 Substrates .Monitor therapy .Tositumomab and Iodine I 131 Tositumomab : Anticoagulants may enhance the adverse / toxic effect of Tositumomab and Iodine I 131 Tositumomab .", "label": "", "metadata": {}, "score": "56.65326"}
{"text": "15 , pp .1960 - 1966 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Prestidge , S. Lee , P. Harper , L. Young , and P. Ockelford , \" Survival in patients with malignancy and venous thromboembolism by tumour subtype and thrombus location , \" Journal of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "56.659363"}
{"text": "Its half - life is 7 - 11 hours and it is dually metabolized by both the liver ( 2/3 ) and kidney ( 1/3 ) , therefore , special consideration must be taken in patients with hepatic or renal impairment [ 38 ] .", "label": "", "metadata": {}, "score": "56.67926"}
{"text": "This increasing burden of atrial fibrillation will lead to a higher incidence of stroke , as patients with atrial fibrillation have a five- to sevenfold greater risk of stroke than the general population .", "label": "", "metadata": {}, "score": "56.705284"}
{"text": "Warfarin has a slow onset of action and has a narrow therapeutic window requiring frequent monitoring .Patients taking warfarin have only a 33 % compliance rate and are frequently outside the targeted INR range increasing the risk of both bleeding and VTE [ 9 , 10 ] .", "label": "", "metadata": {}, "score": "56.705708"}
{"text": "6 , pp .690 - 698 , 2005 .View at Google Scholar . H. C. Diener , \" Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non - valvular atrial fibrillation : pooled analysis from the SPORTIF III and V studies , \" Cerebrovascular Diseases , vol .", "label": "", "metadata": {}, "score": "56.77899"}
{"text": "239 - 245 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. G. Hart , L. A. Pearce , and M. I. Aguilar , \" Meta - analysis : antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "56.840607"}
{"text": "24 , pp .444 - 449 , 2012 .View at Google Scholar .G. C. Connolly , R. Chen , O. Hyrien , et al . , \" Incidence , risk factors and consequences of portal vein and systemic thromboses in hepatocellular carcinoma , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "56.899483"}
{"text": "S. B. Olsson , \" Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non - valvular atrial fibrillation ( SPORTIF III ) : randomised controlled trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "57.05626"}
{"text": "Phase III Clinical Trials .The phase III randomized , double - blind RE - COVER study [ 35 ] compared 6 months of dabigatran etexilate 150 mg twice daily ( . to dose - adjusted warfarin ( .", "label": "", "metadata": {}, "score": "57.08586"}
{"text": "Drug : Phenprocoumon , Ticagrelor , ASA .Study Arm ( s ) .Active Comparator : Phenprocoumon , Ticagrelor , ASA .Phenprocoumon X mg to reach an INR of 2 - 3 on day 5 of triple therapy Ticagrelor 90 mg td ASA 100 mg od for 5 days Atrial Fibrillation : A Review of Recent Studies with a Focus on Those from the Duke Clinical Research Institute .", "label": "", "metadata": {}, "score": "57.090755"}
{"text": "Nonvalvular atrial fibrillation ( to prevent stroke and systemic embolism ) : Adults : Oral : 20 mg once daily with the evening meal .Conversion : .", "label": "", "metadata": {}, "score": "57.123398"}
{"text": "View at Google Scholar .L. Linkins , P. T. Choi , and J. D. Douketis , \" Clinical impact of bleeding in patients taking oral anticoagulant therapy for venous thromboembolism : a meta - analysis , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "57.170155"}
{"text": "Patients with severe liver and kidney disease have generally been excluded from clinical trials of NOAs .Liver impairment is frequently seen in gastrointestinal cancer patients , either as a result of metastatic disease ( the liver is the most common site of metastases for gastrointestinal cancers ) , biliary obstruction , or chemotherapy - related liver toxicity .", "label": "", "metadata": {}, "score": "57.188267"}
{"text": "TF - VIIa complexes are suppressed by VKAs , which block vitamin K - dependent carboxylation of factor VII , but not by NOACs with their more highly selective targets .", "label": "", "metadata": {}, "score": "57.242702"}
{"text": "Anticoagulation with Warfarin in High - Risk Patients .Patients with AF and acute myocardial infarction ( AMI ) are at high risk of death and major cardiovascular outcomes .", "label": "", "metadata": {}, "score": "57.28972"}
{"text": "The risk for bleeding may be increased .Monitor therapy .Nevirapine : May decrease the serum concentration of Rivaroxaban .Monitor therapy .Nintedanib : Anticoagulants may enhance the adverse / toxic effect of Nintedanib .", "label": "", "metadata": {}, "score": "57.435665"}
{"text": "SD Standard deviation , VKA Vitamin K antagonist , VTE Venous thromboembolism .Prins et al .\u00a7 For recurrent VTE , the p - value for the treatment group \u00d7 previous DVT / PE was 0.032 .", "label": "", "metadata": {}, "score": "57.47172"}
{"text": "32 - 38 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. C. Spyropoulos and A. G. G. Turpie , \" Perioperative bridging interruption with heparin for the patient receiving long - term anticoagulation , \" Current Opinion in Pulmonary Medicine , vol .", "label": "", "metadata": {}, "score": "57.48522"}
{"text": "12 , pp .857 - 867 , 2007 .View at Google Scholar \u00b7 View at Scopus . E. M. Hylek , A. S. Go , Y. Chang et al . , \" Effect of intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "57.49105"}
{"text": "Table 4 provides a summary of completed phase III trials of NOAs for the treatment of VTE .Table 4 : Summary of completed phase III trials of novel oral anticoagulants .", "label": "", "metadata": {}, "score": "57.51876"}
{"text": "4 , pp .607 - 615 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. M. Hylek , C. Evans - Molina , C. Shea , L. E. Henault , and S. Regan , \" Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation , \" Circulation , vol .", "label": "", "metadata": {}, "score": "57.545868"}
{"text": "Weighted absolute risk differences and their CIs were calculated using the Mantel - Haenszel asymptotic method with the weights based upon sample sizes per stratum .", "label": "", "metadata": {}, "score": "57.61106"}
{"text": "The rate of warfarin use remained low over time , despite reductions in clopidogrel use from 6 to 12 months after discharge .These findings suggest that providers are using factors other than clinical risk stratification tools to guide anticoagulation decisions in high - risk patients .", "label": "", "metadata": {}, "score": "57.66355"}
{"text": "87 - 97 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. Schuringa and D. Yen , \" Home prophylactic warfarin anticoagulation program after hip and knee arthroplasty , \" Canadian Journal of Surgery , vol .", "label": "", "metadata": {}, "score": "57.67813"}
{"text": "The EINSTEIN Investigators : Oral rivaroxaban for symptomatic venous thromboembolism .N Engl J Med 2010 , 363:2499 - 2510 .The EINSTEIN - PE Investigators : Oral rivaroxaban for the treatment of symptomatic pulmonary embolism .", "label": "", "metadata": {}, "score": "57.694447"}
{"text": "112 - 120 , 2014 .View at Google Scholar . A. Majeed , H. G. Hwang , S. J. Connolly , et al . , \" Management and outcomes of major bleeding during treatment with dabigatran or warfarin , \" Circulation , vol .", "label": "", "metadata": {}, "score": "57.750492"}
{"text": "CBC with differential ; renal function prior to initiation , when clinically indicated , and at least annually ( AHA / ACC / HRS [ January 2014 ] ) ; hepatic function .", "label": "", "metadata": {}, "score": "57.790092"}
{"text": "This delay can expose patients at risk for thromboembolism .Twenty - four hours are recommended before resuming oral anticoagulation after a procedure at low risk of bleeding [ 60 , 62 ] .", "label": "", "metadata": {}, "score": "57.81418"}
{"text": "Neuraxial Anesthesia .For patients without thrombotic risk ( assessed by CHA 2 D 2 -VASc score ) , Benzon et al .[ 78 ] recommend 5 half - life intervals between NOAC 's discontinuation and a neuraxial puncture ( with or without epidural catheter placement ) .", "label": "", "metadata": {}, "score": "57.81527"}
{"text": "10.1186/1477 - 9560 - 11 - 13 PubMed Central View Article PubMed .Gail M , Simon R : Testing for qualitative interactions between treatment effects and patient subsets .", "label": "", "metadata": {}, "score": "57.85638"}
{"text": "10.1056/NEJMoa1207541 View Article PubMed .The EINSTEIN Investigators : Oral rivaroxaban for symptomatic venous thromboembolism .N Engl J Med 2010 , 363 : 2499 - 2510 .", "label": "", "metadata": {}, "score": "57.86545"}
{"text": "12 , pp .3594 - 3599 , 2011 .View at Google Scholar .J. Beyer - Westendorf and H. Buller , \" External and internal validity of open label or double - blind trials in oral anticoagulation : better , worse or just different ? \"", "label": "", "metadata": {}, "score": "58.0429"}
{"text": "C .Pregnancy Considerations .Use during pregnancy is contraindicated in the Canadian labeling .Adverse events were observed in animal reproduction studies .Based on ex - vivo data , rivaroxaban crosses the placenta ( Bapat 2015 ) .", "label": "", "metadata": {}, "score": "58.072357"}
{"text": "175 - 179 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. D. Douketis , A. C. Spyropoulos , F. A. Spencer , et al . , \" Perioperative management of antithrombotic therapy : antithrombotic Therapy and Prevention of Thrombosis , 9th ed : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines , \" Chest , vol .", "label": "", "metadata": {}, "score": "58.120857"}
{"text": "1093 - 1100 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .M. C. Fang , A. S. Go , Y. Chang et al . , \" A new risk scheme to predict warfarin - associated hemorrhage : the ATRIA ( Anticoagulation and Risk Factors in Atrial Fibrillation )", "label": "", "metadata": {}, "score": "58.154396"}
{"text": "e326S - e350S , 2012 .View at Google Scholar . A. Vuylsteke , C. Pagel , C. Gerrard et al . , \" The Papworth Bleeding Risk Score : a stratification scheme for identifying cardiac surgery patients at risk of excessive early postoperative bleeding , \" European Journal of Cardio - thoracic Surgery , vol .", "label": "", "metadata": {}, "score": "58.16423"}
{"text": "Patients were treated for 3 , 6 , or 12 months , as determined locally .Follow - up and outcome assessment Both studies used the same protocol to ascertain out- comes .", "label": "", "metadata": {}, "score": "58.267532"}
{"text": "Salicylates : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Siltuximab : May decrease the serum concentration of CYP3A4 Substrates .Monitor therapy .", "label": "", "metadata": {}, "score": "58.287582"}
{"text": "386 - 387 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. A. Nieto , R. Solano , N. Trapero Iglesias et al . , \" Validation of a score for predicting fatal bleeding in patients receiving anticoagulation for venous thromboembolism , \" Thrombosis Research , vol .", "label": "", "metadata": {}, "score": "58.35556"}
{"text": "Monitor for signs of neurologic impairment ( eg , midline back pain , numbness / weakness of legs , bowel / bladder dysfunction ) ; prompt diagnosis and treatment are necessary .", "label": "", "metadata": {}, "score": "58.432854"}
{"text": "1605 - 1616 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Hijazi , L. Wallentin , A. Siegbahn et al . , \" High sensitivity troponin - T and risk stratification in atrial fibrillation during treatment with apixaban or warfarin , \" Journal of the American College of Cardiology , vol .", "label": "", "metadata": {}, "score": "58.445747"}
{"text": "A subgroup analysis of ARISTOTLE found that apixaban , compared with warfarin , significantly lowered rates of stroke or systemic embolism across all risk categories for stroke , as well as decreasing major bleeding in all risk categories for bleeding [ 50 ] .", "label": "", "metadata": {}, "score": "58.466423"}
{"text": "Firstly , we used an open - label design that could have biased as- sessment of outcomes .Nevertheless , efforts were made to limit investigator bias , including the requirement to use objective and validated tests to confirm suspected recurrent VTE and the use of an independent commit- tee , whose members were blinded to treatment assign- ment , to adjudicate outcome events .", "label": "", "metadata": {}, "score": "58.486595"}
{"text": "The AVERROES trial showed that apixaban was far more effective ( 46 % relative risk reduction in stroke ) and nearly as safe ( nonsignificant 12 % increase risk of major bleeding and no difference in ICH ) as aspirin [ 34 ] .", "label": "", "metadata": {}, "score": "58.56277"}
{"text": "9S-16S , 2009 .View at Google Scholar \u00b7 View at Scopus . S. Lessire , A.-S. Dincq , J. Douxfils , et al . , \" Preventive strategies against bleeding due to nonvitamin K antagonist oral anticoagulants , \" BioMed Research International , vol .", "label": "", "metadata": {}, "score": "58.640793"}
{"text": "283 - 294 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Frost , J. Wang , S. Nepal et al . , \" Apixaban , an oral , direct factor Xa inhibitor : single dose safety , pharmacokinetics , pharmacodynamics and food effect in healthy subjects , \" The British Journal of Clinical Pharmacology , vol .", "label": "", "metadata": {}, "score": "58.715942"}
{"text": "Kaplan - Meier curves . a .Primary efficacy outcome , b .Principal safety outcome and c .Major bleeding .VKA , Vitamin K antagonist .", "label": "", "metadata": {}, "score": "58.83407"}
{"text": "6 , pp .1116 - 1127 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier and A. Clemens , \" Pharmacology , pharmacokinetics , and pharmacodynamics of dabigatran etexilate , an oral direct thrombin inhibitor , \" Clinical and Applied Thrombosis / Hemostasis , vol .", "label": "", "metadata": {}, "score": "58.927383"}
{"text": "The registry has now completed its three - year follow - up period .The ORBIT - AF registry includes approximately 200 sites and 10,000 patients , who are older than 18 years with AF and the ability to follow up every six months .", "label": "", "metadata": {}, "score": "58.966347"}
{"text": "Drugs Interactions .Two mechanisms are mainly involved in NOACs ' metabolism and elimination : the efflux operated by P - glycoprotein ( P - gp ) and the CYP450 isoform CYP3A4 .", "label": "", "metadata": {}, "score": "59.121357"}
{"text": "640 - 641 , 2011 .View at Google Scholar .S. Ghanny , T. E. Warkentin , and M. A. Crowther , \" Reversing anticoagulant therapy , \" Current Drug Discovery Technologies , vol .", "label": "", "metadata": {}, "score": "59.199295"}
{"text": "ALERT : U.S. Boxed Warning .Premature discontinuation increases the risk of thrombotic events : .Premature discontinuation of any oral anticoagulant , including rivaroxaban , increases the risk of thrombotic events .", "label": "", "metadata": {}, "score": "59.218422"}
{"text": "Management in an Emergency Situation .Waiting and postponing semiurgent procedures may be a reasonable strategy to prevent bleeding .It is very important to establish a hospital - wide policy for bleeding management in patients taking NOACs , based on the available blood products and laboratory assays in each institution .", "label": "", "metadata": {}, "score": "59.36889"}
{"text": "Management : Carefully consider risks and benefits of this combination and monitor closely ; Canadian labeling recommends avoiding prasugrel or ticagrelor .Consider therapy modification .", "label": "", "metadata": {}, "score": "59.37986"}
{"text": "155 - 162 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. G. G. Turpie , \" Oral , direct factor Xa inhibitors in development for the prevention and treatment of thromboembolic diseases , \" Arteriosclerosis , Thrombosis , and Vascular Biology , vol .", "label": "", "metadata": {}, "score": "59.390675"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .C. Kearon , E. A. Akl , A. J. Comerota et al . , \" Antithrombotic therapy for VTE disease : antithrombotic therapy and prevention of thrombosis , 9th ed : American College of Chest Physicians evidence - based clinical practice guidelines , \" Chest , vol .", "label": "", "metadata": {}, "score": "59.42106"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .L. Wallentin , S. Yusuf , M. D. Ezekowitz et al . , \" Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation : an analysis of the RE - LY trial , \" The Lancet , vol .", "label": "", "metadata": {}, "score": "59.465286"}
{"text": "Primary efficacy analyses were intention - to - treat ( ITT ) in RE - LY and ARISTOTLE , and per protocol on - treatment in ROCKET AF .", "label": "", "metadata": {}, "score": "59.4995"}
{"text": "The prespecified principal safety outcome was clinically relevant bleeding , defined as the composite of major and nonmajor clinically relevant bleeding , as described previously [ 8 , 9 ] .", "label": "", "metadata": {}, "score": "59.503166"}
{"text": "For epidural anesthesia , DE can not be administrated if a permanent catheter is inserted .For rivaroxaban , the first dose after epidural anesthesia is administered 6 - 10 hours after the end of surgery .", "label": "", "metadata": {}, "score": "59.56353"}
{"text": "S. Schulman and C. Kearon , \" Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non - surgical patients , \" Journal of Thrombosis and Haemostasis , vol .", "label": "", "metadata": {}, "score": "59.664932"}
{"text": "11 , pp .1019 - 1026 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Ansell , J. Hirsh , E. Hylek , A. Jacobson , M. Crowther , and G. Palareti , \" Pharmacology and management of the vitamin K antagonists : American College of Chest Physicians Evidence - Based Clinical Practice Guidelines ( 8th Edition ) , \" Chest , vol .", "label": "", "metadata": {}, "score": "59.674744"}
{"text": "Based on the information gathered through the interviewing process , a practice toolkit that contains a series of tools that address the gaps and barriers to quality care will be developed and shared with all participants .", "label": "", "metadata": {}, "score": "59.72071"}
{"text": "Since these treatment tools have been used in the past to help guide decisions regarding anticoagulation using vitamin K antagonists and antiplatelet agents , a subgroup analysis of ARISTOTLE was performed to determine the treatment effects of apixaban according to stroke and bleeding [ 50 ] .", "label": "", "metadata": {}, "score": "59.730972"}
{"text": "Gastrointestinal endoscopic biopsy without cessation of DE seems to be safe according to current Japanese guidelines [ 67 ] .It is recommended to perform the procedure at the trough drug concentration ( 12 or 24 hours after the last intake ) [ 13 , 63 , 68 ] .", "label": "", "metadata": {}, "score": "59.734154"}
{"text": "Some prerequisites are essential to allow periprocedural decision ( Table 8 ) .The decision about perioperative NOACs management should be written in the medical record .", "label": "", "metadata": {}, "score": "59.825413"}
{"text": "In addition , when interpreting the results of these subgroup analyses , it must be kept in mind that these were noninferiority studies , and thus conclusions about superiority can not be drawn .", "label": "", "metadata": {}, "score": "59.861336"}
{"text": "Warfarin use at discharge following acute myocardial infarction according to CHADS2 and CHA2DS2-VASc scores [ 24 ] .Percentages of medication use were visually estimated from primary publication .", "label": "", "metadata": {}, "score": "59.95618"}
{"text": "J. A. Cairns , S. Connolly , S. McMurtry , M. Stephenson , and M. Talajic , \" Canadian cardiovascular society atrial fibrillation guidelines 2010 : prevention of stroke and systemic thromboembolism in atrial fibrillation and flutter , \" Canadian Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "60.100117"}
{"text": "Postoperative thromboprophylaxis : . CrCl 30 to 50 mL / minute : No dosage adjustment necessary ; use with caution .ESRD requiring hemodialysis : Avoid use .", "label": "", "metadata": {}, "score": "60.113567"}
{"text": "RB has received research support from Bayer HealthCare Pharmaceuticals , Bristol - Myers Squibb , Boehringer and Daiichi Sankyo , and participated in scientific advisory boards organized by all of the former companies .", "label": "", "metadata": {}, "score": "60.122177"}
{"text": "We will use qualitative interviewing to develop a system to categorize patients according to reasons for withholding anticoagulation therapy with the goal of defining performance indicators that can be used for quality assessment of AF therapy within health care systems and clinical practices .", "label": "", "metadata": {}, "score": "60.159393"}
{"text": "Severe hepatic impairment ( Child - Pugh class C ) : There are no dosage adjustments provided in the manufacturer 's labeling ( has not been studied ) .", "label": "", "metadata": {}, "score": "60.15945"}
{"text": "22 , pp .2093 - 2104 , 2013 .View at Google Scholar . A. K. Kakkar , I. Mueller , J. P. Bassand , et al . , \" Risk profiles and antithrombotic treatment of patients newly diagnosed with atrial fibrillation at risk of stroke : perspectives from the International , Observational , Prospective GARFIELD registry , \" PloS ONE , vol . 8 , no .", "label": "", "metadata": {}, "score": "60.277344"}
{"text": "In RE - LY , prospective open - label blinded endpoint evaluation ( PROBE ) trial design obviated the logistical difficulties of mounting a large - scale international double - blind VKA - controlled trial .", "label": "", "metadata": {}, "score": "60.316895"}
{"text": "NOAs are substrates of either the CYP ( rivaroxaban and apixaban ) or p - glycoprotein ( dabigatran and apixaban ) systems .The CYP system , particularly CYP3A4 , is involved in the metabolism of oral chemotherapeutic and targeted agents used in the treatment of gastrointestinal cancers ( such as capecitabine , which can induce CYP2D9 , and sorafenib , sunitinib , imatinib , and erlotinib ) .", "label": "", "metadata": {}, "score": "60.383347"}
{"text": "Table 4 summarises the efficacy outcomes in the active treatment groups , expressed as relative risk reductions ( RRRs ) or increments of event rates , compared to VKA - controlled populations in the trials [ 13 - 15 , 21 ] .", "label": "", "metadata": {}, "score": "60.388607"}
{"text": "Postoperative DVT thromboprophylaxis : Adults : Oral : Note : Initiate therapy after hemostasis has been established , 6 to 10 hours postoperatively .Knee replacement : 10 mg once daily ; recommended total duration of therapy : 12 to 14 days ; ACCP recommendation : Minimum of 10 to 14 days ; extended duration of up to 35 days suggested ( Guyatt 2012 ) .", "label": "", "metadata": {}, "score": "60.392273"}
{"text": "I17-I21 , 2003 .View at Google Scholar . H. T. S\u00f8rensen , L. Mellemkjaer , J. H. Olsen , and J. A. Baron , \" Prognosis of cancers associated with venous thromboembolism , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "60.401417"}
{"text": "113 - 123 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .B. I. Eriksson , D. J. Quinlan , and J. I. Weitz , \" Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development , \" Clinical Pharmacokinetics , vol .", "label": "", "metadata": {}, "score": "60.459244"}
{"text": "View at Google Scholar .R. J. Friedman , A. S. Gallus , F. D. Cushner , G. FitzGerald , and F. A. Anderson Jr. , \" Physician compliance with guidelines for deep - vein thrombosis prevention in total hip and knee arthroplasty , \" Current Medical Research and Opinion , vol .", "label": "", "metadata": {}, "score": "60.489174"}
{"text": "All these scores offer a modest predictive performance of the estimation of the bleeding risk in NOACs treated patients with AF .However , HAS - BLED and HEMORR 2 HAGES scores are superior in terms of clinically relevant bleeding for patients on NOACs [ 58 ] .", "label": "", "metadata": {}, "score": "60.520775"}
{"text": "In contrast , we also know that about one - quarter of patients with AF have moderate or severe valve abnormalities other than mechanical prosthetic valves or clinically significant mitral stenosis .", "label": "", "metadata": {}, "score": "60.542976"}
{"text": "4 , pp .596 - 605 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .S. A. Kozek - Langenecker , \" Perioperative management issues of direct oral anticoagulants , \" Seminars in Hematology , vol .", "label": "", "metadata": {}, "score": "60.5681"}
{"text": "1 , no .8532 , pp .526 - 529 , 1987 .View at Google Scholar \u00b7 View at Scopus . Y. Miyasaka , M. E. Barnes , K. R. Bailey et al . , \" Mortality Trends in Patients Diagnosed With First Atrial Fibrillation .", "label": "", "metadata": {}, "score": "60.588333"}
{"text": "6 , pp .1116 - 1127 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. E. Warkentin , P. Margetts , S. J. Connolly , A. Lamy , C. Ricci , and J. W. Eikelboom , \" Recombinant factor VIIa ( rFVIIa ) and hemodialysis to manage massive dabigatran - associated postcardiac surgery bleeding , \" Blood , vol .", "label": "", "metadata": {}, "score": "60.736366"}
{"text": "Gail M , Simon R : Testing for qualitative interactions between treatment effects and patient subsets .Biometrics 1985 , 41:361 - 372 .van Gogh Investigators , B\u00fcller HR , Cohen AT , Davidson B , Decousus H , Gallus AS , Gent M , Pillion G , Piovella F , Prins MH , Raskob GE : Idraparinux versus standard therapy for venous thromboembolic disease .", "label": "", "metadata": {}, "score": "60.81789"}
{"text": "At the same time , the need for caution with their use in patients with severely impaired renal function should be emphasised .Introduction .Atrial fibrillation ( AF ) increases the risk of embolic stroke .", "label": "", "metadata": {}, "score": "60.940323"}
{"text": "Trial registration : EINSTEIN - PE : ClinicalTrials.gov , NCT00439777 ; EINSTEIN - DVT : ClinicalTrials.gov , NCT00440193 .Prins et al .Introduction Venous thromboembolism ( VTE ) , the collective term for deep - vein thrombosis ( DVT ) and/or pulmonary em- bolism ( PE ) , is a relatively common cardiovascular dis- order .", "label": "", "metadata": {}, "score": "61.048626"}
{"text": "Patients receiving apixaban instead of warfarin had lower rates of intracranial bleeding and decreased mortality .Apixaban has 27 % renal excretion .Similar to ROCKET - AF , patients taking medications affecting the CYP3A4 pathway were excluded from ARISTOTLE for potential drug - drug interactions [ 43 ] .", "label": "", "metadata": {}, "score": "61.05661"}
{"text": "There were significant reductions in ICH that mirror the significant RRRs observed in haemorrhagic stroke events .Taken together , they suggest a brain - protective effect for these NOACs , the exact mechanism of which remains to be elucidated .", "label": "", "metadata": {}, "score": "61.057915"}
{"text": "Background .Dabigatran etexilate ( Pradaxa , Boehringer Ingelheim Pharmaceuticals , Ridgefield CT ) is an orally available direct thrombin inhibitor with a half - life of 12 - 14 hours and rapid onset of action ( maximum activity is achieved within 2 - 3 hours ) [ 30 ] .", "label": "", "metadata": {}, "score": "61.08264"}
{"text": "Warfarin is far more effective than either aspirin or the combination of aspirin and clopidogrel and has comparable bleeding rates [ 31 - 33 ] .", "label": "", "metadata": {}, "score": "61.12"}
{"text": "446 - 455 , 2003 .View at Google Scholar \u00b7 View at Scopus .M. Khatod , M. C. Inacio , S. A. Bini , and E. W. Paxton , \" Prophylaxis against pulmonary embolism in patients undergoing total hip arthroplasty , \" Journal of Bone and Joint Surgery , vol .", "label": "", "metadata": {}, "score": "61.196663"}
{"text": "Patients .Between March 2007 and March 2011 , a total of 8282 patients were randomized at 314 sites in 38 countries ; 4151 patients were assigned to receive rivaroxaban and 4131 were assigned to receive standard - therapy ( Figure 1 ) .", "label": "", "metadata": {}, "score": "61.22831"}
{"text": "Both arms were terminated early due to excess thromboembolic and excess bleeding events in the dabigatran arm .There have also been case reports of patients with mechanical valves developing thrombus on the valves shortly after being changed from warfarin to dabigatran [ 37 , 55 ] .", "label": "", "metadata": {}, "score": "61.240173"}
{"text": "Interval between Last Dose and Invasive Procedure or Surgery .The interval between the last dose and the invasive procedure or surgery depends on the bleeding risk of the procedure and the drug half - life ( Table 3 ) .", "label": "", "metadata": {}, "score": "61.264645"}
{"text": "A RE - LY subanalysis found myocardial ischaemic events ( composite of MI , unstable angina , cardiac arrest , and cardiac death ) to be numerically , albeit not statistically significantly , lower among subjects randomised to dabigatran compared to the VKA [ 51 ] .", "label": "", "metadata": {}, "score": "61.310604"}
{"text": "21 , pp .2689 - 2696 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. D. Fihn , C. M. Callahan , D. C. Martin , M. B. McDonell , J. G. Henikoff , and R. H. White , \" The risk for and severity of bleeding complications in elderly patients treated with warfarin , \" Annals of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "61.311134"}
{"text": "Bayer HealthCare Pharmaceuticals .Department of Medicine , University of Ottawa and the Ottawa Hospital Research Institute .the EINSTEIN Investigators .References .Silverstein MD , Heit JA , Mohr DN , Petterson TM , O'Fallon WM , Melton LJ III : Trends in the incidence of deep vein thrombosis and pulmonary embolism : a 25-year population - based study .", "label": "", "metadata": {}, "score": "61.32722"}
{"text": "PSW has received research support from Bristol- Myers Squibb , Pfizer ; has participated on scientific advisory boards for Bayer Schering Pharma , Pfizer , and Boehringer Ingelheim ; and has received honoraria from Bayer Schering Pharma , Pfizer , and Biomerieux .", "label": "", "metadata": {}, "score": "61.350178"}
{"text": "PSW has received research support from Bristol - Myers Squibb , Pfizer ; has participated on scientific advisory boards for Bayer Schering Pharma , Pfizer , and Boehringer Ingelheim ; and has received honoraria from Bayer Schering Pharma , Pfizer , and Biomerieux .", "label": "", "metadata": {}, "score": "61.350178"}
{"text": "While its oral administration is more convenient , the narrow therapeutic window , multitude of dietary and drug - drug interactions , long half - life , and need for frequent monitoring make the administration of warfarin challenging , particularly in the cancer patient .", "label": "", "metadata": {}, "score": "61.43071"}
{"text": "Subgroup analyses did not include cancer patients .Apixaban .Background .Apixaban ( Eliquis , Pfizer , New York , NY ; Bristol - Myers Squibb , New York , NY ) is a direct factor Xa inhibitor that reaches peak concentration 3 hours after oral administration with a half - life of around 12 hours .", "label": "", "metadata": {}, "score": "61.433907"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. A. Nelson , J. P. Vavalle , C. H. May et al . , \" Warfarin use and long - term outcomes in patients with acute myocardial infarction and atrial fibrillation , \" Journal of Thrombosis and Thrombolysis , pp . 1 - 7 , 2013 .", "label": "", "metadata": {}, "score": "61.453545"}
{"text": "4 , Article ID e002686 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. H. Baron , P. S. Kamath , and R. D. McBane , \" Management of antithrombotic therapy in patients undergoing invasive procedures , \" The New England Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "61.472015"}
{"text": "Using currently accepted methods of VTE prophylaxis , the rate of symptomatic DVT is approximately 1%-3 % , and the rate of pulmonary embolism ( PE ) is approximately 0.2%-1.1 % [ 2 , 5 - 8 ] .", "label": "", "metadata": {}, "score": "61.518482"}
{"text": "Healthy Japanese subjects were found to have 20 % to 40 % higher exposures compared with other ethnicities , including Chinese subjects .Use : Labeled Indications .", "label": "", "metadata": {}, "score": "61.631638"}
{"text": "References .114 , pp . e257-e354 , 2006 .View at Publisher \u00b7 View at Google Scholar .W. M. Feinberg , J. L. Blackshear , A. Laupacis , R. Kronmal , and R. G. Hart , \" Prevalence , age distribution , and gender of patients with atrial fibrillation : analysis and implications , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "61.6388"}
{"text": "More than half of ROCKET AF subjects had prior stroke , and nearly two - thirds had heart failure at baseline .Withdrawal rates at end of study exceeded 20 % in ROCKET AF , ARISTOTLE and the dabigatran arms of RE - LY [ 13 - 15 ] .", "label": "", "metadata": {}, "score": "61.82547"}
{"text": "However , the ACT is affected by a lot of preanalytical [ 112 ] and analytical variables [ 113 , 114 ] .Finally , target ACT should be redetermined for the periprocedural use of NOACs for AF ablation [ 111 - 117 ] .", "label": "", "metadata": {}, "score": "61.859108"}
{"text": "ESRD requiring hemodialysis : Avoid use .Note : In patients with severe or end - stage chronic kidney disease , warfarin remains the anticoagulant of choice ( AHA / ACC / HRS [ January 2014 ] ) .", "label": "", "metadata": {}, "score": "61.94323"}
{"text": "123 , no . 1 , pp .24 - 34 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Falck - Ytter , C. W. Francis , N. A. Johanson et al . , \" Prevention of VTE in orthopedic surgery patients .", "label": "", "metadata": {}, "score": "61.97006"}
{"text": "Routine laboratory tests are altered by NOACs and quantitative measurements are not widely performed .Most data are based on expert 's opinions .Introduction .", "label": "", "metadata": {}, "score": "62.03149"}
{"text": "19 - 25 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. A. Heit , W. Michael O'Fallon , T. M. Petterson et al . , \" Relative impact of risk factors for deep vein thrombosis and pulmonary embolism : a population - based study , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "62.06488"}
{"text": "218 - 226 , 2008 , Erratum in : Journal of Clinical Pharmacology , vol .48 , no .11 , p.1366 - 1367 , 2008 .", "label": "", "metadata": {}, "score": "62.090393"}
{"text": "P - gp actively transports molecules with diverse conformations , including drugs , across tissue monolayers [ 35 ] .Compared to rivaroxaban and apixaban , oral dabigatran etexilate 's slow intestinal absorption renders it relatively more sensitive to p - gp efflux in the gut ( Figure 1 ) .", "label": "", "metadata": {}, "score": "62.127815"}
{"text": "Clinician Oriented Overview of Pharmacokinetic Properties of NOACs .Dabigatran Etexilate ( Pradaxa , Boehringer - Ingelheim Pharma GmBH , Ingelheim am Rhein , Germany ) : 75 mg , 110 mg , and 220 mg Capsules .", "label": "", "metadata": {}, "score": "62.152115"}
{"text": "Other trials are testing the new drugs for related conditions , including for heart failure and for embolic stroke of undetermined origin , a subset of cryptogenic stroke [ 61 ] .", "label": "", "metadata": {}, "score": "62.23613"}
{"text": "25 , pp .1846 - 1850 , 2000 .View at Google Scholar . H. K. Chew , T. Wun , D. Harvey , H. Zhou , and R. H. White , \" Incidence of venous thromboembolism and its effect on survival among patients with common cancers , \" Archives of Internal Medicine , vol .", "label": "", "metadata": {}, "score": "62.23632"}
{"text": "3 - 13 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. D. Douketis , P. B. Berger , A. S. Dunn et al . , \" The perioperative management of antithrombotic therapy : American College of Chest Physicians evidence - based clinical practice guidelines ( 8th edition ) , \" Chest , vol .", "label": "", "metadata": {}, "score": "62.317642"}
{"text": "Conversion from continuous infusion unfractionated heparin : Initiate rivaroxaban at the time of heparin discontinuation .Conversion to continuous infusion unfractionated heparin : Discontinue rivaroxaban and initiate continuous infusion unfractionated heparin at the time the next dose of rivaroxaban would have been taken .", "label": "", "metadata": {}, "score": "62.42085"}
{"text": "Once absorbed into the intestinal bloodstream , dabigatran etexilate is hydrolysed by plasma esterases to its active principle , dabigatran .The latter is no longer a substrate for p - gp efflux .", "label": "", "metadata": {}, "score": "62.48458"}
{"text": "6 , pp .1238 - 1247 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. T. Yin and S. Wessler , \" Investigation of the apparent thrombogenicity of thrombin , \" Thrombosis et Diathesis Haemorrhagica , vol .", "label": "", "metadata": {}, "score": "62.522095"}
{"text": "Except for minimal procedures which can be achieved without stopping NOACs , other experts or expert groups propose a window without any NOAC , according to the CrCl and/or the type of surgery .", "label": "", "metadata": {}, "score": "62.556458"}
{"text": "Coagulation times as measured by conventional prothrombin time ( PT ) and activated partial thromboplastin time ( aPTT ) are prolonged by the factor Xa antagonists , and dabigatran , respectively [ 29 - 31 ] .", "label": "", "metadata": {}, "score": "62.814335"}
{"text": "Hence , a coating of dabigatran etexilate is applied onto a tartaric acid core to form tiny pellets contained within gel capsules .The higher rates of dyspepsia observed with dabigatran ( versus warfarin ) may be due to the tartaric acid core in the dabigatran formulation [ 32 ] .", "label": "", "metadata": {}, "score": "62.831528"}
{"text": "Thrombin time ( TT ) was demonstrated to be too sensitive towards dabigatran [ 89 , 101 ] .However , this may guide the clinician in the perioperative setting since a normal TT indicates no clinically relevant anticoagulant effect of dabigatran .", "label": "", "metadata": {}, "score": "62.8733"}
{"text": "BLD is a member of steering committees for Bayer and Daiichi Sankyo .HD is a member of the study management and co - ordination Committee for the EINSTEIN study program ; has received grants from Bayer Schering Pharma ; and has participated as a board member for Daiichi Sankyo , Sanofi - aventis , and GlaxoSmithKline .", "label": "", "metadata": {}, "score": "62.95449"}
{"text": "BLD is a member of steering committees for Bayer and Daiichi Sankyo .HD is a member of the study management and co - ordination Committee for the EINSTEIN study program ; has received grants from Bayer Schering Pharma ; and has participated as a board member for Daiichi Sankyo , Sanofi - aventis , and GlaxoSmithKline .", "label": "", "metadata": {}, "score": "62.95449"}
{"text": "22 , pp .2166 - 2176 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .I. M. Ogilvie , N. Newton , S. A. Welner , W. Cowell , and G. Y. H. Lip , \" Underuse of oral anticoagulants in atrial fibrillation : a systematic review , \" The American Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "63.015217"}
{"text": "74 - 90 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus Management of Venous Thromboembolism in Patients with Advanced Gastrointestinal Cancers : What Is the Role of Novel Oral Anticoagulants ?", "label": "", "metadata": {}, "score": "63.082733"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .Z. Hijazi , J. Oldgren , U. Andersson et al . , \" Cardiac biomarkers are associated with an increased risk of stroke and death in patients with atrial fibrillation : a randomized evaluation of long - term anticoagulation therapy ( RE - LY ) substudy , \" Circulation , vol .", "label": "", "metadata": {}, "score": "63.092"}
{"text": "Prior Stroke or TIA .Patients with previous stroke or TIA are at higher risk of major bleeding and stroke or systemic embolism [ 46 ] .", "label": "", "metadata": {}, "score": "63.167282"}
{"text": "Perioperative Management of NOACs .Forty percent of these interruptions were before surgical or invasive procedure .In the perioperative context , the balance between thrombosis ( in case of anticoagulation interruption ) and bleeding ( in case of anticoagulation continuation ) should be assessed for each patient [ 43 ] .", "label": "", "metadata": {}, "score": "63.18268"}
{"text": "9 , no .11 , pp .2153 - 2158 , 2011 .View at Google Scholar .G. Piaggio , D. R. Elbourne , D. G. Altman , S. J. Pocock , and S. J. W. Evans , \" Reporting of noninferiority and equivalence randomized trials : an extension of the CONSORT statement , \" Journal of the American Medical Association , vol .", "label": "", "metadata": {}, "score": "63.27685"}
{"text": "Plasma : 2 to 4 hours .Half - Life Elimination .Terminal : 5 to 9 hours ; Elderly : 11 to 13 hours .", "label": "", "metadata": {}, "score": "63.391235"}
{"text": "In addition to the type of VTE prophylaxis used , another important consideration is the duration of prophylaxis .The average time to diagnosis of symptomatic VTE after THA and TKA is approximately 21 days and 10 days , respectively [ 11 ] .", "label": "", "metadata": {}, "score": "63.41639"}
{"text": "The Columbus Investigators : Low - molecular - weight heparin in the treatment of patients with venous thromboembolism .N Engl J Med 1997 , 337:657 - 662 .", "label": "", "metadata": {}, "score": "63.437836"}
{"text": "A total of 430 patients ( 5.2 % ) had known active cancer at baseline , whereas 167 patients ( 2.0 % ) were diagnosed with cancer during the study .", "label": "", "metadata": {}, "score": "63.456608"}
{"text": "4902 - 4907 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. S. Epstein , G. A. Soff , M. Capanu et al . , \" Analysis of incidence and clinical outcomes in patients with thromboembolic events and invasive exocrine pancreatic cancer , \" Cancer , vol .", "label": "", "metadata": {}, "score": "63.476498"}
{"text": "DVT , PE , reduction of the risk of recurrent DVT / PE : .US labeling : .Canadian labeling : .Nonvalvular atrial fibrillation : .", "label": "", "metadata": {}, "score": "63.49739"}
{"text": "Patient Education .( HCAHPS :During this hospital stay , were you given any medicine that you had not taken before ?Before giving you any new medicine , how often did hospital staff tell you what the medicine was for ?", "label": "", "metadata": {}, "score": "63.655342"}
{"text": "Strokes secondary to AF have a worse prognosis than in patients without AF [ 12 , 13 ] .Moreover , AF is an independent risk factor for mortality as seen in the Framingham population with an adjusted odds ratio of 1.5 in men and 1.9 in women [ 14 ] .", "label": "", "metadata": {}, "score": "63.93898"}
{"text": "5 , pp .469 - 473 , 1995 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .G. M. Novaro , C. R. Asher , D. L. Bhatt et al . , \" Meta - analysis comparing reported frequency of atrial fibrillation after acute coronary syndromes in asians versus whites , \" The American Journal of Cardiology , vol .", "label": "", "metadata": {}, "score": "63.964615"}
{"text": "VKA , Vitamin K antagonist .Prins et al .The difference was deter- mined primarily by the reductions in the numbers of intracranial ( five vs. 13 ) , retroperitoneal ( one vs. eight )", "label": "", "metadata": {}, "score": "64.03139"}
{"text": "The difference was determined primarily by the reductions in the numbers of intracranial ( five vs. 13 ) , retroperitoneal ( one vs. eight )( Table 3 ) , and gastrointestinal ( including rectal and anal ) bleeding events ( 15 vs. 26 ) .", "label": "", "metadata": {}, "score": "64.64117"}
{"text": "Devices implants in most of Canadian centers are performed with NOAC interruption without LMWH bridging [ 76 ] .Again , this study demonstrates the necessity of an individual assessment of each patient , on a case - by - case basis [ 77 ] .", "label": "", "metadata": {}, "score": "64.736145"}
{"text": "10 , pp .3484 - 3488 , 2002 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. D. Douketis , M. A. Crowther , G. A. Foster , and J. S. Ginsberg , \" Does the location of thrombosis determine the risk of disease recurrence in patients with proximal deep vein thrombosis ? \" The American Journal of Medicine , vol .", "label": "", "metadata": {}, "score": "64.83557"}
{"text": "Detailed Description .Not Provided .Study Type ICMJE .Interventional .Study Phase .Phase 4 .Study Design ICMJE .Allocation : Randomized Endpoint Classification : Pharmacokinetics / Dynamics Study Intervention Model : Parallel Assignment Masking : Open Label Primary Purpose : Basic Science .", "label": "", "metadata": {}, "score": "64.86894"}
{"text": "Conclusions .In the field of oral anticoagulation , clinicians will be more frequently confronted about their management of NOACs in the pre- and postoperative setting .", "label": "", "metadata": {}, "score": "64.9414"}
{"text": "US labeling : .Mild hepatic impairment ( Child - Pugh class A ) : There are no dosage adjustments provided in the manufacturer 's labeling .", "label": "", "metadata": {}, "score": "65.13184"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . A. Khorana , N. M. Kuderer , E. Culakova , G. H. Lyman , and C. W. Francis , \" Development and validation of a predictive model for chemotherapy- associated thrombosis , \" Blood , vol . 111 , no .", "label": "", "metadata": {}, "score": "65.27664"}
{"text": "10.1016/0140 - 6736(92)91054-C View Article PubMed .The Columbus Investigators : Low - molecular - weight heparin in the treatment of patients with venous thromboembolism .", "label": "", "metadata": {}, "score": "65.43615"}
{"text": "49 , no . 9 , pp .986 - 992 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . E. J. Benjamin , P. A. Wolf , R. B. D'Agostino , H. Silbershatz , W. B. Kannel , and D. Levy , \" Impact of atrial fibrillation on the risk of death : the Framingham heart study , \" Circulation , vol .", "label": "", "metadata": {}, "score": "65.54085"}
{"text": "View at Google Scholar \u00b7 View at Scopus .J. Sgouros and A. Maraveyas , \" Excess premature ( 3-month ) mortality in advanced pancreatic cancer could be related to fatal vascular thromboembolic events .", "label": "", "metadata": {}, "score": "65.63593"}
{"text": "4 , pp .289 - 296 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .R. Cappato , H. Calkins , S. Chen et al . , \" Updated worldwide survey on the methods , efficacy , and safety of catheter ablation for human atrial fibrillation , \" Circulation : Arrhythmia and Electrophysiology , vol .", "label": "", "metadata": {}, "score": "65.99535"}
{"text": "Monitor therapy .Vitamin E ( Oral ) : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Vorapaxar : May enhance the adverse / toxic effect of Anticoagulants .", "label": "", "metadata": {}, "score": "66.03492"}
{"text": "It decreases if the etiology is provoked ( e.g. , trauma , fractures , and pregnancy ) , but if the underlying cause is idiopathic , the risk of recurrence is higher [ 52 ] .", "label": "", "metadata": {}, "score": "66.05568"}
{"text": "Venous thromboembolism ( VTE ) is a serious and frequent complication of malignancy .In ambulatory cancer patients , the rate of VTE is reported to be 100-fold higher than the general population [ 1 - 3 ] with an annual incidence of around 1 in 200 [ 4 ] .", "label": "", "metadata": {}, "score": "66.109024"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. Stangier and A. Clemens , \" Pharmacology , pharmacokinetics , and pharmacodynamics of dabigatran etexilate , an oral direct thrombin inhibitor , \" Clinical and Applied Thrombosis / Hemostasis , vol .", "label": "", "metadata": {}, "score": "66.116615"}
{"text": "US labeling recommends avoidance in patients with estimated creatinine clearance 15 to 80 mL / min unless prospective benefits outweigh the risks .See monograph for details of Canadian labeling .", "label": "", "metadata": {}, "score": "66.26108"}
{"text": "The percentage of drug eliminated after 2 , 3 , 4 , and 5 half - lives is 75 % , 87.5 % , 93.8 % , and 96.9 % , respectively [ 69 ] .", "label": "", "metadata": {}, "score": "66.43301"}
{"text": "1850 - 1859 , 2014 .View at Google Scholar . A. C. Spyropoulos , R. M. Bauersachs , H. Omran , and M. Cohen , \" Periprocedural bridging therapy in patients receiving chronic oral anticoagulation therapy , \" Current Medical Research and Opinion , vol .", "label": "", "metadata": {}, "score": "66.545364"}
{"text": "Markers of inflammation that have been studied in AF include interleukin-6 ( IL-6 ) and C - reactive protein ( CRP ) .Initially , a small study reported an association between IL-6 and a composite outcome of stroke and death [ 22 ] .", "label": "", "metadata": {}, "score": "66.545456"}
{"text": "Genitourinary : Urinary tract infection ( 1 % ) .Neuromuscular & skeletal : Back pain ( 4 % ) , limb pain ( 2 % ) , osteoarthritis ( 2 % ) , muscle spasm ( 1 % ) .", "label": "", "metadata": {}, "score": "66.64276"}
{"text": "Each study was event - driven and required a number of events to provide 90 % power using a margin of 2.0 for the upper limit of the 95 % confidence interval ( CI ) for the estimated hazard ratio , and a two - sided alpha of 0.05 .", "label": "", "metadata": {}, "score": "66.74418"}
{"text": "However , a special care to bleeding at the punctures sites is necessary and therefore ultrasound guided techniques are very useful .Hemoperfusion over a charcoal filter is under evaluation [ 89 ] .", "label": "", "metadata": {}, "score": "66.83656"}
{"text": "2370 - 2375 , 2001 .View at Google Scholar \u00b7 View at Scopus . A. J. Camm , P. Kirchhof , G. Y. Lip , et al . , \" Guidelines for the management of atrial fibrillation : the task force for the management of atrial fibrillation of the European Society of Cardiology ( ESC ) , \" Europace , vol .", "label": "", "metadata": {}, "score": "66.983376"}
{"text": "The \" Groupe d'Int\u00e9r\u00eat en H\u00e9mostase P\u00e9riop\u00e9ratoire \" ( GIHP ) proposes a unique scheme : 1 day of interruption in case of low risk bleeding surgery or procedure and 5 for other procedures , whatever the molecule , renal function , and concomitant medications [ 13 ] .", "label": "", "metadata": {}, "score": "67.01806"}
{"text": "For the Arterial Side .In developed countries , atrial fibrillation ( AF ) affects about 1.5 to 2 % of the population .This arrhythmia is associated with a 5-fold increased risk of stroke ( AF is associated with 15 - 20 % of all strokes [ 44 ] ) , a 3-fold increased incidence in congestive heart failure , and a higher mortality [ 45 ] .", "label": "", "metadata": {}, "score": "67.11994"}
{"text": "P - gp efflux transporters in the blood - brain barrier provide protection against entry of potential noxious endogenous and exogenous compounds , and have been implicated in development of resistance to oncological and microbiological therapeutic agents [ 64 ] .", "label": "", "metadata": {}, "score": "67.13543"}
{"text": "However , the weight of evidence shall have to lie chiefly with RE - LY , the largest trial for dabigatran , which ultimately did not demonstrate a statistically significant increase in MI risk .", "label": "", "metadata": {}, "score": "67.174614"}
{"text": "The bleeding risk is multifactorial and its assessment needs to consider patient - specific and procedure - specific variables [ 53 ] .Patient - Specific Variables .", "label": "", "metadata": {}, "score": "67.20652"}
{"text": "The EINSTEIN - PE Investigators : Oral rivaroxaban for the treatment of symptomatic pulmonary embolism .N Engl J Med 2012 , 366 : 1287 - 1297 .", "label": "", "metadata": {}, "score": "67.21112"}
{"text": "The current recommendations for the duration of prophylaxis are a minimum of 10 days , with extension up to 35 days for patients undergoing THA [ 2 ] .", "label": "", "metadata": {}, "score": "67.32933"}
{"text": "Table 5 summarises the safety outcomes in the active treatment groups , expressed as RRR or increments of event rates , compared to VKA - controlled populations .", "label": "", "metadata": {}, "score": "67.42599"}
{"text": "Brand Names : U.S. .Xarelto .Pharmacologic Category .Anticoagulant .Pharmacology .Inhibits platelet activation and fibrin clot formation via direct , selective and reversible inhibition of factor Xa ( FXa ) in both the intrinsic and extrinsic coagulation pathways .", "label": "", "metadata": {}, "score": "67.54448"}
{"text": "233 - 241 , 1951 .View at Google Scholar \u00b7 View at Scopus .G. H. Sack Jr. , J. Levin , and W. R. Bell , \" Trousseau 's syndrome and other manifestations of chronic disseminated coagulopathy in patients with neoplasms : clinical , pathophysiologic , and therapeutic features , \" Medicine , vol .", "label": "", "metadata": {}, "score": "67.6095"}
{"text": "For example , the CHA2DS2-VASc score has a C - statistic of 0.55 - 0.64 , where 1.0 would represent the perfect ability to correctly rank risk and 0.5 would indicate correct classification only half the time or random chance [ 15 ] .", "label": "", "metadata": {}, "score": "67.73074"}
{"text": "Are NOAs Safe in Patients with Gastrointestinal Cancers ?Several potential safety concerns specific to the gastrointestinal cancer population ( and cancer patients as a whole ) exist with NOAs that have not been extensively investigated .", "label": "", "metadata": {}, "score": "67.78321"}
{"text": "Omacetaxine : Anticoagulants may enhance the adverse / toxic effect of Omacetaxine .Specifically , the risk for bleeding - related events may be increased .", "label": "", "metadata": {}, "score": "67.804855"}
{"text": "Background : The acute coronary syndrome ( ACS ) is a complication of coronary artery disease ( CAD ) and associated with increased mortality .Dual antiplatelet therapy of acetylsalicylic acid ( ASA ) with P2Y12 receptor antagonists such as clopidogrel is a cornerstone in the treatment of patients with advanced CAD .", "label": "", "metadata": {}, "score": "67.915665"}
{"text": "4 , pp .692 - 699 , 2007 .View at Google Scholar . A. Y. Lee and M. N. Levine , \" Venous thromboembolism and cancer : risks and outcomes , \" Circulation , vol .", "label": "", "metadata": {}, "score": "67.96041"}
{"text": "Additional file Additional file 1 : Members of the EINSTEIN Investigators .Abbreviations DVT : Deep - vein thrombosis ; INR : International normalized ratio ; PE : Pulmonary embolism ; VKA : Vitamin K antagonist ; VTE : Venous thromboembolism .", "label": "", "metadata": {}, "score": "68.30731"}
{"text": "Deep vein thrombosis treatment : Treatment of DVT .Nonvalvular atrial fibrillation : Prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation ( AF ) .", "label": "", "metadata": {}, "score": "68.318085"}
{"text": "Bioavailability is around 50 % .Apixaban is eliminated via multiple pathways : predominantly via the fecal route ( 56 % ) and 25 - 29 % via renal excretion [ 37 ] .", "label": "", "metadata": {}, "score": "68.38866"}
{"text": "Monitor therapy .Tibolone : May enhance the anticoagulant effect of Anticoagulants .Monitor therapy .Tipranavir : May enhance the anticoagulant effect of Anticoagulants .", "label": "", "metadata": {}, "score": "68.40582"}
{"text": "Thrombin both activates platelets and catalyzes the conversion of fibrinogen to fibrin .Absorption .Rapid .Distribution .Metabolism .Hepatic via CYP3A4/5 and CYP2J2 .", "label": "", "metadata": {}, "score": "68.50448"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .J. B. Olesen , G. Y. Lip , M. L. Hansen et al . , \" Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation : nationwide cohort study , \" BMJ , vol .", "label": "", "metadata": {}, "score": "68.64725"}
{"text": "VTE in Gastrointestinal Cancers .Gastrointestinal malignancies include cancers of the esophagus , stomach , small intestine , appendix , colon , rectum , anus , pancreas , ampulla of Vater , gallbladder , biliary tree , and liver .", "label": "", "metadata": {}, "score": "69.10953"}
{"text": "Deferasirox : Anticoagulants may enhance the adverse / toxic effect of Deferasirox .Specifically , the risk for GI ulceration / irritation or GI bleeding may be increased .", "label": "", "metadata": {}, "score": "69.26793"}
{"text": "Note : This is not a comprehensive list of all side effects .Patient should consult prescriber for additional questions .Intended Use and Disclaimer : Should not be printed and given to patients .", "label": "", "metadata": {}, "score": "69.27756"}
{"text": "Introduction .Venous thromboembolism ( VTE ) is a common complication after total hip arthroplasty ( THA ) and total knee arthroplasty ( TKA ) .", "label": "", "metadata": {}, "score": "69.36255"}
{"text": "Overall inclusion of papers was limited to studies published until May 30 , 2014 .Indications and Posology of NOACs .Table 1 summarizes the approved indications by the Food and Drug Administration and the European Commission , the posology , and the dose adaptation of the different NOACs .", "label": "", "metadata": {}, "score": "69.428986"}
{"text": "Pulmonary embolism treatment : Treatment of pulmonary embolism .Reduction in the risk ( secondary prevention ) of recurrent deep vein thrombosis and/or pulmonary embolism : Reduction in the risk of recurrence of DVT and pulmonary embolism following initial 6 months of treatment for DVT and/or pulmonary embolism .", "label": "", "metadata": {}, "score": "69.53165"}
{"text": "Edoxaban : May enhance the anticoagulant effect of Anticoagulants .Management : Some limited combined use may be indicated during periods of transition from one anticoagulant to another .", "label": "", "metadata": {}, "score": "69.69214"}
{"text": "For dabigatran , there is no consensus regarding the management of patients taking dabigatran who are referred for AF ablation .The results depend on the period of dabigatran interruption .", "label": "", "metadata": {}, "score": "69.694115"}
{"text": "Annales Francaises d'Anesthesie et de Reanimation , vol .23 , no .6 , pp .589 - 596 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. M. Hussein , A. L. Georgiadis , and A. I. Qureshi , \" Point - of - care testing for anticoagulation monitoring in neuroendovascular procedures , \" The American Journal of Neuroradiology , vol .", "label": "", "metadata": {}, "score": "69.71197"}
{"text": "AWAL and SDB are employees of Bayer HealthCare Pharmaceuticals .RB has received research support from Bayer HealthCare Pharmaceuticals , Bristol- Myers Squibb , Boehringer and Daiichi Sankyo , and participated in scientific advisory boards organized by all of the former companies .", "label": "", "metadata": {}, "score": "69.757996"}
{"text": "10.1001/archinte.158.6.585 View Article PubMed .Oger E : Incidence of venous thromboembolism : a community - based study in Western France .EPI - GETBP Study Group .", "label": "", "metadata": {}, "score": "70.043884"}
{"text": "Monitor for any signs or symptoms of blood loss .Non - valvular atrial fibrillation is defined as atrial fibrillation that occurs in the absence of rheumatic mitral valve disease , mitral valve repair , or prosthetic heart valve ( AHA / ACC / HRS [ January 2014 ] ) .", "label": "", "metadata": {}, "score": "70.31653"}
{"text": "A global registry called the RE - LY registry , including 47 countries with 15,174 patients with AF , was created to determine if there were differences in the treatment of AF globally [ 64 ] .", "label": "", "metadata": {}, "score": "70.56338"}
{"text": "Thus , \" nonvalvular \" AF is a misnomer .When used to identify the population for which the new drugs are not suitable this term should be limited to moderate or severe mitral stenosis or mechanical prosthetic valves .", "label": "", "metadata": {}, "score": "70.59691"}
{"text": "Venous thromboembolism is a common complication after THA and TKA and creates a substantial burden to patients , providers , and costs to the healthcare system .", "label": "", "metadata": {}, "score": "70.752975"}
{"text": "This trial will start enrolling patients in 2014 and will follow them for one year .Implementation of Demonstration Project for Health Systems , Atrial Fibrillation ( INFORM - AF ) , is a separate initiative underway that we designed to improve treatment for stroke prevention in AF in the United States health systems .", "label": "", "metadata": {}, "score": "70.869705"}
{"text": "Deoxycholic Acid : Anticoagulants may enhance the adverse / toxic effect of Deoxycholic Acid .Specifically , the risk for bleeding or bruising in the treatment area may be increased .", "label": "", "metadata": {}, "score": "70.95379"}
{"text": "The plasma peak after ingestion is at 1.5 - 3.0 hours and the plasma trough level is 11 - 14 hours after ingestion in healthy volunteers [ 28 ] .", "label": "", "metadata": {}, "score": "70.98488"}
{"text": "MHP and AWAL created the initial draft version of this manuscript .All authors made critical revisions of the manuscript for important intellectual content , approved the final version of the manuscript for submission , and contributed to the study concept , design and implementation .", "label": "", "metadata": {}, "score": "70.99103"}
{"text": "Venous thromboembolism ( VTE ) is a common complication after total hip and total knee arthroplasty .Currently used methods of VTE prophylaxis after these procedures have important limitations , including parenteral administration , and unpredictable plasma levels requiring frequent monitoring and dose adjustment leading to decreased patient compliance with recommended guidelines .", "label": "", "metadata": {}, "score": "71.0137"}
{"text": "Metabolites are eliminated equally via renal pathway and via hepatobiliary route in the feces [ 35 ] .Clearance is mildly influenced by renal function [ 36 ] .", "label": "", "metadata": {}, "score": "71.17461"}
{"text": "Figure 1 : Dabigatran etexilate : a p - gp substrate .Using energy from adenosine triphosphate , p - gp receptors in the intestinal wall actively transport molecules across the epithelial monolayer .", "label": "", "metadata": {}, "score": "71.32915"}
{"text": "Creatinine clearance ( CrCl ) estimation based on the Cockroft and Gault formula [ 30 , 31 ] is recommended in elderly patients to calculate doses and avoid overmedication [ 9 ] .", "label": "", "metadata": {}, "score": "71.49549"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .P. A. Wolf , R. D. Abbott , and W. B. Kannel , \" Atrial fibrillation : a major contributor to stroke in the elderly .", "label": "", "metadata": {}, "score": "71.655396"}
{"text": "Apixaban is a selective and reversible oral direct FXa inhibitor .The plasma peak after ingestion is at 2 - 3 hours and the half - life elimination is 8 - 15 hours in healthy volunteers [ 28 ] .", "label": "", "metadata": {}, "score": "71.66067"}
{"text": "The three agents can be used in mild hepatic impairment ( Child - Pugh A ) , while DE and apixaban are allowed in moderate hepatic impairment ( Child - Pugh B ) , but not in severe hepatic impairment ( Child - Pugh C ) [ 70 ] .", "label": "", "metadata": {}, "score": "71.75723"}
{"text": "638.e4 - 645 . e4 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .T. Wilke , A. Groth , S. Mueller , et al . , \" Oral anticoagulation use by patients with atrial fibrillation in Germany .", "label": "", "metadata": {}, "score": "72.44125"}
{"text": "Excretion is predominantly renal and caution must be used in patients with severe renal impairment [ 33 , 34 ] .Because of predictable pharmacokinetics , routine monitoring of coagulation parameters is not required .", "label": "", "metadata": {}, "score": "72.88768"}
{"text": "Avoid combination .Test Interactions .Prolongs activated partial thromboplastin time ( aPTT ) , HepTest \u00ae , and Russell viper venom time .Adverse Reactions .", "label": "", "metadata": {}, "score": "72.91803"}
{"text": "6 , pp .1124 - 1131 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Omran , R. Bauersachs , S. Rubenacker , F. Goss , and C. Hammerstingl , \" The HAS - BLED score predicts bleedings during bridging of chronic oral anticoagulation .", "label": "", "metadata": {}, "score": "73.24933"}
{"text": "In fact , gastrointestinal primary tumor site , and specifically upper gastrointestinal cancer ( gastroesophageal and pancreas ) , has been shown to be independently associated with increased VTE risk in both early - stage malignancy [ 8 ] and advanced cancer treated with chemotherapy [ 7 , 14 ] .", "label": "", "metadata": {}, "score": "73.45453"}
{"text": "Same as current .Current Other Outcome Measures ICMJE .Not Provided .Original Other Outcome Measures ICMJE .Not Provided .Descriptive Information .Brief Title ICMJE .", "label": "", "metadata": {}, "score": "73.69266"}
{"text": "Introduction .Venous thromboembolism ( VTE ) , the collective term for deep - vein thrombosis ( DVT ) and/or pulmonary embolism ( PE ) , is a relatively common cardiovascular disorder .", "label": "", "metadata": {}, "score": "74.00886"}
{"text": "Titusville , NJ : Janssen Pharmaceuticals , Inc ; 2011 .Kubitza D , Becka M , Voith B , Zuehlsdorf M , Wensing G. Safety , pharmacodynamics , and pharmacokinetics of single doses of BAY 59 - 7939 , an oral , direct factor Xa inhibitor .", "label": "", "metadata": {}, "score": "74.13965"}
{"text": "HAS - BLED score is used to assess 1-year risk of major bleeding in patients with AF under VKAs [ 54 ] ( Table 5 ) .", "label": "", "metadata": {}, "score": "74.63055"}
{"text": "View at Publisher \u00b7 View at Google Scholar .59 , no . 13 , pp .1168 - 1174 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . H. Yamaji , T. Murakami , K. Hina et al . , \" Usefulness of dabigatran etexilate as periprocedural anticoagulation therapy for atrial fibrillation ablation , \" Clinical Drug Investigation , vol .", "label": "", "metadata": {}, "score": "74.788284"}
{"text": "Storage .Store at 25 \u00b0 C ( 77 \u00b0 F ) ; excursions permitted to 15 \u00b0 C to 30 \u00b0 C ( 59 \u00b0 F to 86 \u00b0 F ) .", "label": "", "metadata": {}, "score": "75.229904"}
{"text": "28 , no .6 , pp .963 - 969 , 1950 .View at Google Scholar \u00b7 View at Scopus .J. R. Miller , A. H. Baggenstross , and M. W. Comfort , \" Carcinoma of the pancreas ; effect of histological types and grade of malignancy on its behavior , \" Cancer , vol .", "label": "", "metadata": {}, "score": "75.5761"}
{"text": "How- ever , INR monitoring was intensive and required assess- ment at least once a month .The time patients spent in the target therapeutic range ( INR , 2.0 - 3.0 ) was in line with that achieved in contemporary studies [ 18]. There-", "label": "", "metadata": {}, "score": "75.834526"}
{"text": "6 , pp .594 - 604 , 2009 , Erratum in : The New England Journal of Medicine , vol .361 , no .", "label": "", "metadata": {}, "score": "75.835266"}
{"text": "The investigators would also like to thank David Whitford for editorial assistance in the preparation of the manuscript , with funding from Bayer HealthCare Pharmaceuticals and Janssen Scientific Affairs , LLC .", "label": "", "metadata": {}, "score": "76.07093"}
{"text": "The investigators would also like to thank David Whitford for editorial assistance in the preparation of the manuscript , with funding from Bayer HealthCare Pharmaceuticals and Janssen Scientific Affairs , LLC .", "label": "", "metadata": {}, "score": "76.07093"}
{"text": "Major bleeding was defined as bleeding that was fatal , occurred in a critical organ , requiring reoperation , or was clinically overt with a drop in the hemoglobin level of at least 2 g / dL or requiring at least 2 units of blood transfusion .", "label": "", "metadata": {}, "score": "76.170654"}
{"text": "371 - 378 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . S. Mikal and A. J. A. Campbell , \" Carcinoma of the pancreas .", "label": "", "metadata": {}, "score": "76.587845"}
{"text": "Oger E : Incidence of venous thromboembolism : a community - based study in Western France .EPI - GETBP Study Group .Groupe d'Etude de la Thrombose de Bretagne Occidentale .", "label": "", "metadata": {}, "score": "76.84338"}
{"text": "You must ultimately rely on your own discretion , experience and judgment in diagnosing , treating and advising patients .About .Terms & Privacy .", "label": "", "metadata": {}, "score": "76.886185"}
{"text": "Abstract .Atrial fibrillation is the most common arrhythmia and accounts for one - third of hospitalizations for rhythm disorders in the United States .The prevalence of atrial fibrillation averages 1 % and increases with age .", "label": "", "metadata": {}, "score": "77.200226"}
{"text": "12 , pp .857 - 867 , 2007 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . \"The Atrial Fibrillation Investigators .", "label": "", "metadata": {}, "score": "77.27671"}
{"text": "Cell - surface tissue factor ( TF ) , which is found in high concentrations in the brain , may offer an explanation [ 59 ] .", "label": "", "metadata": {}, "score": "78.71098"}
{"text": "Introduction .Atrial fibrillation ( AF ) is the most common arrhythmia and accounts for one - third of hospitalizations for rhythm disorders in the United States [ 1 ] .", "label": "", "metadata": {}, "score": "79.3806"}
{"text": "236 - 241 , 1994 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . Y. Miyasaka , M. E. Barnes , B. J. Gersh et al . , \" Secular trends in incidence of atrial fibrillation in Olmsted County , Minnesota , 1980 to 2000 , and implications on the projections for future prevalence , \" Circulation , vol .", "label": "", "metadata": {}, "score": "79.72604"}
{"text": "The authors declare that there is no conflict of interests regarding the publication of this paper .Acknowledgments .Meena P. Rao M.D. MPH received research / research grants from Medtronic Foundation ; consultant fees / honoraria were provided by Daiichi Sanyko .", "label": "", "metadata": {}, "score": "79.740616"}
{"text": "Received : 15 August 2013 Accepted : 9 September 2013 Published : 20 September 2013 References 1 .Silverstein MD , Heit JA , Mohr DN , Petterson TM , O'Fallon WM , Melton LJ III : Trends in the incidence of deep vein thrombosis and pulmonary embolism : a 25-year population - based study .", "label": "", "metadata": {}, "score": "79.749016"}
{"text": "All authors made critical revisions of the manuscript for important intellectual content , approved the final version of the manuscript for submission , and contributed to the study concept , design and implementation .", "label": "", "metadata": {}, "score": "80.656006"}
{"text": "Central nervous system : Fatigue ( 1 % ) , syncope ( 1 % ) .Dermatologic : Wound secretion ( 3 % ) , pruritus ( 2 % ) , skin blister ( 1 % ) .", "label": "", "metadata": {}, "score": "81.49266"}
{"text": "To Bridge or Not to Bridge during the Perioperative Interruption .For patients on VKA , the procedure is well established [ 12 , 60 ] .", "label": "", "metadata": {}, "score": "82.253"}
{"text": "T. Bekaii - Saab had a Research Funding [ Pfizer]-Ohio State University ; Consultant for Bristol - Meyers Squibb .No other conflicts from other authors .", "label": "", "metadata": {}, "score": "82.744484"}
{"text": "The members of the Writing Committee take responsibility for the content and integrity of this article .Abbreviations .DVT : .Deep - vein thrombosis .", "label": "", "metadata": {}, "score": "83.86935"}
{"text": "Consider therapy modification .Hemin : May enhance the anticoagulant effect of Anticoagulants .Avoid combination .Herbs ( Anticoagulant / Antiplatelet Properties ) ( eg , Alfalfa , Anise , Bilberry ) : May enhance the adverse / toxic effect of Anticoagulants .", "label": "", "metadata": {}, "score": "84.04726"}
{"text": "View at Google Scholar Management of Non - Vitamin K Antagonist Oral Anticoagulants in the Perioperative Setting .Received 30 May 2014 ; Accepted 5 August 2014 ; Published 3 September 2014 .", "label": "", "metadata": {}, "score": "84.45508"}
{"text": "The authors would like to thank Dr. Spero R. Cataland , MD , Department of Hematology , The Ohio State University Medical Center , for his preliminary review of the manuscript .", "label": "", "metadata": {}, "score": "84.83646"}
{"text": "In those with an intermediate clot burden , these inci- dences were 2.2 % ( 41 of 1873 ) and 2.6 % ( 49 of 1881 ) , re- spectively .", "label": "", "metadata": {}, "score": "84.93236"}
{"text": "154 - 163 , 2013 .View at Publisher \u00b7 View at Google Scholar Current Secondary Outcome Measures ICMJE ( submitted : March 13 , 2013 ) .", "label": "", "metadata": {}, "score": "85.168076"}
{"text": "12 , pp .3053 - 3061 , 2012 .View at Google Scholar .18 , no .17 , pp .3078 - 3083 , 2000 .", "label": "", "metadata": {}, "score": "87.0889"}
{"text": "Subscribe to receive email notifications whenever new articles are published .This material is provided for educational purposes only and is not intended for medical advice , diagnosis or treatment .", "label": "", "metadata": {}, "score": "87.981476"}
{"text": "10 University of Oklahoma Health Sciences Center , College of Public Health , Oklahoma City , OK , USA .11 Bayer HealthCare Pharmaceuticals , Whippany , NJ , USA .", "label": "", "metadata": {}, "score": "88.14761"}
{"text": "3 Klinikum Darmstadt , Darmstadt , Germany .4 Hospital Benefic\u00eancia Portuguesa , S\u00e3o Paulo , Brazil .5 Department of Medicine , University Hospitals of Geneva , Faculty of Medicine , Geneva , Switzerland . 6 Department of Haematology , Prince of Wales Hospital , Sydney , New South Wales , Australia . 7 Department of Haematological Medicine , King 's College Hospital , London , UK . 8 University of Washington School of Medicine , Seattle , WA , USA .", "label": "", "metadata": {}, "score": "88.90718"}
{"text": "Department of Haematological Medicine , King 's College Hospital .University of Washington School of Medicine .Service de M\u00e9decine et Th\u00e9rapeutique , CHU Saint - Etienne .", "label": "", "metadata": {}, "score": "89.183624"}
{"text": "19 , pp .2387 - 2394 , 2011 .View at Google Scholar .123 , no .21 , pp .2363 - 2372 , 2011 .", "label": "", "metadata": {}, "score": "90.26797"}
{"text": "10 , pp .1360 - 1420 , 2010 .View at Google Scholar .123 , no .10 , pp .e269-e367 , 2011 .", "label": "", "metadata": {}, "score": "90.2711"}
{"text": "Urine ( 66 % primarily via active tubular secretion [ 36 % as unchanged drug ; 30 % as inactive metabolites ] ) ; feces ( 28 % [ 7 % as unchanged drug ; 21 % as inactive metabolites ] ) .", "label": "", "metadata": {}, "score": "92.19026"}
{"text": "Maastricht University Medical Center .Bayer HealthCare AG .Klinikum Darmstadt .Hospital Benefic\u00eancia Portuguesa .Department of Medicine , University Hospitals of Geneva , Faculty of Medicine .", "label": "", "metadata": {}, "score": "94.80296"}
{"text": "Appendix .Members of the EINSTEIN Investigators are listed in the supplementary information ( Additional file 1 ) .Authors ' information .The EINSTEIN study group Writing Committee : .", "label": "", "metadata": {}, "score": "94.85111"}
{"text": "108 , pp .65 - 73 , 2012 .View at Google Scholar .10 , no .4 , pp .692 - 694 , 2012 .", "label": "", "metadata": {}, "score": "95.07243"}
{"text": "9591 , pp .949 - 956 , 2007 , Erratum in : The Lancet , vol .370 , no .9604 , p.2004 , 2007 .", "label": "", "metadata": {}, "score": "95.97194"}
{"text": "447 - 451 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .370 , no .9586 , pp .", "label": "", "metadata": {}, "score": "97.872284"}
{"text": "4 , pp .506 - 509 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 285 , no .", "label": "", "metadata": {}, "score": "98.048744"}
{"text": "264 - 268 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .106 , no .6 - 7 , pp .", "label": "", "metadata": {}, "score": "98.824425"}
{"text": "10 , pp .946 - 952 , 1998 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .137 , no . 2 , pp .", "label": "", "metadata": {}, "score": "99.27132"}
{"text": "19 , pp .1767 - 1772 , 2011 .View at Google Scholar \u00b7 View at Scopus .93 B , no .11 , pp .", "label": "", "metadata": {}, "score": "99.510376"}
{"text": "119 - 125 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .271 , no .11 , pp .", "label": "", "metadata": {}, "score": "99.57841"}
{"text": "4 , pp .433 - 441 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .138 , no .", "label": "", "metadata": {}, "score": "100.02942"}
{"text": "5 , pp .360 - 362 , 1999 .View at Google Scholar \u00b7 View at Scopus .89 , no .6 , pp .", "label": "", "metadata": {}, "score": "100.3108"}
{"text": "107 , no .5 , pp .985 - 997 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "100.69755"}
{"text": "6 , pp .1109 - 1122 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .14 , no .", "label": "", "metadata": {}, "score": "100.85545"}
{"text": "126 , no . 3 , pp .343 - 348 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "100.94824"}
{"text": "19 , pp .1788 - 1790 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus . 285 , no .", "label": "", "metadata": {}, "score": "101.369965"}
{"text": "The authors have no conflict of interests to disclose .Authors ' Contribution .Anne - Sophie Dincq and Sarah Lessire contributed equally to this work .", "label": "", "metadata": {}, "score": "101.3783"}
{"text": "462 - 466 , 2004 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .38 , no .4 , pp .", "label": "", "metadata": {}, "score": "101.47377"}
{"text": "28 , no .10 , pp .973 - 977 , 1978 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "101.655106"}
{"text": "183 - 191 , 2012 .View at Publisher \u00b7 View at Google Scholar .93 , no . 1 , pp .91 - 95 , 2011 .", "label": "", "metadata": {}, "score": "101.77744"}
{"text": "810 - 815 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .137 , no . 2 , pp .", "label": "", "metadata": {}, "score": "102.00321"}
{"text": "157 , no .11 , pp .1237 - 1240 , 1997 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "102.00452"}
{"text": "104 , no .12 , pp .669 - 676 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "102.088684"}
{"text": "47 , no . 3 , pp .337 - 346 , 2008 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "102.36129"}
{"text": "11 , pp .893 - 900 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .166 , pp .", "label": "", "metadata": {}, "score": "103.25521"}
{"text": "172 - 197 , 2003 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .63 , no .10 , pp .", "label": "", "metadata": {}, "score": "103.34952"}
{"text": "151 , no . 3 , pp .713 - 719 , 2006 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "104.096085"}
{"text": "6 , pp .1064 - 1083 , 2009 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus", "label": "", "metadata": {}, "score": "105.112976"}
{"text": "58 , no .4 , pp .395 - 401 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "105.907455"}
{"text": "PubMed Central View Article PubMed .Chest 2012 , 141 : e419S - e494S. 10.1378/chest.11 - 2301 PubMed Central View Article PubMed .Copyright .", "label": "", "metadata": {}, "score": "106.00101"}
{"text": "625.e1 - 632 .e1 , 2013 .View at Publisher \u00b7 View at Google Scholar .6 , no .4 , pp .461 - 469 , 2013 .", "label": "", "metadata": {}, "score": "107.317"}
{"text": "147 , no . 9 , pp .1561 - 1564 , 1987 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "107.84462"}
{"text": "1105 - 1114 , 2013 .View at Google Scholar .285 , no .22 , pp .2864 - 2870 , 2001 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "107.865395"}
{"text": "331 - 339 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .380 , no .9855 , pp .", "label": "", "metadata": {}, "score": "108.33602"}
{"text": "326 - 333 , 2014 .View at Google Scholar .33 , no . 2 , pp .171 - 257 , 2012 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "110.863594"}
{"text": "1385 - 1413 , 2012 .View at Google Scholar .137 , no . 2 , pp .263 - 272 , 2010 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "113.085785"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .138 , no .5 , pp .1093 - 1100 , 2010 .", "label": "", "metadata": {}, "score": "120.915085"}
{"text": "View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .367 , no .9526 , pp .1903 - 1912 , 2006 .", "label": "", "metadata": {}, "score": "121.33941"}
{"text": "View at Publisher \u00b7 View at Google Scholar .11 , no .4 , pp .756 - 760 , 2013 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "127.205414"}
{"text": "View at Publisher \u00b7 View at Google Scholar .106 , no .5 , pp .868 - 876 , 2011 .View at Publisher \u00b7 View at Google Scholar \u00b7 View at Scopus .", "label": "", "metadata": {}, "score": "128.54172"}
{"text": "Copyright \u00a9 2012 Tan Ru San et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "129.22395"}
{"text": "Received 24 February 2014 ; Accepted 24 June 2014 ; Published 19 August 2014 .Academic Editor : Lei Xi .Copyright \u00a9 2014 Meena P. Rao et al .", "label": "", "metadata": {}, "score": "131.57921"}
{"text": "Received 11 September 2012 ; Accepted 24 January 2013 .Copyright \u00a9 2013 Robert D. Russell et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "131.81438"}
{"text": "Academic Editor : Lars Carl Borris .Copyright \u00a9 2012 Ludmila Katherine Martin and Tanios Bekaii - Saab .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "135.95387"}
{"text": "Copyright \u00a9 2014 Anne - Sophie Dincq et al .This is an open access article distributed under the Creative Commons Attribution License , which permits unrestricted use , distribution , and reproduction in any medium , provided the original work is properly cited .", "label": "", "metadata": {}, "score": "140.39832"}
